0001628280-24-002813.txt : 20240201 0001628280-24-002813.hdr.sgml : 20240201 20240201085423 ACCESSION NUMBER: 0001628280-24-002813 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 24585168 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-Q 1 cah-20231231.htm 10-Q cah-20231231
0000721371--06-302024Q2falsehttp://fasb.org/us-gaap/2023#GainLossOnSalesOfAssetsAndAssetImpairmentCharges00007213712023-07-012023-12-3100007213712024-01-26xbrli:shares00007213712023-10-012023-12-31iso4217:USD00007213712022-10-012022-12-3100007213712022-07-012022-12-31iso4217:USDxbrli:shares00007213712023-12-3100007213712023-06-300000721371us-gaap:CommonStockMember2023-09-300000721371us-gaap:RetainedEarningsMember2023-09-300000721371us-gaap:TreasuryStockCommonMember2023-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000721371us-gaap:NoncontrollingInterestMember2023-09-3000007213712023-09-300000721371us-gaap:NoncontrollingInterestMember2023-10-012023-12-310000721371us-gaap:CommonStockMember2023-10-012023-12-310000721371us-gaap:TreasuryStockCommonMember2023-10-012023-12-310000721371us-gaap:RetainedEarningsMember2023-10-012023-12-310000721371us-gaap:CommonStockMember2023-12-310000721371us-gaap:RetainedEarningsMember2023-12-310000721371us-gaap:TreasuryStockCommonMember2023-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000721371us-gaap:NoncontrollingInterestMember2023-12-310000721371us-gaap:CommonStockMember2022-09-300000721371us-gaap:RetainedEarningsMember2022-09-300000721371us-gaap:TreasuryStockCommonMember2022-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000721371us-gaap:NoncontrollingInterestMember2022-09-3000007213712022-09-300000721371us-gaap:NoncontrollingInterestMember2022-10-012022-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-012022-12-310000721371us-gaap:CommonStockMember2022-10-012022-12-310000721371us-gaap:TreasuryStockCommonMember2022-10-012022-12-310000721371us-gaap:RetainedEarningsMember2022-10-012022-12-310000721371us-gaap:CommonStockMember2022-12-310000721371us-gaap:RetainedEarningsMember2022-12-310000721371us-gaap:TreasuryStockCommonMember2022-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000721371us-gaap:NoncontrollingInterestMember2022-12-3100007213712022-12-310000721371us-gaap:CommonStockMember2023-06-300000721371us-gaap:RetainedEarningsMember2023-06-300000721371us-gaap:TreasuryStockCommonMember2023-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000721371us-gaap:NoncontrollingInterestMember2023-06-300000721371us-gaap:NoncontrollingInterestMember2023-07-012023-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-12-310000721371us-gaap:CommonStockMember2023-07-012023-12-310000721371us-gaap:TreasuryStockCommonMember2023-07-012023-12-310000721371us-gaap:RetainedEarningsMember2023-07-012023-12-310000721371us-gaap:CommonStockMember2022-06-300000721371us-gaap:RetainedEarningsMember2022-06-300000721371us-gaap:TreasuryStockCommonMember2022-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000721371us-gaap:NoncontrollingInterestMember2022-06-3000007213712022-06-300000721371us-gaap:NoncontrollingInterestMember2022-07-012022-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-12-310000721371us-gaap:CommonStockMember2022-07-012022-12-310000721371us-gaap:TreasuryStockCommonMember2022-07-012022-12-310000721371us-gaap:RetainedEarningsMember2022-07-012022-12-310000721371cah:TransactionDataSystemInvestmentMember2023-12-31xbrli:pure0000721371cah:OutcomesDivestitureMember2023-07-012023-12-310000721371cah:TransactionDataSystemInvestmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300000721371us-gaap:EmployeeSeveranceMember2023-06-300000721371us-gaap:FacilityClosingMember2023-06-300000721371us-gaap:EmployeeSeveranceMember2023-07-012023-12-310000721371us-gaap:FacilityClosingMember2023-07-012023-12-310000721371us-gaap:EmployeeSeveranceMember2023-12-310000721371us-gaap:FacilityClosingMember2023-12-310000721371cah:PharmaceuticalMember2023-06-300000721371cah:MedicalMember2023-06-300000721371cah:PharmaceuticalMember2023-07-012023-12-310000721371cah:MedicalMember2023-07-012023-12-310000721371cah:PharmaceuticalMember2023-12-310000721371cah:MedicalMember2023-12-310000721371cah:MedicalUnitMember2023-07-012023-09-30utr:Rate0000721371cah:MedicalUnitMember2023-06-300000721371cah:MedicalUnitMember2023-12-310000721371cah:MedicalUnitMember2023-09-300000721371cah:MedicalUnitMember2023-07-012023-12-310000721371cah:MedicalUnitMember2023-04-012023-06-300000721371cah:MedicalMember2022-10-012022-12-310000721371cah:MedicalMember2022-07-012022-09-300000721371cah:IPRDTrademarksandOtherMember2023-12-310000721371us-gaap:CustomerRelationshipsMember2023-12-310000721371cah:TrademarksAndPatentsMember2023-12-310000721371us-gaap:DevelopedTechnologyRightsMember2023-12-310000721371cah:IPRDTrademarksandOtherMember2023-06-300000721371us-gaap:CustomerRelationshipsMember2023-06-300000721371cah:TrademarksAndPatentsMember2023-06-300000721371us-gaap:DevelopedTechnologyRightsMember2023-06-300000721371us-gaap:CommercialPaperMember2023-12-310000721371us-gaap:RevolvingCreditFacilityMember2023-12-310000721371cah:CommittedReceivablesSalesFacilityProgramMembercah:ShortTermCreditFacilitiesMember2023-12-310000721371cah:ShortTermCreditFacilitiesMember2023-12-310000721371cah:CVSHealthMember2014-07-312014-07-310000721371cah:NewYorkOpioidStewardshipActMember2018-04-300000721371cah:NewYorkOpioidStewardshipActMember2022-07-012023-06-300000721371cah:NewYorkOpioidStewardshipActMember2023-06-300000721371cah:TotalOpioidLitigationMember2023-12-310000721371cah:OpioidLawsuitsMember2023-12-31cah:statescah:numberOfUSTerritories0000721371cah:OpioidLawsuitsMemberstpr:AL2023-11-300000721371cah:OpioidLawsuitsMemberstpr:AL2023-10-012023-12-310000721371cah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2021-07-012024-01-310000721371cah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-02-012028-06-300000721371stpr:WVcah:OpioidLawsuitsMember2022-07-310000721371cah:OpioidLawsuitsMembercah:NativeAmericanTribesMember2022-10-310000721371cah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-01-012024-03-310000721371cah:TotalOpioidLitigationMemberus-gaap:SubsequentEventMember2024-01-012024-03-310000721371cah:PrivatePartiesMembercah:OpioidLawsuitsMemberus-gaap:SubsequentEventMember2024-01-26cah:lawsuit0000721371cah:PrivatePartiesMembercah:OpioidLawsuitsMembercah:ClassActionLawsuitsMemberus-gaap:SubsequentEventMember2024-01-260000721371cah:PrivatePartiesMembercah:OpioidLawsuitsMemberstpr:GA2023-01-012023-03-31cah:plaintiff0000721371cah:PrivatePartiesMembercah:OpioidLawsuitsMemberstpr:ALus-gaap:SubsequentEventMember2024-07-012024-07-010000721371cah:OpioidLawsuitsMember2022-07-012023-06-300000721371cah:ProductLiabilityLawsuitsMemberus-gaap:SubsequentEventMember2024-01-260000721371cah:ProductLiabilityLawsuitsMembercah:AlamedaCountyMemberus-gaap:SubsequentEventMember2024-01-262024-01-260000721371cah:IVCApril2023AgreementMembercah:ProductLiabilityLawsuitsMember2023-04-302023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-05-012023-09-300000721371cah:OtherAgreementsMembercah:ProductLiabilityLawsuitsMemberus-gaap:SubsequentEventMember2021-07-012024-01-260000721371cah:ProductLiabilityLawsuitsMember2022-07-012023-06-300000721371srt:MinimumMembercah:ProductLiabilityLawsuitsMember2023-12-310000721371cah:MedicalUnitGoodwillImpairmentMembersrt:ScenarioForecastMember2023-07-012024-06-300000721371cah:MedicalUnitGoodwillImpairmentMemberus-gaap:SubsequentEventMember2024-01-012024-06-300000721371srt:MinimumMember2023-12-310000721371srt:MaximumMember2023-12-310000721371cah:CareFusionMember2023-12-310000721371cah:CareFusionMember2023-06-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000721371us-gaap:FairValueMeasurementsRecurringMember2023-12-310000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300000721371us-gaap:FairValueMeasurementsRecurringMember2023-06-300000721371us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000721371us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000721371us-gaap:CashFlowHedgingMember2022-10-012022-12-310000721371us-gaap:CashFlowHedgingMember2023-07-012023-12-310000721371us-gaap:CashFlowHedgingMember2022-07-012022-12-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-10-012023-12-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-07-012023-12-310000721371us-gaap:CashFlowHedgingMembersrt:ScenarioForecastMemberus-gaap:ForeignExchangeContractMemberus-gaap:SubsequentEventMember2024-01-012024-12-310000721371cah:September2025Memberus-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-31iso4217:JPY0000721371cah:June2027Memberus-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000721371cah:January2023Memberus-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000721371cah:January2023Member2023-07-012023-12-310000721371us-gaap:ForeignExchangeContractMember2023-10-012023-12-310000721371us-gaap:ForeignExchangeContractMember2022-10-012022-12-310000721371us-gaap:ForeignExchangeContractMember2023-07-012023-12-310000721371us-gaap:ForeignExchangeContractMember2022-07-012022-12-310000721371us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-10-012022-12-310000721371us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-07-012022-12-310000721371us-gaap:FairValueInputsLevel2Member2023-12-310000721371us-gaap:FairValueInputsLevel2Member2023-06-300000721371cah:A250MillionShareRepurchaseProgramMember2023-10-012023-12-310000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2023-11-022023-11-020000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2023-10-012023-12-310000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2023-12-132023-12-130000721371cah:A500MillionShareRepurchaseProgramMember2023-07-012023-09-300000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-07-012023-09-300000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-07-012023-12-310000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-10-312023-10-310000721371cah:A500MillionShareRepurchaseProgramMember2023-04-012023-06-300000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-04-012023-06-300000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-04-012023-09-300000721371us-gaap:TreasuryStockCommonMembercah:A500MillionShareRepurchaseProgramMember2023-08-162023-08-160000721371cah:A250MillionShareRepurchaseProgramMember2022-10-012022-12-310000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2022-10-012022-12-310000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2022-10-012023-03-310000721371us-gaap:TreasuryStockCommonMembercah:A250MillionShareRepurchaseProgramMember2023-01-132023-01-130000721371cah:A1BillionShareRepurchaseProgramMember2022-04-012022-06-300000721371us-gaap:TreasuryStockCommonMembercah:A1BillionShareRepurchaseProgramMember2022-04-012022-06-300000721371us-gaap:TreasuryStockCommonMembercah:A1BillionShareRepurchaseProgramMember2022-07-012022-12-310000721371us-gaap:TreasuryStockCommonMembercah:A1BillionShareRepurchaseProgramMember2022-12-232022-12-230000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-12-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-12-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-12-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-12-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-12-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-12-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-31cah:segment0000721371cah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMemberus-gaap:OperatingSegmentsMember2023-10-012023-12-310000721371cah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMemberus-gaap:OperatingSegmentsMember2022-10-012022-12-310000721371cah:PharmaceuticalMembercah:NuclearPrecisionHealthSolutionsMemberus-gaap:OperatingSegmentsMember2023-10-012023-12-310000721371cah:PharmaceuticalMembercah:NuclearPrecisionHealthSolutionsMemberus-gaap:OperatingSegmentsMember2022-10-012022-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2023-10-012023-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2022-10-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicaldistributionandproductsMembercah:MedicalMember2023-10-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicaldistributionandproductsMembercah:MedicalMember2022-10-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:CardinalHealthAtHomeMembercah:MedicalMember2023-10-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:CardinalHealthAtHomeMembercah:MedicalMember2022-10-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2023-10-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2022-10-012022-12-310000721371us-gaap:OperatingSegmentsMember2023-10-012023-12-310000721371us-gaap:OperatingSegmentsMember2022-10-012022-12-310000721371us-gaap:CorporateNonSegmentMember2023-10-012023-12-310000721371us-gaap:CorporateNonSegmentMember2022-10-012022-12-310000721371cah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMemberus-gaap:OperatingSegmentsMember2023-07-012023-12-310000721371cah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMemberus-gaap:OperatingSegmentsMember2022-07-012022-12-310000721371cah:PharmaceuticalMembercah:NuclearPrecisionHealthSolutionsMemberus-gaap:OperatingSegmentsMember2023-07-012023-12-310000721371cah:PharmaceuticalMembercah:NuclearPrecisionHealthSolutionsMemberus-gaap:OperatingSegmentsMember2022-07-012022-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2023-07-012023-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2022-07-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicaldistributionandproductsMembercah:MedicalMember2023-07-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicaldistributionandproductsMembercah:MedicalMember2022-07-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:CardinalHealthAtHomeMembercah:MedicalMember2023-07-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:CardinalHealthAtHomeMembercah:MedicalMember2022-07-012022-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2023-07-012023-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2022-07-012022-12-310000721371us-gaap:OperatingSegmentsMember2023-07-012023-12-310000721371us-gaap:OperatingSegmentsMember2022-07-012022-12-310000721371us-gaap:CorporateNonSegmentMember2023-07-012023-12-310000721371us-gaap:CorporateNonSegmentMember2022-07-012022-12-310000721371country:US2023-10-012023-12-310000721371country:US2022-10-012022-12-310000721371us-gaap:NonUsMember2023-10-012023-12-310000721371us-gaap:NonUsMember2022-10-012022-12-310000721371country:US2023-07-012023-12-310000721371country:US2022-07-012022-12-310000721371us-gaap:NonUsMember2023-07-012023-12-310000721371us-gaap:NonUsMember2022-07-012022-12-310000721371cah:MedicalUnitMember2022-07-012022-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2023-12-310000721371cah:PharmaceuticalMemberus-gaap:OperatingSegmentsMember2023-06-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2023-12-310000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2023-06-300000721371us-gaap:CorporateNonSegmentMember2023-12-310000721371us-gaap:CorporateNonSegmentMember2023-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-310000721371us-gaap:RestrictedStockUnitsRSUMember2022-10-012022-12-310000721371us-gaap:PerformanceSharesMember2023-10-012023-12-310000721371us-gaap:PerformanceSharesMember2022-10-012022-12-310000721371us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-12-310000721371us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-12-310000721371us-gaap:PerformanceSharesMember2023-07-012023-12-310000721371us-gaap:PerformanceSharesMember2022-07-012022-12-310000721371us-gaap:RestrictedStockUnitsRSUMember2023-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2023-12-310000721371us-gaap:PerformanceSharesMembercah:Fiscal2022Membersrt:MinimumMember2023-07-012023-12-310000721371us-gaap:PerformanceSharesMembercah:Fiscal2023Membersrt:MinimumMember2023-07-012023-12-310000721371us-gaap:PerformanceSharesMembercah:Fiscal2023Membersrt:MaximumMember2023-07-012023-12-310000721371us-gaap:PerformanceSharesMembercah:Fiscal2022Membersrt:MaximumMember2023-07-012023-12-310000721371us-gaap:PerformanceSharesMembersrt:MinimumMembercah:Fiscal2024Member2023-07-012023-12-310000721371us-gaap:PerformanceSharesMembersrt:MaximumMembercah:Fiscal2024Member2023-07-012023-12-310000721371us-gaap:PerformanceSharesMember2023-06-300000721371us-gaap:PerformanceSharesMember2023-12-310000721371us-gaap:SubsequentEventMember2024-02-012024-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio31-0958666
(State or other jurisdiction of
incorporation or organization)		(IRS Employer
Identification No.)
7000 Cardinal Place,Dublin,Ohio43017
(Address of principal executive offices)(Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  þ    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  þ
The number of the registrant’s common shares, without par value, outstanding as of January 26, 2024, was the following:243,233,153.


Cardinal Health
Q2 Fiscal 2024 Form 10-Q
Table of Contents

About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and fiscal 2023 and to FY24 and FY23 are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our “2023 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.

 1
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&A
Overview
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at December 31, 2023 and June 30, 2023, and in our condensed consolidated statements of earnings/(loss) for the three and six months ended December 31, 2023 and 2022. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2023 Form 10-K.



 2
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AOverview
Overview of Consolidated Results
Revenue
During the three and six months ended December 31, 2023, revenue increased 12 percent and 11 percent to $57.4 billion and $112.2 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers.
GAAP and Non-GAAP Operating Earnings/(Loss)
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
GAAP operating earnings/(loss)$482 $(119)N.M.$468 $18 N.M.
Surgical gown recall income
(1)— (1)— 
State opioid assessment related to prior fiscal years— (6)— (6)
Shareholder cooperation agreement costs— 2 — 8 
Restructuring and employee severance28 17 53 46 
Amortization and other acquisition-related costs63 71 127 142 
Impairments and (gain)/loss on disposal of assets, net1 710 538 863 
Litigation (recoveries)/charges, net(11)(207)(52)(180)
Non-GAAP operating earnings$562 $467 20 %$1,133 $891 27 %
The sum of the components and certain computations may reflect rounding adjustments.
We had GAAP operating earnings of $482 million during the three months ended December 31, 2023 and a GAAP operating loss of $119 million during the three months ended December 31, 2022, which reflects the $709 million pre-tax goodwill impairment charge related to the Medical segment recognized during the three months ended December 31, 2022.
We had GAAP operating earnings of $468 million and $18 million during the six months ended December 31, 2023 and 2022, respectively, which included $581 million and $863 million pre-tax goodwill impairment charges related to the Medical segment, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to goodwill impairment.
GAAP operating earnings during the three and six months ended December 31, 2022 were favorably impacted by litigation recoveries. See "Results of Operations" section of this MD&A and Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to litigation recoveries.
Non-GAAP operating earnings during the three and six months ended December 31, 2023 increased 20 percent and 27 percent, respectively, due to an increase in Pharmaceutical and Medical segment profit.

 3
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AOverview
GAAP and Non-GAAP Diluted EPS
Three Months Ended December 31,Six Months Ended December 31,
($ per share)2023
2022
Change
2023
2022
Change
GAAP diluted EPS (1)
$1.43 $(0.50)N.M.$1.44 $(0.08)N.M.
Surgical gown recall income
— — — — 
State opioid assessment related to prior fiscal years— (0.02)— (0.02)
Shareholder cooperation agreement costs
— 0.01 — 0.02 
Restructuring and employee severance0.09 0.05 0.16 0.13 
Amortization and other acquisition-related costs0.19 0.20 0.38 0.40 
Impairments and (gain)/loss on disposal of assets, net (2)
0.14 2.06 1.71 2.46 
Litigation (recoveries)/charges, net(0.03)(0.48)(0.14)(0.39)
Non-GAAP diluted EPS (1)
$1.82 $1.32 38 %$3.55 $2.52 41 %
The sum of the components and certain computations may reflect rounding adjustments.
The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
(1)Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2)For the six months ended December 31, 2023, impairments and (gain)/loss on disposal of assets, net includes a pre-tax goodwill impairment charge of $581 million related to the Medical segment. For fiscal 2024, the net tax benefit related to the impairment charge is $45 million and is included in the annual effective tax rate. As a result, the tax benefit for the six months ended December 31, 2023 increased approximately by an incremental $65 million and will increase the provision for income taxes for the remainder of fiscal 2024.
For the three and six months December 31, 2022, impairments and (gain)/loss on disposal of assets, net included cumulative pre-tax goodwill impairment charges of $709 million and $863 million, respectively, related to the Medical segment. For fiscal 2023, the net tax benefit related to these impairment charges was $68 million and was included in the annual effective tax rate. As a result, the amount of tax benefit increased approximately by an incremental $118 million and $140 million for the three and six months ended December 31, 2022, respectively, and increased the provision for income taxes for the remainder of fiscal 2023.
During the three and six months ended December 31, 2023, GAAP diluted EPS was favorably impacted by an increase in Pharmaceutical and Medical segment profit. GAAP diluted EPS was adversely impacted by the goodwill impairment charges related to the Medical segment, which had a $(1.91) per share after tax impact during the six months ended December 31, 2023, and $(2.05) and $(2.46) per share after tax impact during the three and six months ended December 31, 2022, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A, and Note 4 and Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional detail. GAAP EPS during the three and six months ended December 31, 2022 also includes the favorable impact of litigation recoveries as described further in the "Results of Operations" section of this MD&A and Note 6 of the "Notes to Condensed Consolidated Financial Statements."
During the three and six months ended December 31, 2023, non-GAAP diluted EPS increased 38 percent and 41 percent to $1.82 and $3.55 per share, respectively, due to higher non-GAAP operating earnings, a lower share count and interest expense.

Cash and Equivalents
Our cash and equivalents balance was $4.6 billion at December 31, 2023 compared to $4.0 billion at June 30, 2023. During the six months ended December 31, 2023, net cash provided by operating activities was $1.7 billion, which includes the impact of our annual payment of $378 million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "National Opioid Settlement Agreement"). In addition, during the six months ended December 31, 2023, we deployed $750 million for share repurchases, $255 million for cash dividends and $206 million for capital expenditures.

 4
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AOverview
Significant Developments in Fiscal 2024 and Trends
Operating and Segment Reporting Structure Changes
In January 2024, we announced a change in our organizational structure and have re-aligned our reporting structure under two reportable segments, effective January 1, 2024: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other. Results in this Form 10-Q are reported under our prior organizational and reporting structure. The following indicates the changes from the second quarter of fiscal 2024 to the new reporting structure, which will be reported for the first time in the third quarter of fiscal 2024:
•Pharmaceutical and Specialty Solutions segment: This reportable segment will be comprised of all businesses formerly within our Pharmaceutical segment except Nuclear and Precision Health Solutions.
•Global Medical Products and Distribution segment: This reportable segment will be comprised of all businesses formerly within our Medical segment except at-Home Solutions and OptiFreight Logistics.
•Other: This will consist of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics.

Pharmaceutical Segment
Specialty Networks Acquisition
On January 31, 2024, we announced that we had entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology. The acquisition will further expand our offering in key therapeutic areas by enhancing our downstream provider-focused analytics capabilities and service offerings and by accelerating our upstream data and research opportunities with biopharma manufacturers.
This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. We plan to fund the acquisition with available cash.
COVID-19 Vaccine Distribution
Pharmaceutical segment profit was favorably impacted during the three and six months ended December 31, 2023 on a year-over-year basis in part due to the company beginning to distribute the recently commercially available COVID-19 vaccines following U.S. Food and Drug Administration approval of updated vaccines in September 2023. The timing, magnitude and profit impact of vaccine distribution volume for the remainder of fiscal 2024 and beyond remains uncertain.
Generics Program
The performance of our Pharmaceutical segment generics program positively impacted the year-over-year comparison of Pharmaceutical segment profit during the three and six months ended December 31, 2023. The Pharmaceutical segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health") and generic pharmaceutical contract manufacturing and sourcing costs.
The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharmaceutical segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharmaceutical segment profit and consolidated operating earnings during the remainder of fiscal 2024.

Medical Segment
Inflationary Impacts
Beginning in fiscal 2022, Medical segment profit was negatively affected by incremental inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor, and global supply chain constraints. Since that time, we have taken actions to partially mitigate these impacts, including implementing certain price increases and evolving our pricing and

 5
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AOverview
commercial contracting processes to provide us with greater pricing flexibility. In addition, decreases in some product-related costs have been recognized as the higher-cost inventory moved through our supply chain and was replaced by lower-cost inventory. These net inflationary impacts negatively affected Medical segment profit during fiscal 2023. The net inflationary impacts were less significant during the three and six months ended December 31, 2023 and had a favorable impact on Medical segment profit on a year-over-year basis.
We expect these net inflationary impacts to continue to affect Medical segment profit during the remainder of fiscal 2024, but to a significantly lesser extent than in fiscal 2023 and prior periods, due to our mitigation actions, together with continued decreases in certain product-related costs. However, these inflationary costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. Our actions to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent or on the timeline we anticipate.
Volumes within Products and Distribution
Medical segment profit was adversely impacted during fiscal 2023 in part due to lower volumes within products and distribution, which includes our Cardinal Health branded medical products. We expect Cardinal Health branded medical products sales growth in fiscal 2024 and beyond. The timing, magnitude and profit impact of this anticipated sales growth is subject to risks and uncertainties, which may impact Medical segment profit.
Medical Segment Goodwill
The change in segment structure as discussed above will result in changes to the composition of our reporting units. Accordingly, we will be required to reallocate the goodwill in reporting units affected by the change using a relative fair value approach and assess goodwill for impairment both before and after the reallocation. While we have not identified any indicators of impairment during the three months ended December 31, 2023 within the current reporting units, we may recognize a goodwill impairment charge following the reallocation if the carrying value of a new reporting unit exceeds its estimated fair value.
During the three months ended September 30, 2023, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) ("Medical Unit") due to an increase in the risk-free interest rate. This testing resulted in a pre-tax charge of $581 million which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail. Adverse changes in key assumptions or a significant change in industry or economic trends during the remainder of fiscal 2024 and beyond could result in additional goodwill impairments.
Shareholder Cooperation Agreement
In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, the Board. In connection with this extension, the Board has extended the term of the Business Review Committee until July 15, 2024.
The evaluation and implementation of any actions recommended by the Business Review Committee and the Board have impacted and may continue to impact our business, financial position and results of operations during the remainder of fiscal 2024 and beyond. We have incurred, and may incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee.


 6
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Results of Operations
Revenue
3637
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
Pharmaceutical$53,520 $47,673 12 %$104,526 $93,501 12 %
Medical3,928 3,797 3 %7,688 7,575 1 %
Total segment revenue57,448 51,470 12 %112,214 101,076 11 %
Corporate(3)(1)N.M.(6)(4)N.M.
Total revenue$57,445 $51,469 12 %$112,208 $101,072 11 %
Pharmaceutical Segment
Pharmaceutical segment revenue increased during the three and six months ended December 31, 2023 due to branded and specialty pharmaceutical sales growth, largely from existing customers, which increased revenue by $5.8 billion and $10.9 billion, respectively.
Medical Segment
Medical segment revenue increased during the three and six months ended December 31, 2023, primarily due to sales growth in at-Home Solutions and in products and distribution. The increase in products and distribution was primarily driven by higher Cardinal Health brand volumes and the effect of price increases to mitigate inflationary impacts partially offset by the adverse impact of personal protective equipment ("PPE") volumes and pricing.
Cost of Products Sold
Cost of products sold for the three and six months ended December 31, 2023 increased 12 percent to $55.6 billion and $108.6 billion, respectively, compared to the prior-year periods due to the factors affecting the changes in revenue and gross margin.



 7
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Gross Margin
10851086
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
Gross margin$1,846 $1,663 11 %$3,614 $3,277 10 %
Gross margin increased during the three and six months ended December 31, 2023 primarily due to the beneficial comparison to the prior-year net inflationary impacts in the Medical segment, the performance of our generics program in the Pharmaceutical segment and increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from COVID-19 vaccine distribution.
Gross margin rate declined 2 basis points during both the three and six months ended December 31, 2023, with the impact of unfavorable changes in overall product mix mostly offset by the beneficial comparison to the prior-year net inflationary impacts in the Medical segment and the performance of our generics program in the Pharmaceutical segment. The changes in overall product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.
Distribution, Selling, General and Administrative ("SG&A") Expenses
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
SG&A expenses$1,283 $1,191 8 %$2,480 $2,388 4 %
During the three and six months ended December 31, 2023, SG&A expenses increased primarily due to higher costs to support sales growth, expenses related to investment projects and compensation-related costs.



 8
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Segment Profit
We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
30373038
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
Pharmaceutical$518 $464 12 %$1,025 $895 15 %
Medical71 17 N.M142 9 N.M
Total segment profit589 481 22 %1,167 904 29 %
Corporate(107)(600)N.M.(699)(886)N.M.
Total consolidated operating earnings/(loss)$482 $(119)N.M.$468 $18 N.M.
Pharmaceutical Segment Profit
Pharmaceutical segment profit increased during the three and six months ended December 31, 2023 primarily due to the performance of our generics program and increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from COVID-19 vaccine distribution, partially offset by higher costs to support sales growth.
Medical Segment Profit
Medical segment profit increased during the three and six months ended December 31, 2023 due to the beneficial comparison to the prior-year net inflationary impacts, including the effects of mitigation actions.
Corporate
The changes in Corporate during the three and six months ended December 31, 2023 were due to the factors discussed in the "Other Components of Consolidated Operating Earnings/(Loss)" section that follows.

 9
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Other Components of Consolidated Operating Earnings/(Loss)
In addition to revenue, gross margin and SG&A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:
Three Months Ended December 31,Six Months Ended December 31,
(in millions)2023202220232022
Restructuring and employee severance$28 $17 $53 $46 
Amortization and other acquisition-related costs63 71 127 142 
Impairments and (gain)/loss on disposal of assets, net1 710 538 863 
Litigation (recoveries)/charges, net(11)(207)(52)(180)
Restructuring and Employee Severance
Restructuring and employee severance costs during the three and six months ended December 31, 2023 were primarily related to certain projects resulting from reviews of our strategy, portfolio, capital-allocation framework and operations and the implementation of certain enterprise-wide cost-savings measures. During the three and six months ended December 31, 2022, costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $63 million and $71 million for the three months ended December 31, 2023 and 2022, respectively, and $127 million and $142 million for the six months ended December 31, 2023 and 2022, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
We recognized $581 million of pre-tax non-cash goodwill impairment charges related to our Medical segment during the six months ended December 31, 2023, and $709 million and $863 million during the three and six months ended December 31, 2022, respectively, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements."
Litigation (Recoveries)/Charges, Net
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $31 million and $71 million during the three and six months ended December 31, 2023, respectively, and $66 million during the three and six months ended December 31, 2022.
During the three and six months ended December 31, 2023, we recognized a $22 million charge related to an agreement in principle with the Alabama Attorney General, under which we would pay approximately $123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. See Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
We recognized income of $46 million and $25 million during the three and six months ended December 31, 2022, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for the Cordis OptEase and TrapEase inferior vena cava ("IVC") product liability due to the execution of certain settlement agreements.
During the three and six months ended December 31, 2022, we recognized income of $93 million due to net proceeds from the settlement of a shareholder derivative litigation matter.
Earnings/(Loss) Before Income Taxes
In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:
Three Months Ended December 31,Six Months Ended December 31,
(in millions)20232022Change20232022Change
Other (income)/expense, net$(16)$(7)N.M.$(18)$(5)N.M.
Interest expense, net8 25 (68)%22 50 (56)%
Interest Expense, Net
During the three and six months ended December 31, 2023, interest expense decreased by 68 percent and 56 percent, respectively, primarily due to increased interest income from cash and equivalents.


 10
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Provision for Income Taxes
The effective tax rate was 27.7 percent and 5.4 percent during the three months ended December 31, 2023 and 2022, respectively, and 22.4 percent and 30.0 percent during the six months ended December 31, 2023 and 2022, respectively. These tax rates reflect the impact of the tax effects of goodwill impairment charges as well as certain other discrete items. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information, during the three and six months ended December 31, 2023 and 2022.
Tax Effects of Goodwill Impairment Charges
During the six months ended December 31, 2023, we recognized cumulative pre-tax goodwill impairment charges of $581 million related to the Medical Unit. The net tax benefit related to these charges is $45 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charges recorded during the six months ended December 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the six months ended December 31, 2023 resulted in recognizing an incremental interim tax benefit of approximately $65 million which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended December 31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at December 31, 2023. The incremental interim tax benefit will reverse in the future quarters of fiscal 2024.

 11
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&ALiquidity and Capital Resources
Liquidity and Capital Resources
We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. If we decide to engage in one or more acquisitions in addition to the acquisition of Specialty Networks, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.
Cash and Equivalents
Our cash and equivalents balance was $4.6 billion at December 31, 2023 compared to $4.0 billion at June 30, 2023.
During the six months ended December 31, 2023, net cash provided by operating activities was $1.7 billion, which includes the impact of our annual payment of $378 million related to the National Opioid Settlement Agreement. In addition, we deployed cash of $750 million for share repurchases, $255 million for cash dividends and $206 million for capital expenditures.
At December 31, 2023, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of
customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at December 31, 2023 includes $670 million of cash held by subsidiaries outside of the United States.



Other Financing Arrangements and Financial Instruments
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at December 31, 2023 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC ("CHF") through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC was added as a seller under our committed receivables sales facility.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December 31, 2023, we were in compliance with this financial covenant.

Long-Term Debt and Other Short-Term Borrowings
We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both December 31, 2023 and June 30, 2023.


 12
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&ALiquidity and Capital Resources
Capital Deployment
Opioid Litigation Settlement Agreement
We had $5.47 billion accrued at December 31, 2023 related to certain opioid litigation, as further described within Note 6 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to occur through 2038. During the six months ended December 31, 2023, we made our third annual payment of $378 million under the National Opioid Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made.
In January 2024, we made payments of approximately $238 million to prepay at a pre-negotiated discount certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we expect to recognize income of approximately $100 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings/(loss) during the three months ended March 31, 2024.
Capital Expenditures
Capital expenditures during the six months ended December 31, 2023 and 2022 were $206 million and $155 million, respectively.

Dividends
On each of May 11, 2023, August 9, 2023, and November 14, 2023, our Board of Directors approved a quarterly dividend of $0.5006 per share, or $2.00 per share on an annualized basis, which were paid on July 15, 2023, October 15, 2023, and January 15, 2024 to shareholders of record on July 3, 2023, October 3, 2023, and January 2, 2024, respectively.
Share Repurchases
During the six months ended December 31, 2023, we deployed $750 million for repurchases of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. We funded the ASR programs with available cash. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
As of December 31, 2023, we have $3.5 billion remaining under our existing share repurchase authorization.
Specialty Networks Acquisition
On January 31, 2024, we announced that we had entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for a purchase price of $1.2 billion in cash, subject to certain adjustments. We plan to fund the acquisition with available cash.

 13
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&AOther Items

Other Items
The MD&A in our 2023 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2023. Other than in connection with our proposed acquisition of Specialty Networks, there have been no subsequent material changes outside of the ordinary course of business to those items. See Note 14 of the "Notes to Condensed Consolidated Financial Statements" for additional information.


Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June 30, 2023. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2023 Form 10-K and our Form 10-Q for the quarters ended September 30, 2023.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K and our other filings with the SEC since June 30, 2023.
Goodwill
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

Changes to Reportable Segments for Fiscal 2024
As discussed in the Overview section of this MD&A, effective January 1, 2024, we implemented a new enterprise operating and segment reporting structure. The updated structure comprises two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other.
This change in segment structure will result in changes to the composition of our reporting units. Accordingly, we will be required to reallocate the goodwill in reporting units affected by the change using a relative fair value approach and assess goodwill for impairment both before, and after the reallocation. While we have not identified any indicators of impairment during the three months ended December 31, 2023 within the current reporting units, we may recognize a goodwill impairment charge following the reallocation if the carrying value of a new reporting unit exceeds its estimated fair value.
Medical Unit Goodwill
Potential changes in the reporting units within our Medical operating segment may result in a goodwill impairment charge. As of December 31, 2023, the total goodwill balance within the Medical Unit was $139 million. As discussed above, we have not identified any indicators of impairment during the three months ended December 31, 2023 within our reporting units, including the Medical Unit.
During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit due to an increase

 14
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


MD&A
Other Items
in the risk-free interest rate used in the discount rate. Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the six months ended December 31, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent. See Note 4 of the "Notes to Condensed Consolidated Financial Statements" for further discussion.
While we consider the assumptions used in our determination of the estimated fair value of the Medical Unit to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2024 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; manufacturing cost inefficiencies resulting from lower than anticipated sales volume, an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends.
Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent, the fair value for the Medical Unit would have further decreased by approximately $450 million. Additionally, a hypothetical 25 basis point decrease in long-term gross margin rates, which could be impacted by changes in Cardinal Health branded medical product sales growth rate assumptions, would have further decreased the fair value for the Medical Unit by approximately $300 million.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing
resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively.



 15
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
•Surgical gown recall costs or income includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
•Shareholder cooperation agreement costs includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance.
•Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance and realigning operations.

 16
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
•Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt divided by (earnings/(loss) before income taxes adjusted for the nine items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

 17
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
GAAP to Non-GAAP Reconciliation
(in millions, except per common share amounts)Operating Earnings/(Loss)
Operating Earnings Growth Rate
Earnings/(Loss) Before Income TaxesProvision for/(Benefit From) Income Taxes
Net Earnings/(Loss)1
Net Earnings1 Growth Rate
Diluted EPS1,2
Diluted EPS1 Growth Rate
Three Months Ended December 31, 2023
GAAP$482 N.M.$490 $136 $353 N.M.$1.43 N.M.
Surgical gown recall income
(1)(1)— (1)— 
Restructuring and employee severance28 28 7 21 0.09 
Amortization and other acquisition-related costs63 63 17 46 0.19 
Impairments and (gain)/loss on disposal of assets, net
1 1 (33)34 0.14 
Litigation (recoveries)/charges, net (11)(11)(5)(6)(0.03)
Non-GAAP$562 20 %$569 $121 $447 29 %$1.82 38 %
Three Months Ended December 31, 2022
GAAP$(119)(87)%$(137)$(7)$(130)N.M.$(0.50)N.M.
State opioid assessment related to prior fiscal years(6)(6)(2)(4)(0.02)
Shareholder cooperation agreement costs2 2 1 1 0.01 
Restructuring and employee severance17 17 4 13 0.05 
Amortization and other acquisition-related costs71 71 18 53 0.20 
Impairments and (gain)/loss on disposal of assets, net 3
710 710 173 537 2.06 
Litigation (recoveries)/charges, net(207)(207)(83)(124)(0.48)
Non-GAAP$467 — %$450 $104 $346 (3)%$1.32 4 %
Six Months Ended December 31, 2023
GAAP
$468 N.M.$464 $104 $358 N.M.$1.44 N.M.
Surgical gown recall income
(1)(1)— (1)— 
Restructuring and employee severance53 53 14 39 0.16 
Amortization and other acquisition-related costs127 127 33 94 0.38 
Impairments and (gain)/loss on disposal of assets, net 3
538 538 112 426 1.71 
Litigation (recoveries)/charges, net(52)(52)(16)(36)(0.14)
Non-GAAP
$1,133 27 %$1,129 $247 $880 30 %$3.55 41 %
Six Months Ended December 31, 2022
GAAP$18 N.M.$(27)$(8)$(20)N.M.$(0.08)N.M.
State opioid assessment related to prior fiscal years(6)(6)(2)(4)(0.02)
Shareholder cooperation agreement costs
8 8 2 6 0.02 
Restructuring and employee severance46 46 10 36 0.13 
Amortization and other acquisition-related costs142 142 37 105 0.40 
Impairments and (gain)/loss on disposal of assets, net 3
863 863 207 656 2.46 
Litigation (recoveries)/charges, net (180)(180)(76)(104)(0.39)
Non-GAAP$891 (10)%$846 $170 $675 (7)%$2.52 (2)%

 18
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
1    Attributable to Cardinal Health, Inc.
2    For the three and six months ended December 31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 261 million and 266 million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and six months ended December 31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 263 million and 268 million common shares, which includes potentially dilutive shares.
3    For the six months ended December 31, 2023, impairments and (gain)/loss on disposal of assets, net includes a pre-tax goodwill impairment charge of $581 million related to the Medical segment. For fiscal 2024, the net tax benefit related to the impairment charge is $45 million and is included in the annual effective tax rate. As a result, the tax benefit for the six months ended December 31, 2023 increased approximately by an incremental $65 million and will increase the provision for income taxes for the remainder of fiscal 2024.
For the three and six months December 31, 2022, impairments and (gain)/loss on disposal of assets, net included cumulative pre-tax goodwill impairment charges of $709 million and $863 million, respectively, related to the Medical segment. For fiscal 2023, the net tax benefit related to these impairment charges was $68 million and was included in the annual effective tax rate. As a result, the amount of tax benefit increased approximately by an incremental $118 million and $140 million for the three and six months ended December 31, 2022, respectively, and increased the provision for income taxes for the remainder of fiscal 2023.

The sum of the components and certain computations may reflect rounding adjustments.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.


 19
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Other

Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2023 Form 10-K since the end of fiscal 2023 through December 31, 2023.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December 31, 2023. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 20
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Other
Legal Proceedings
The legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Risk Factors
You should carefully consider the information in this Form 10-Q, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K, our Form 10-Q for the quarter ended September 30, 2023, and our other filings with the SEC since June 30, 2023. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Our pending acquisition of Specialty Networks subjects us to various risks and uncertainties.
As discussed in the MD&A section, on January 31, 2024, we announced that we had entered into a definitive agreement to acquire Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. The acquisition will further expand the Pharmaceutical segment's portfolio of Specialty services. We plan to fund the acquisition with available cash.
Consummation of the pending acquisition is subject to various risks and uncertainties, including the following: the ability to successfully complete the acquisition on a timely basis, including receipt of required regulatory approvals and satisfaction of other closing conditions; and the conditions of the credit markets.
If we are successful in completing the acquisition, we will be subject to other risks, including the following: we may fail to realize the synergies and other benefits we expect from the acquisition; the use of a significant portion of our cash may have an adverse effect on our liquidity, limit our flexibility in responding to other business opportunities, and increase our vulnerability to adverse economic and industry conditions; we may fail to retain key personnel of the acquired businesses; future developments may impair the value of our purchased goodwill or intangible assets; we may face difficulties establishing, integrating or combining operations and systems; we may face challenges retaining the customers of the acquired businesses; we may encounter unforeseen internal control, regulatory or compliance issues; and we may face other additional risks relating to regulatory matters, legal proceedings, and tax laws or positions.
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
Issuer Purchases of Equity Securities
PeriodTotal Number
of Shares
Purchased (1)
Average Price Paid per Share (2,3)
Total Number of Shares
Purchased
as Part of Publicly Announced Programs (2,3,4)
Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (4)
(in millions)
October 20231,251,107 $79.94 1,250,909 $3,843 
November 20231,967,452 101.66 1,967,342 3,543 
December 2023444,271 112.57 444,161 3,493 
Total3,662,830 $95.57 3,662,412 $3,493 
(1)Reflects 198, 110 and 110 common shares purchased in October, November and December 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On November 6, 2023, we entered into an ASR program to purchase common shares for an aggregate purchase price of $250 million and received an initial delivery of 2.0 million common shares using a reference price of $101.66. The ASR program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On August 16, 2023, we entered into an ASR program to purchase common shares for an aggregate purchase price of $500 million and received an initial delivery of 4.4 million common shares using a reference price of $90.57. The ASR program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(4)On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of December 31, 2023, we had $3.5 billion authorized for share repurchases remaining under this program.


 21
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Other
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended December 31, 2023, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.

 22
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Financial Statements

Condensed Consolidated Statements of Earnings/(Loss)
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(in millions, except per common share amounts)2023202220232022
Revenue$57,445 $51,469 $112,208 $101,072 
Cost of products sold55,599 49,806 108,594 97,795 
Gross margin1,846 1,663 3,614 3,277 
Operating expenses:
Distribution, selling, general and administrative expenses1,283 1,191 2,480 2,388 
Restructuring and employee severance28 17 53 46 
Amortization and other acquisition-related costs63 71 127 142 
Impairments and (gain)/loss on disposal of assets, net1 710 538 863 
Litigation (recoveries)/charges, net(11)(207)(52)(180)
Operating earnings/(loss)482 (119)468 18 
Other (income)/expense, net(16)(7)(18)(5)
Interest expense, net8 25 22 50 
Earnings/(loss) before income taxes490 (137)464 (27)
Provision for/(benefit from) income taxes136 (7)104 (8)
Net earnings/(loss)354 (130)360 (19)
Less: Net earnings attributable to noncontrolling interests(1)— (2)(1)
Net earnings/(loss) attributable to Cardinal Health, Inc.$353 $(130)$358 $(20)
Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:
Basic$1.44 $(0.50)$1.45 $(0.08)
Diluted1.43 (0.50)1.44 (0.08)
Weighted-average number of common shares outstanding:
Basic245261247266
Diluted246261248266
Cash dividends declared per common share$0.5006 $0.4957 $1.0012 $0.9914 
See notes to condensed consolidated financial statements.

 23
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Comprehensive Income/(Loss)
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(in millions)2023202220232022
Net earnings/(loss)$354 $(130)$360 $(19)
Other comprehensive income/(loss):
Foreign currency translation adjustments and other6 20 (5)(38)
Net unrealized gain on derivative instruments, net of tax4 10 1 6 
Total other comprehensive income/(loss), net of tax10 30 (4)(32)
Total comprehensive income/(loss)364 (100)356 (51)
Less: comprehensive income attributable to noncontrolling interests
(1)— (2)(1)
Total comprehensive income/(loss) attributable to Cardinal Health, Inc.$363 $(100)$354 $(52)
See notes to condensed consolidated financial statements.


 24
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Balance Sheets
(in millions)December 31, 2023June 30, 2023
(Unaudited)
Assets
Current assets:
Cash and equivalents$4,591 $4,043 
Trade receivables, net11,788 11,344 
Inventories, net18,451 15,940 
Prepaid expenses and other2,816 2,362 
Assets held for sale12 144 
Total current assets37,658 33,833 
Property and equipment, net2,446 2,462 
Goodwill and other intangibles, net5,371 6,081 
Other assets1,098 1,041 
Total assets$46,573 $43,417 
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable$34,259 $29,813 
Current portion of long-term obligations and other short-term borrowings1,188 792 
Other accrued liabilities2,839 3,059 
Liabilities related to assets held for sale— 42 
Total current liabilities38,286 33,706 
Long-term obligations, less current portion3,535 3,909 
Deferred income taxes and other liabilities8,199 8,653 
Shareholders’ deficit:
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none
— — 
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares at December 31, 2023 and June 30, 2023
2,855 2,747 
Accumulated deficit(425)(534)
Common shares in treasury, at cost: 83 million shares and 76 million shares at December 31, 2023 and June 30, 2023, respectively
(5,724)(4,914)
Accumulated other comprehensive loss(155)(151)
Total Cardinal Health, Inc. shareholders' deficit(3,449)(2,852)
Noncontrolling interests2 1 
Total shareholders’ deficit(3,447)(2,851)
Total liabilities and shareholders’ deficit$46,573 $43,417 
See notes to condensed consolidated financial statements.


 25
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Shareholders' Deficit
(Unaudited)
Common Shares
Accumulated Deficit
Treasury SharesAccumulated Other
Comprehensive
Loss		Noncontrolling Interests
Total
Shareholders’ Deficit
(in millions)Shares IssuedAmountSharesAmount
Three Months Ended December 31, 2023
Balance at September 30, 2023327 $2,728 $(654)(80)$(5,400)$(165)$1 $(3,490)
Net earnings
353 1 354 
Other comprehensive income, net of tax
10 10 
Employee stock plans activity, net of shares withheld for employee taxes— 27 — 30 57 
Share repurchase program activity100 (4)(354)(254)
Dividends declared(123)(123)
Other(1)1 — (1)
Balance at December 31, 2023327 $2,855 $(425)(83)$(5,724)$(155)$2 $(3,447)
Three Months Ended December 31, 2022
Balance at September 30, 2022327 $2,576 $(301)(65)$(3,880)$(176)$1 $(1,780)
Net loss(130)— (130)
Other comprehensive income, net of tax30 30 
Employee stock plans activity, net of shares withheld for employee taxes— 21 1 26 47 
Share repurchase program activity150 (4)(400)(250)
Dividends declared(129)(129)
Balance at December 31, 2022327 $2,747 $(560)(68)$(4,254)$(146)$1 $(2,212)
Six Months Ended December 31, 2023
Balance at June 30, 2023327 $2,747 $(534)(76)$(4,914)$(151)$1 $(2,851)
Net earnings
358 2 360 
Other comprehensive loss, net of tax
(4)(4)
Employee stock plans activity, net of shares withheld for employee taxes8 1 49 57 
Share repurchase program activity100 (9)(859)(759)
Dividends declared(249)(249)
Other— 1 (1)(1)
Balance at December 31, 2023327 $2,855 $(425)(83)$(5,724)$(155)$2 $(3,447)
Six Months Ended December 31, 2022
Balance at June 30, 2022327 $2,813 $(280)(54)$(3,128)$(114)$3 $(706)
Net earnings/(loss)
(20)1 (19)
Other comprehensive loss, net of tax(32)(32)
Purchase of noncontrolling interests
(2)(2)
Employee stock plans activity, net of shares withheld for employee taxes— (16)2 74 58 
Share repurchase program activity(50)(16)(1,200)(1,250)
Dividends declared(260)(260)
Other(1)(1)
Balance at December 31, 2022327 $2,747 $(560)(68)$(4,254)$(146)$1 $(2,212)
See notes to condensed consolidated financial statements.

 26
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended December 31,
(in millions)20232022
Cash flows from operating activities:
Net earnings/(loss)$360 $(19)
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization347 341 
Impairments and (gain)/loss on disposal of assets, net538 863 
Share-based compensation57 48 
Provision for bad debts43 59 
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables(487)(919)
Increase in inventories(2,536)(1,643)
Increase in accounts payable4,446 2,954 
Other accrued liabilities and operating items, net(1,034)(1,064)
Net cash provided by operating activities1,734 620 
Cash flows from investing activities:
Proceeds from divestitures, net of cash sold9 — 
Additions to property and equipment(206)(155)
Proceeds from disposal of property and equipment2 2 
Purchases of investments(2)(5)
Proceeds from investments1 1 
Proceeds from net investment hedge terminations28 — 
Net cash used in investing activities(168)(157)
Cash flows from financing activities:
Reduction of long-term obligations(15)(13)
Net tax proceeds from share-based compensation
1 9 
Dividends on common shares(255)(271)
Purchase of treasury shares(750)(1,250)
Net cash used in financing activities(1,019)(1,525)
Effect of exchange rate changes on cash and equivalents1 (1)
Net increase/(decrease) in cash and equivalents548 (1,063)
Cash and equivalents at beginning of period4,043 4,717 
Cash and equivalents at end of period$4,591 $3,654 

See notes to condensed consolidated financial statements.

 27
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
Recently Issued Financial Accounting Standards
Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the six months ended December 31, 2023.


 28
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
2. Divestitures
On June 5, 2023, we signed a definitive agreement to contribute the OutcomesTM business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the six months ended December 31, 2023, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.
We determined that the divestiture of the OutcomesTM business does not meet the criteria to be classified as discontinued operations. The OutcomesTM business operated within our Pharmaceutical segment.


3. Restructuring and Employee Severance
The following tables summarize restructuring and employee severance costs:
Three Months Ended December 31,
(in millions)20232022
Employee-related$8 $10 
Facility exit and other20 7 
Total restructuring and employee severance$28 $17 
Six Months Ended December 31,
(in millions)20232022
Employee-related$15 $29 
Facility exit and other38 17 
Total restructuring and employee severance$53 $46 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.
Restructuring and employee severance costs during the three and six months ended December 31, 2023 were primarily related to certain projects resulting from review of our strategy portfolio, capital-allocation framework and operation and the implementation of certain enterprise-wide cost-savings measures. During the three and six months ended December 31, 2022, restructuring and employee severance costs were primarily related to implementation of certain enterprise-wide cost-saving measures.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions8 4 12 
Payments and other adjustments(18)(1)(19)
Balance at December 31, 2023$34 $5 $39 

 29
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements

4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2023$2,649 $1,960 $4,609 
Goodwill acquired, net of purchase price adjustments— (3)(3)
Foreign currency translation adjustments and other— (1)(1)
Goodwill impairment— (581)(581)
Balance at December 31, 2023$2,649 $1,375 $4,024 
(1) At December 31, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.
We have not identified any indicators of impairment during the three months ended December 31, 2023 within our reporting units, including the Medical Unit.
During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit due to an increase in the risk-free interest rate used in the discount rate. Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the six months ended December 31, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively.

Other Intangible Assets
The following tables summarize other intangible assets by class at:
December 31, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 N/A
Total indefinite-life intangibles12 — 12 N/A
Definite-life intangibles:
Customer relationships3,175 2,357 818 9
Trademarks, trade names and patents546 394 152 7
Developed technology and other1,022 657 365 8
Total definite-life intangibles4,743 3,408 1,335 8
Total other intangible assets$4,755 $3,408 $1,347 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
Total amortization of intangible assets was $63 million and $71 million for the three months ended December 31, 2023 and 2022, respectively, and $127 million and $142 million for the six months ended December 31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $127 million, $226 million, $206 million, $174 million and $148 million.

 30
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements

5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both December 31, 2023 and June 30, 2023. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $34.3 billion and $29.8 billion at December 31, 2023 and June 30, 2023, respectively.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December 31, 2023, we were in compliance with this financial covenant.
6. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation ("CVS Health") for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during first quarter of fiscal year 2024.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or

 31
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital
system and other healthcare providers, businesses and Individuals.
We have also received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil request for information, subpoenas and other request from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations.
In total, as of December 31, 2023, we have $5.47 billion accrued for these matters, of which $420 million is included in other accrued liabilities and remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrong doing. Please see below for additional description of these matters.
States & Political Subdivisions
In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities").
In November 2023, we reached an agreement in principle with the Alabama Attorney General, under which we would pay approximately $123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the three and six months ended December 31, 2023, we recognized a

 32
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
$22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to this agreement.
Through January 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.9 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
Prepayment of Future Payment Years
In January 2024, we made payments of approximately $238 million to prepay at a pre-negotiated discount certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we expect to recognize income of approximately $100 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings/(loss) during the three months ended March 31, 2024.
Private Plaintiffs
The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of January 26, 2023 were 395. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs; however, we are vigorously defending ourselves in all these matters.
A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.
Cordis IVC Filter Matters
We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle 2,798 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits.
Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in

 33
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
the product liability lawsuits. We intend to vigorously defend ourselves against these claims.
We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At December 31, 2023, we had a total of $300 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $31 million and $71 million during the three and six months ended December 31, 2023, respectively, and $66 million during the three and six months ended December 31, 2022.
7. Income Taxes
Fluctuations in our provision for income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three and six months ended December 31, 2023, the effective tax rate was 27.7 percent and 22.4 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2023.
During the three and six months ended December 31, 2022, the effective tax rate was 5.4 percent and 30.0 percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2022.
Tax Effects of Goodwill Impairment Charge
During the six months ended December 31, 2023, we recognized a $581 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to these charges is $45 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the six months ended December 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the six months ended December 31, 2023 resulted in recognizing an incremental interim tax benefit of approximately $65 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended December 31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at December 31, 2023. This interim tax benefit will reverse in future quarters of fiscal 2024.
Unrecognized Tax Benefits
We had $959 million and $1.0 billion of unrecognized tax benefits at December 31, 2023 and June 30, 2023, respectively. The December 31, 2023 and June 30, 2023 balances include $864 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At December 31, 2023 and June 30, 2023, we had $52 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $30 million, exclusive of penalties and interest.

 34
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. As a result, the indemnification receivable was reduced. The indemnification receivable was $20 million and $82 million at December 31, 2023 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.

8. Fair Value Measurements
Assets and Liabilities Measured on a Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
December 31, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,708 $— $— $1,708 
Other investments (1)102 — — 102 
Liabilities:
Forward contracts (2)— (73)— (73)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
Assets Measured on a Nonrecurring Basis
As discussed further in Note 2, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment during the six months ended December 31, 2023.


 35
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative
instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December 31, 2023 and 2022, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the six months ended December 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million each. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains and losses recognized in other comprehensive income/(loss) were immaterial and a $2 million loss for the three months ended December 31, 2023 and 2022, respectively, and a $1 million gain and a $2 million gain for the six months ended December 31, 2023 and 2022, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $1 million and immaterial for the three months ended December 31, 2023 and 2022, respectively, and $2 million and immaterial for the six months ended December 31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
During the six months ended December 31, 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.
During the six months ended December 31, 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.

 36
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $16 million and $43 million during the three months ended December 31, 2023 and 2022, respectively, and $5 million and $21 million during the six months ended December 31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million during both the three months ended December 31, 2023 and 2022, and $7 million and $8 million during the six months ended December 31, 2023 and 2022, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $3 million gain during the three months ended December 31, 2023 and 2022, respectively, and an immaterial loss and a $3 million loss during the six months ended December 31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are the Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December 31, 2023 and June 30, 2023 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)December 31, 2023June 30, 2023
Estimated fair value$4,527 $4,417 
Carrying amount4,723 4,701 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
10. Shareholders' Deficit
We repurchased $750 million and $1.3 billion of our common shares, in the aggregate, through share repurchase programs during the six months ended December 31, 2023 and 2022, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.
During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.
During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.
During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.
During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial

 37
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements

delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(5)5 — 
Amounts reclassified to earnings— (4)(4)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $1 million
(5)1 (4)
Balance at December 31, 2023$(142)$(13)$(155)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(38)11 (27)
Amounts reclassified to earnings— (5)(5)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(38)6 (32)
Balance at December 31, 2022$(140)$(6)$(146)

11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.
The following tables reconcile the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:
Three Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic245 261 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted246 261 
Six Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic247 266 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted248 266 
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and six months ended December 31, 2023, respectively.
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million and 5 million for the three and six months ended December 31, 2022, respectively. For both the three and six months ended December 31, 2022, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.
12. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in

 38
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements


the United States through our Cardinal Health at-Home Solutions division.
In January 2024, we announced a change in our organizational structure and have re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other. The following indicates the changes in our reporting structure effective January 1, 2024:
•Pharmaceutical and Specialty Solutions segment: This reportable segment will comprise all businesses formerly within our Pharmaceutical segment except Nuclear and Precision Health Solutions.
•Global Medical Products and Distribution segment: This reportable segment will comprise all businesses formerly within our Medical segment except at-Home Solutions and OptiFreight Logistics.
•Other: This will consist of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics.
Revenue
The following tables present revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$53,190 $47,391 
Nuclear and Precision Health Solutions330 282 
Pharmaceutical segment revenue
53,520 47,673 
Medical Products and Distribution (2)
3,167 3,099 
Cardinal Health at-Home Solutions761 698 
Medical segment revenue
3,928 3,797 
  Total segment revenue57,448 51,470 
Corporate (3)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$103,872 $92,938 
Nuclear and Precision Health Solutions654 563 
Pharmaceutical segment revenue
104,526 93,501 
Medical Products and Distribution (2)
6,243 6,239 
Cardinal Health at-Home Solutions1,445 1,336 
Medical segment revenue
7,688 7,575 
  Total segment revenue112,214 101,076 
Corporate (3)(6)(4)
Total revenue$112,208 $101,072 

(1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(2)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following tables present revenue by geographic area:
Three Months Ended December 31,
(in millions)20232022
United States$56,241 $50,333 
International1,207 1,137 
  Total segment revenue57,448 51,470 
Corporate (1)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
United States$109,798 $98,810 
International2,416 2,266 
  Total segment revenue112,214 101,076 
Corporate (1)(6)(4)
Total revenue$112,208 $101,072 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation

 39
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements


methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income);
•state opioid assessment related to prior fiscal years;
•shareholder cooperation agreement costs;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in Note 4, we recognized cumulative pre-tax goodwill impairment charges of $581 million and $863 million during the six months ended December 31, 2023 and $709 million during the three months ended December 31, 2022;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $14 million and $5 million for the three months ended December 31, 2023 and 2022, respectively, and $20 million and $11 million for the six months ended December 31, 2023 and 2022, respectively.
The following tables present segment profit by reportable segment and Corporate:
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical
$518 $464 
Medical71 17 
Total segment profit589 481 
Corporate(107)(600)
Total operating earnings/(loss)$482 $(119)

Six Months Ended December 31,
(in millions)20232022
Pharmaceutical
$1,025 $895 
Medical142 9 
Total segment profit1,167 904 
Corporate(699)(886)
Total operating earnings/(loss)$468 $18 
The following table presents total assets for each reportable segment and Corporate at:
(in millions)December 31,
2023		June 30,
2023
Pharmaceutical$31,018 $28,077 
Medical
9,817 10,130 
Corporate 5,738 5,210 
Total assets$46,573 $43,417 


13. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following tables provide total share-based compensation expense by type of award:
Three Months Ended December 31,
(in millions)20232022
Restricted share unit expense$17 $15 
Performance share unit expense11 10 
Total share-based compensation
$28 $25 
Six Months Ended December 31,
(in millions)20232022
Restricted share unit expense$38 $32 
Performance share unit expense19 16 
Total share-based compensation
$57 $48 
The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended December 31, 2023 and 2022, respectively, and $8 million and $6 million for the six months ended December 31, 2023 and 2022, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.

 40
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Notes to Financial Statements

The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.69 
Vested(1.0)60.80 
Canceled and forfeited(0.1)69.55 
Nonvested at December 31, 20232.0 $69.44 
At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.6 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at December 31, 20231.4 $96.55 
At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $60 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.
14. Subsequent Events
On January 31, 2024, we announced that we had entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology. The acquisition will further expand our offering in key therapeutic areas by enhancing our downstream provider-focused analytics capabilities and service offerings and by accelerating our upstream data and research opportunities with biopharma manufacturers.
This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. We plan to fund the acquisition with available cash.


 41
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Exhibits
Exhibits
Exhibit
Number		Exhibit Description
3.1
3.2
10.1
31.1
31.2
32.1
99.1
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
* Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation S0-K under the Exchange Act. The company undertakes to furnish supplemental copies of any of the omitted schedules to the SEC upon request.
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.

 42
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Form 10-Q Cross Reference Index


Form 10-Q Cross Reference Index
N/ANot applicable



 43
Cardinal Health | Q2 Fiscal 2024 Form 10-Q


Additional Information
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cardinal Health, Inc.
Date:February 1, 2024/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 44
Cardinal Health | Q2 Fiscal 2024 Form 10-Q

 EX-10.1 2 a24q2_10qx123123xexhibit101.htm EX-10.1 Document
Exhibit 10.1
MUFG Bank, Ltd., as Agent and a Financial Institution
1221 Avenue of the Americas
New York, NY 10020
Attention: Rudy Liu
PNC Bank, National Association, as the LC Bank and as a Financial Institution
The Tower at PNC Plaza
300 Fifth Avenue, 11th Floor
Pittsburgh, PA 15222
Attention: Brian Stanley
The Bank of Nova Scotia, as a Financial Institution
250 Vesey Street, 24th Floor
New York, NY 10281
Attention: Gig Morris
Wells Fargo Bank, N.A., as a Managing Agent
1100 Abernathy Road NE – 16th Floor
Suite 1600
Atlanta, GA 30328-5657
Attention: Bria Brown
Bank of America, National Association, as a Financial Institution
13510 Ballantyne Corporate Place
Charlotte, NC 28277
Attention: Chris Haynes and Ross Glynn

October 23, 2023
Re: Consent to Amendment to Performance Guaranty
Ladies and Gentlemen:
Reference is hereby made to (i) the Performance Guaranty, dated as of September 1, 2023 (the “CH 23 Guaranty”) executed by Cardinal Health, Inc., an Ohio corporation (the “Performance Guarantor”) in favor of Cardinal Health 23 Funding, LLC, a Nevada limited liability company and (ii) the Seventh Amended and Restated Performance Guaranty, dated as of November 14, 2016 (the “CH Funding Guaranty,” together with the CH 23 Guaranty, the “Guaranties,” and each, a “Guaranty”) executed by the Performance Guarantor in favor of Cardinal Health Funding, LLC, a Nevada limited liability company. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Guaranties.
Section 7 of each Guaranty requires that the Performance Guarantor comply at all times with Section 6.12 of the Credit Agreement, without giving effect to any amendment, modification or waiver thereof (or any amendment or modification of any defined term in the Credit Agreement that would directly or indirectly change the covenants set forth in such Section 6.12), unless such amendment, modification or waiver is consented to in writing by the Agent, the Required Financial Institutions and all LC Banks (in each case, in their capacities as such under the Receivables Purchase Agreement) (collectively, the “Consenting Parties”).
Effective as of February 27, 2023, Section 6.12 of the Credit Agreement was amended and restated to read as set forth on Exhibit A, attached hereto (the “Credit Agreement Amendment and Restatement”). The full text of the Credit Agreement Amendment and Restatement is available as Exhibit 10.1 to the Current Report on Form 8-K publicly filed by the Performance Guarantor on March 2, 2023.
If you consent to updating Section 7 of each Guaranty to refer to the Credit Agreement, as amended and restated as of February 27, 2023, please so indicate by executing where indicated, below, and delivering this signed letter to us at your earliest convenience. Upon receipt of the consent of the Consenting Parties, Section 7 of each Guaranty shall be deemed to refer to the Credit Agreement as amended and restated as of February 27, 2023.
If you have any questions or would like to discuss, please feel free to reach out to Scott Zimmerman at (###) ###-####, Jeff Cui at (###) ###-#### or Jeremy Sell at (###) ###-####.


Very truly yours,
CARDINAL HEALTH, INC.,
as Performance Guarantor
By: /s/ Scott Zimmerman    
Name: Scott Zimmerman
Title: Treasurer



WELLS FARGO BANK, N.A.,
as a Financial Institution and as Managing Agent for WF’s Purchaser Group
By:     /s/ Ryan Tozier    
Name: Ryan Tozier
Title: Managing Director

S-2


PNC BANK, NATIONAL ASSOCIATION,
as a Financial Institution and as Managing Agent for PNC’s Purchaser Group
By: /s/ Michael Brown    
Name: Michael Brown
Title: Executive Vice President
PNC BANK, NATIONAL ASSOCIATION,
as an LC Bank
By: /s/ Michael Brown    
Name: Michael Brown
Title: Executive Vice President

S-3


VICTORY RECEIVABLES CORPORATION,
as a Conduit
By: /s/ Kevin J. Corrigan    
Name: Kevin J. Corrigan
Title: Vice President
MUFG BANK, LTD.,
as Related Financial Institution for Victory


By: /s/ Helen Ellis    
Name: Helen Ellis
Title: Managing Director
MUFG BANK, LTD.,
as Managing Agent for Victory’s Purchaser Group
By: /s/ Helen Ellis    
Name: Helen Ellis
Title: Managing Director
MUFG BANK, LTD.,
as Agent
By: /s/ Helen Ellis    
Name: Helen Ellis
Title: Managing Director

S-4


LIBERTY STREET FUNDING LLC,
as a Conduit
By: /s/ Kevin J. Corrigan    
Name: Kevin J. Corrigan
Title: Vice President
THE BANK OF NOVA SCOTIA,
as Related Financial Institution for Liberty Street and as Managing Agent for Liberty Street’s Purchaser Group
By: /s/ Doug Noe    
Name: Doug Noe
Title: Managing Director

S-5


BANK OF AMERICA, NATIONAL ASSOCIATION,
as a Managing Agent and a Financial Institution

By: /s/ Ross Glynn    
Name:    Ross Glynn
Title: Vice President
S-6


EXHIBIT A
THIRD AMENDED AND RESTATED FIVE-YEAR CREDIT
AGREEMENT


6.12    Consolidated Net Leverage Ratio.

The Company shall not permit the Consolidated Net Leverage Ratio as of the last day of any fiscal quarter of the Company (each such date, a “Test Date”) to be greater than 3.75 to 1.00; provided that if a Material Acquisition is consummated, then, upon written notice by the Company given to the Administrative Agent in the applicable Compliance Certificate, solely for the first four Test Dates occurring on or after the date such Material Acquisition is consummated, in lieu of the foregoing, the Company shall not permit the Consolidated Net Leverage Ratio on any such Test Date to be greater than 4.25 to 1.00 (each such period, a “Leverage Holiday”); and provided, further, if the Company requests a Leverage Holiday, then the Company shall not be permitted to request a subsequent Leverage Holiday until at least one full fiscal quarter has transpired thereafter where no Leverage Holiday was in effect at any time during such fiscal quarter.

A-7

 EX-31.1 3 a24q2_10qx123123xexhibit311.htm EX-31.1 Document
Exhibit 31.1

I, Jason M. Hollar, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 1, 2024
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer


 EX-31.2 4 a24q2_10qx123123xexhibit312.htm EX-31.2 Document
Exhibit 31.2

I, Aaron E. Alt, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 1, 2024
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 EX-32.1 5 a24q2_10qx123123xexhibit321.htm EX-32.1 Document
Exhibit 32.1

Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and Aaron E. Alt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:
(1)the Periodic Report on Form 10-Q for the quarter ended December 31, 2023 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 1, 2024
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 EX-99.1 6 a24q2_10qx123123xexhibit991.htm EX-99.1 Document
Exhibit 99.1



Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended June 30, 2023 (the “2023 Form 10-K”), our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
•competitive pressures in the markets in which we operate, including pricing pressures;
•uncertainties relating to the pricing of and demand for generic pharmaceuticals;
•significantly increased costs for commodities and other materials used in the Global Medical Products and Distribution segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases;
•uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program;
•changes in the timing or frequency of the introduction of branded pharmaceuticals;
•uncertainties related to the timing, magnitude and profit impact of the distribution of recently commercially available COVID-19 vaccines;
•material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;
•any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;
•continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the U.S. Department of Justice which concerns our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances;
•risks associated with the national opioid settlement agreement, including the risk that the maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us;
•uncertainties related to Cardinal Health Brand products, including our ability to manage cost and infrastructure, retain margin, increase volume and improve performance;
•risks arising from acquisitions, including possible liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
•risks associated with the tax benefit from our self-insurance loss claims, including, certain state courts' interpretation of laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position;
•disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;
•risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties;
•our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;
•our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
•costs or claims resulting from quality issues, or other potential or alleged errors or defects in our manufacturing or sourcing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits;
•actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;


•shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;
•the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
•uncertainties with respect to certain business process initiatives, including IT infrastructure activities and outsourcing relationships, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;
•difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities;
•manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce ethylene oxide ("EtO") emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
•risks associated with industry reliance on EtO to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread;
•the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;
•risks arising from possible violations of healthcare fraud and abuse laws;
•risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
•risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
•risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;
•risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers;
•risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;
•changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
•unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix;
•risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;
•uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;
•reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;
•changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
•changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;
•uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions;
•changes in hospital buying groups or hospital buying practices;
•changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;
•changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;


•continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;
•risks to our business and information and controls systems in the event that business process improvements, infrastructure modernization or initiatives to use third-party service providers for key systems and processes are not effectively implemented;
•the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers;
•the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;
•the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent;
•losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;
•risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience additional supply disruptions as a result of the Uyghur Forced Labor Prevention Act or other similar regulations;
•our ability to maintain adequate intellectual property protections;
•our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;
•bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
•risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;
•uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;
•risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;
•our ability to introduce and market new products and our ability to keep pace with advances in technology;
•significant charges to earnings if goodwill or intangible assets become impaired;
•uncertainties relating to general political, business, industry, regulatory and market conditions;
•certain risks arising from the ongoing COVID-19 pandemic; and
•other factors described in the “Risk Factors” section of the 2023 Form 10-K.
The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.

 EX-101.SCH 7 cah-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Discontinued Operations and Disposal Groups (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Discontinued Operations and Disposal Groups (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Restructuring and Employee Severance Narative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Shareholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Share-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cah-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 cah-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 cah-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Derivative Liability, Notional Amount Derivative Liability, Notional Amount Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Proceeds from net investment hedge terminations Proceeds from Hedge, Investing Activities Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Pharmaceutical Pharmaceutical Member Pharmaceutical [Member] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Share Units Performance Share Unit Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Discontinued Operations and Disposal Groups [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Loss Contingency, Pending Claims, Number Loss Contingency, Pending Claims, Number Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Vesting Period in years for Shares Vesting Period in years for Shares Vesting Period in years for Shares Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Product Liability Lawsuits Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Shareholders' Equity Equity [Text Block] Income Taxes Tax Credit Carryforward [Table] Deferred income taxes and other liabilities Deferred Tax and Other Liabilities, Noncurrent Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] WEST VIRGINIA WEST VIRGINIA Reporting Unit [Domain] Reporting Unit [Domain] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Authorized—500 thousand shares, Issued—none Preferred Stock, Value, Issued Weighted-Average Grant Date Fair Value per Share Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds from divestitures, net of cash sold Proceeds from Divestiture of Businesses Maturity Date Maturity Date [Axis] Maturity Date Fair Value Measurements, Recurring and Nonrecurring Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Dividends on common shares Payments of Ordinary Dividends, Common Stock PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Common shares in treasury, at cost: 83 million shares and 76 million shares at December 31, 2023 and June 30, 2023, respectively Treasury, balance at beginning of period Treasury, balance at end of period Treasury Stock, Value Goodwill [Roll Forward] Goodwill [Roll Forward] Outcomes divestiture [Axis] Outcomes divestiture [Axis] Outcomes divestiture Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Common shares in treasury Treasury, balance at beginning of period (in shares) Treasury, balance at end of period (in shares) Treasury Stock, Common, Shares June 2027 June 2027 [Member] June 2027 Estimated Litigation Liability Estimated Litigation Liability Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Other investments Investments, Fair Value Disclosure Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Net earnings/(loss) attributable to Cardinal Health, Inc. Net Income (Loss) Attributable to Parent Net Income (Loss) Total current liabilities Liabilities, Current Derivative, Name [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Gross Intangible, Total other intangible assets Intangible Assets, Gross (Excluding Goodwill) Liabilities and Shareholders’ Deficit Liabilities and Equity [Abstract] Committed Receivables Sales Facility Program [Member] Committed Receivables Sales Facility Program [Member] Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Shareholders’ deficit: Equity, Attributable to Parent [Abstract] Project costs on investment and other spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. Medical Medical Member Medical [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Increase in trade receivables Increase (Decrease) in Receivables September 2025 September 2025 [Member] September 2025 Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Cost of products sold Cost of Goods and Services Sold Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Restricted Share Units Performance Share Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Indemnification Receivable Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name $1 billion share repurchase program $1 billion share repurchase program [Member] $1 billion share repurchase program Net tax proceeds from share-based compensation Net proceeds/(tax withholdings) from share-based compensation The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Beginning balance Ending balance Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Plaintiff Type [Domain] Plaintiff Type [Domain] [Domain] for Plaintiff Type [Axis] Forward Contract Derivative Assets (Liabilities), at Fair Value, Net Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Estimated annual amortization of intangible assets - Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast [Member] Forecast [Member] Cash dividends declared per common share Common Stock, Dividends, Per Share, Declared Measurement Frequency [Axis] Measurement Frequency [Axis] Restricted Share Units Restricted Share Unit Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Settling U.S Territories Settling U.S Territories Settling U.S Territories Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Goodwill and other intangibles, net Intangible Assets, Net (Including Goodwill) Employee stock options, restricted share units, and performance share units (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Proceeds from investments Proceeds from sale of available-for-sale securities and other investments The cash inflow from sales of available-for-sale securities and other investments. Revenue Total revenue Revenues Outcomes divestiture [Domain] Outcomes divestiture [Domain] Outcomes divestiture [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Increase in inventories Increase (Decrease) in Inventories Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common shares, without par value: Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Beginning Balance Ending Balance Restructuring Reserve Award Type [Axis] Award Type [Axis] Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. Interest expense, net Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Income As A Result Of Prepayments Income As A Result Of Prepayments Income as a result of prepayments at a pre-negotiated discount certain future payment amounts Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Estimated annual amortization of intangible assets - Remainder of Fiscal Year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Loss Contingencies Loss Contingencies [Table] Schedule of Transactions Related to Restricted Share Units Under the Plans Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Accounts Payable Accounts Payable Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Net Intangible Finite-Lived Intangible Assets, Net Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Restatement Determination Date Restatement Determination Date Fiscal 2022 [Member] Fiscal 2022 [Member] Fiscal 2022 Agreements [Axis] Agreements [Axis] Agreement Award Date [Domain] Award Date [Domain] Treasury shares acquired, average price per share (in usd per share) Shares Acquired, Average Cost Per Share Goodwill Impairment [Axis] Goodwill Impairment [Axis] Goodwill Impairment Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Derivative Asset, Notional Amount Derivative Asset, Notional Amount Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and equivalents at beginning of period Cash and equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Estimated fair value Debt Instrument, Fair Value Disclosure Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common shares, issued Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Gross margin Gross Profit Employee-related costs Severance Costs Current portion of long-term obligations and other short-term borrowings Long-Term Debt and Lease Obligation, Current Security Exchange Name Security Exchange Name Distribution, selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Target performance goal (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Employee Stock Option Employee Stock Option [Member] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Total comprehensive income attributable to Cardinal Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary of Restructuring and Employee Severance Restructuring and Related Costs [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Reclassification out of Accumulated Other Comprehensive Loss [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Tabular List, Table Tabular List [Table Text Block] Currency Swap [Member] Currency Swap [Member] Entity Address, Address Line One Entity Address, Address Line One Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Subsequent Event [Table] Subsequent Event [Table] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Outcomes Divestiture [Member] Outcomes Divestiture [Member] Outcomes Divestiture Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Short Term Credit Facilities Member Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Subsequent Event Subsequent Event [Member] Equity Method Investments, Fair Value Disclosure Equity Method Investments, Fair Value Disclosure Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Derivative [Table] Derivative [Table] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Preferred shares, without par value: Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Income Statement [Abstract] Income Statement [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Long-Term Obligations and Other Short-Term Borrowings [Abstract] Long-Term Obligations and Other Short-Term Borrowings [Abstract] Long-Term Obligations and Other Short-Term Borrowings [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Stockholders' Equity, Other Shares Stockholders' Equity, Other Shares Net Intangible Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Nonvested at beginning of period (in usd per share) Nonvested at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Taxes Tax Credit Carryforward [Line Items] Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Prepaid expenses and other Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Trademarks, trade names and patents Trademarks And Patents Member The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation Gain (Loss) Change in Discount Rate, Fair Value Input Change in Discount Rate, Fair Value Input Change in Discount Rate, Fair Value Input Debt, Long-Term and Short-Term, Combined Amount Debt, Long-Term and Short-Term, Combined Amount Inventories, net Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Net Operating Loss Carryback [Domain] CARES Act [Domain] CARES Act Insurance Recoveries Insurance Recoveries Disposal Groups, Including Discontinued Operations, Disclosure Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Entity Interactive Data Current Entity Interactive Data Current Total Shareholder Return Amount Total Shareholder Return Amount Purchase of treasury shares Purchase of treasury shares Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Trademarks and patents IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Segments [Domain] Segments [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Transaction Data System Investment Transaction Data System Investment [Member] Transaction Data System Investment Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Litigation (recoveries)/charges, net Gain (Loss) Related to Litigation Settlement Name Outstanding Recovery, Individual Name Nuclear Precision Health Services [Member] Nuclear Precision Health Solutions [Member] Nuclear Precision Health Solutions Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Assets held for sale Disposal Group, Including Discontinued Operation, Assets Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fiscal 2023 [Member] Fiscal 2023 [Member] Fiscal 2023 Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Basic (in shares) Income (Loss) from Continuing Operations, Per Basic Share Estimated annual amortization of intangible assets - Year One Finite-Lived Intangible Asset, Expected Amortization, Year One Medical distribution and products [Member] Medical distribution and products [Member] Medical distribution and products [Member] Schedule of Total Share-based Compensation Expense by Type of Award Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Dividends Dividends Earnings/(Loss) per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Basic [Abstract] PEO PEO [Member] Loss Contingency, Estimate of Possible Loss Loss Contingency, Estimate of Possible Loss Other Stockholders' Equity, Other Medical Unit Goodwill Impairment [Member] Medical Unit Goodwill Impairment [Member] Medical Unit Goodwill Impairment Settling States Settling States Settling States AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Other Short-term Borrowings Other Short-Term Borrowings Estimated Litigation Liability, Current Estimated Litigation Liability, Current Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Interest Rate Swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Litigation Settlement, Expense Litigation Settlement, Expense Liabilities related to assets held for sale Disposal Group, Including Discontinued Operation, Liabilities Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Credit Facility [Axis] Credit Facility [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Income/(Loss) AOCI Attributable to Parent AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency Accrual, Period Increase (Decrease) Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Lawsuit Type [Domain] Lawsuit Type [Domain] [Domain] for Lawsuit Type [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Assets and Liabilities Held for Sale [Table] Disposal Groups, Including Discontinued Operations [Table] Opioid Litigation [Domain] Opioid Litigation [Domain] Opioid Litigation [Domain] Fiscal 2024 [Member] Fiscal 2024 [Member] Fiscal 2024 ALABAMA ALABAMA $500 million share repurchase program $500 million share repurchase program [Member] $500 million share repurchase program Date Initiated [Domain] Date Initiated [Domain] Date Initiated [Domain] Tax benefit related to share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Number of reportable segments Number of Reportable Segments January 2023 January 2023 [Member] January 2023 CareFusion [Member] CareFusion [Member] CareFusion [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Goodwill Impairment [Domain] Goodwill Impairment [Domain] Goodwill Impairment [Domain] Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Authorized—755 million shares, Issued—327 million shares at December 31, 2023 and June 30, 2023 Common Stock, Value, Issued GEORGIA GEORGIA Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Shares that would be antidilutive as a result of net loss Shares that would be antidilutive as a result of net loss Shares that would be antidilutive as a result of net loss All Individuals All Individuals [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Litigation Case [Domain] Litigation Case [Domain] Other (income)/expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Medical Unit Medical Unit [Member] Medical Unit Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Unrecognized tax benefits Unrecognized Tax Benefits PEO Name PEO Name Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred shares, authorized Preferred Stock, Shares Authorized Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Goodwill by Reportable Segment Schedule of Goodwill [Table Text Block] Long-term Purchase Commitment, Period Long-Term Purchase Commitment, Period Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Maturity Date [Domain] Maturity Date [Domain] Maturity Date [Domain] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] Other accrued liabilities Other Accrued Liabilities, Current Corporate Corporate, Non-Segment [Member] Other accrued liabilities and operating items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Depreciation and amortization Depreciation, Depletion and Amortization Impairments and (gain)/loss on disposal of assets, net Gain (Loss) on Sale of Assets and Asset Impairment Charges Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Total Cardinal Health, Inc. shareholders' deficit Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Commercial Paper [Member] Commercial Paper [Member] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Goodwill impairment Goodwill, Impairment Loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Reporting Unit [Axis] Reporting Unit [Axis] Subsegments [Axis] Subsegments [Axis] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Events [Abstract] Long-term obligations, less current portion Long-Term Debt and Lease Obligation Earnings/(loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Restructuring and Employee Severance Restructuring and Related Activities Disclosure [Text Block] Preferred shares, issued Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Level 2 Fair Value, Inputs, Level 2 [Member] Effective Date [Axis] Date Initiated [Axis] Date Initiated Net Investment Hedging [Member] Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Net Intangible, Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Total Opioid Litigation [Member] Total Opioid Litigation [Member] Total Opioid Litigation Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Share-based compensation Share-Based Payment Arrangement, Noncash Expense Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Common Stock Common Stock [Member] Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Axis] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Earnings Per Share [Text Block] Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total shareholders’ deficit Balance at beginning of period Balance at end of period Equity, Including Portion Attributable to Noncontrolling Interest Product Liability Accrual, Period Expense Product Liability Accrual, Period Expense Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Trade receivables, net Receivables, Net, Current Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Total other comprehensive income/(loss), net of tax Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Liabilities: Liabilities [Abstract] Net earnings/(loss) Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments, Contingent Liabilities and Litigation Commitments and Contingencies Disclosure [Text Block] Diluted (in shares) Income (Loss) from Continuing Operations, Per Diluted Share Developed technology and other Developed Technology Rights [Member] Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Segment Profit by Reportable Segment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total liabilities and shareholders’ deficit Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Net unrealized gain on derivative instruments, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Additions Restructuring Costs Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Arrangement Duration Trading Arrangement Duration Net Operating Loss Carryback [Axis] Net Operating Loss Carryback [Axis] Net Operating Loss Carryback Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] CVS Health CVS Health [Member] CVS Health [Member] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act Restructuring and employee severance Total restructuring and employee severance Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Purchase of noncontrolling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Termination Date Trading Arrangement Termination Date Increase in accounts payable Increase (Decrease) in Accounts Payable Common shares, authorized Common Stock, Shares Authorized Other Agreements [Member] Other Agreements [Member] Other Agreements Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Canceled and forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Agreements [Domain] Agreements [Domain] Agreements [Domain] Loss Contingency, Number of Plaintiffs Loss Contingency, Number of Plaintiffs Estimated annual amortization of intangible assets - Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Axis] Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Restructuring Charges [Abstract] Restructuring Charges [Abstract] Estimated annual amortization of intangible assets - Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Narative [Abstract] Narative [Abstract] Narative [Abstract] Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Employee- Related Costs Employee Severance [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Payments and other adjustments Payments for Restructuring Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Reduction of long-term obligations Repayments of Long-Term Debt Treasury Stock, Common Treasury Shares Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Native American tribes Native American tribes [Member] Native American tribes Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Loss Contingency Accrual Loss Contingency Accrual Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Total share-based compensation Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Gross Intangible Finite-Lived Intangible Assets, Gross Provision for/(benefit from) income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit) Non-US [Member] Non-US [Member] Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Axis] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Alameda County [Member] Alameda County [Member] Alameda County [Member] Private Parties [Member] Private Parties [Member] Private Parties [Member] Fair Value Disclosures Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Award Date [Axis] Award Date [Axis] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Payments for Legal Settlements Payments for Legal Settlements Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Equity [Abstract] Equity [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Fair Value Hedging Fair Value Hedging [Member] Cash and equivalents Cash and Cash Equivalents, at Carrying Value Opioid Litigation [Axis] Opioid Litigation [Axis] Opioid Litigation Total comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Assets: Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Aggregate Annual Assessment Aggregate Annual Assessment Aggregate Annual Assessment Treasury shares acquired (in shares) Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Purchases of investments Purchase of available-for-sale securities and other investments The cash outflow from purchases of available-for-sale securities and other investments. Diluted (in shares) Weighted-average common shares–diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Interest Income (Expense), Nonoperating, Net Interest Income (Expense), Nonoperating, Net Operating expenses: Operating Expenses [Abstract] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Total assets Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Segment Revenue from External Customers by Geographic Area [Line Items] Segment Revenue from External Customers by Geographic Area [Line Items] [Line Items] for Segment Revenue from External Customers by Geographic Area [Table] UNITED STATES UNITED STATES Recurring Fair Value, Recurring [Member] IVC April 2023 Agreement IVC April 2023 Agreement [Member] IVC April 2023 Agreement Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Segment Information Segment Reporting Disclosure [Text Block] Net increase/(decrease) in cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Scenario [Axis] Scenario [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average common shares–basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating earnings/(loss) Total operating earnings Operating Income (Loss) Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Facility Exit and Other Costs Facility Closing [Member] $250 million share repurchase program [Member] $250 million share repurchase program [Member] $250 million share repurchase program Tax Matters Agreement [Domain] Tax Matters Agreement [Domain] [Domain] for Tax Matters Agreement [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Operating and Reportable Segment Segments [Axis] Segments [Axis] Statement of Stockholders' Equity Statement [Line Items] Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Schedule of Transactions Related to Performance Share Units Under the Plans Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Scenario [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Type of Restructuring [Domain] Type of Restructuring [Domain] Noncontrolling Interest Noncontrolling Interest [Member] EX-101.PRE 11 cah-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 cah-20231231_g1.jpg begin 644 cah-20231231_g1.jpg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end GRAPHIC 13 cah-20231231_g2.jpg begin 644 cah-20231231_g2.jpg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end GRAPHIC 14 cah-20231231_g3.jpg begin 644 cah-20231231_g3.jpg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end GRAPHIC 15 cah-20231231_g4.jpg begin 644 cah-20231231_g4.jpg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æ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end GRAPHIC 16 cah-20231231_g5.jpg begin 644 cah-20231231_g5.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@! MX (4 P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP+_ (*L MZCJ&C_\ !+[]H[5M)OYK6ZM?@3XMEMKFVE*20R+HUT5=67!5@0"".017OM?/ MG_!6K_E%=^TK_P!D#\8?^F6[H _GL_X)(?\ !#?]L/\ X*O_ +)=Y^U5X*_X M*0:OX,-IXKO-$AT34DU"Z+R6\5O)YIGCNUVAO/ P$)&W/.:^PO\ @V=_;!_; M:^#'_!0SXN_\$<_VS?BGJ7C%?!UCJ-QHMYJFL2Z@=-OM/NX8)H[:>;]X;2>* M;SE1L!3$I"(9) ?BW_@C3^VC_P %]?@5^QW>?#3_ ()F?LAP>,_A_<^,+VX? MQ(W@F74'AU.2&W6:,3"X2,;46$[60@;LG(-?HW_P;E_\$AOVX/@;^U!\2_\ M@I]_P4JM'TWXC^/K.[M--T2]O+>:]D>]NH[J]U"Y%LQBMRS11QQPJ?BA^VW\5OVQ_VD[?P_X5TCQKH-M::EXQ\0.88I)+SQ M!B"!9&):1A'Q'&"Q$?0A>/VJ_9A_:_\ V8OVT? $GQ1_96^-_A_QSH4%V;6Z MO="O1(;:< $Q31G#POM(8*ZJ2K @8(-?SV_\&\/_ 3!_98_X**?MS_M0:Y^ MUQX%?Q;X=\!:^HL/#$VJ7-M:S7M]?ZD%N91;R1M(T4=K,J MM'GL<$@$>Y_\ M&V'@/3?V5_\ @NI^V/\ L9_"Z[N[;P-H4&JII>ES73R[(M/UZ."RWLQ)D>." M[D3>V2=Q)ZF@#]5_VB_^"OG_ 3-_9,^(\WP@_:$_;/\%>'/%%J%^W:%+?-< M7-F6 95G2!7,#%2&"R;3@@XP0:]2\/\ [4_[.'BS]G^X_:K\*?&[PUJGPWM= M&N-5N?&NG:M'/IT5G;JS3S-,A*J(PC[P>4*," 017\_OQC^&W_!M9^R%\8OB MWX ^-OC'XH?M@?%SQCXAN@8/#]I/+?:1J,C2&>-+NUEM;6XN&N'9WE3S2A3: M$!#JT_\ P0-\4Z[?_P#!NS^WKX/N]0EDT[3?"WB*YLK=W)6*2?PU*LI4=MP@ MCS]* /VGN?\ @L+_ ,$O[1?!KS_MQ_#[;\09Y(?"$BZVK+J!2X:V9@0"(T\] M7BWR;4+HR@DJ<;&L_P#!47_@GAX=C\?2Z]^V-X"LQ\+=0-A\0!8'GSC-#+&(URS,A !-?C5_P:\_\ !%+]DK]K3]F'2/V]_P!HZTU[6/%G MA?XM(W@6VAUEHK&PM]+EMKI$>#!699;IYO,5L@KC;M9F8\1_P3#_ ."=W[.W M_!1#_@X(_;%\*?M6>%Y_$O@SPA\1_&&L#PH=2GMK:_U%O$EQ;V\L_D.C.L4< MMR0N1\SC)V[E8 _//V>=8_:N\+?MB>!;GX>^'[L6NM^)GUI M(HK&X;[D$J2;9$E?(V1E=\F1M#9%=;^RQ^VE^RG^VYX+N_B#^R?\>/#WCK2K M"[^S:C/H=YO>SF(R$FB8"2$D!Y-;NDMKV2SU9;#34N6CD627R(+VU&.ZMI\$JP#QDCO MB[X0_: \9_$[]K_XM>,_$ESYNG:!:SRWVCZC(\K7$27EK+:VL]PT[DNZ>8T9 MCVA 0ZM2_P"" O[5OQ/_ &7O^"#O[;'Q(\!Z_=6M]X.G%UX5E#G.G:C?6 M! M65E*]P*^A+3QCX1O_"4?C^Q\4Z;-H4NG"_BUN*^C:T> MT*>8+@3 [#$4^??G;MYSBOP2_P""(W_!O?\ L0_M^_\ !'>Y_:!^.OA^]U#X MH_%.?7O[ \;S:S=A_#9 MO*^T0J,E_FCFDC*A?EH _5[X-_\ !7O_ ()C_M!_&%/@'\&?VW/ &O\ BZ>X M:WL='L]: -_*#CR[:1P([IC@D")G) )&1S7H'[27[:7[*7['L>AR_M0?'OPW MX&7Q-*^9'G_?%?RP_M@>./^"#-C_P3O\#:+^PI M'X\TG]I'P@^DW=_XPN+.^@_MF[PGVXN[S&*$+(3-"8D0IY*JI^9L_6O_ <6 M?'[Q!^U-_P $ZO\ @GM^T/XQF$FM>+M*FU#7)0H427S6>DBY< = 9A(0.P(H M _??]I+]J[]F_P#8]\#6OQ,_:A^,V@^!O#]]JT>F6FK>(;T002WCQ2RI K'J MYCAE8#TC;TK\R/\ @YW_ ."T/CG]CK]G3P;\+/V'_C_HFF>-/B1 E]J.H::P MDU6R\.SP.8+VS).(1.ZLBS[2R[24*-AA#_P>J,!_P2Q\! GD_'[2L#_N":Y7 MQU_P=)?LY?"'2?V&/V2?VKK#PRZ>.M9\"Z-X9U'6#?S%9=,MM)6YAA\DOY2E M99Y6WA0YW8)( /T&_X+*>)OV7/^"E'_!+OP?XE^&?_ 5!\%_"_P *Q?%* MQQ\4)M3F>RO+V#3K])-,$D$B,93YID()QB Y&<8^ZOA'XM^&GP _8R\'>*OB M)\;-#/A;PO\ #S2O[0\?ZGJ26UAG[5<:-JQE?S+F M21^2H^7=@=@*X'_@X#^(?COXJ?L\_P#!/C_@G3HGBNYTGP[\2O#7A^Y\2&!R M%N)7@TRQLV8=&$7VBY?:<@LR'JH- '['_LV_\%8_^";W[7OQ%;X1_LX?MC>" MO%/B?8[0:%::B8KFZ5 2Y@294-QM4%CY6["@L>.:[7]J7]MC]DS]B7PI9^-? MVK_V@/#/@33]1F:'37U[4!'+>NH!=8(1F28J&4ML5MH8$XR*_/+]H'_@T]_9 M)NO'/PH^)7_!/[XEZE\ O$?PZU2.\U'Q';)=ZY<:M) TSX*?\$:_#_[;W@#]K'_@JQ^UCXEU"?2O"XMM-^ 6EVLE MS'JUFAN-DJI9A9[2-KF1I&DEE59F@\O?A2H /T?_ &4/^"AG[$G[W26-G->R1NZPQ M,[)&N68 9P!W/M7\P_[&/[%W[2G_ =5_'#XM_M%_M%_M[R^"[+POK,(T3P8 MFG/J_P#9MO661PJHH&2Q)X YS7\_'[:O_!L3^T%:?M"^)/VR/^"(/[6&BQV]QK=SJ_\$'_ (<_\%8/^";? M_!33QI_P36_:"T+XC^._@4MG=+H'Q#NO#>HR>';&[CMX[RUN+6]F5X;99H6: M&2V64J+A@N2Z$M^IO[6/_!13]A_]AB33;;]K3]IKPMX'NM80R:7I^K7Q-W,-*8P05,FW:#QG/%?DM_P0_P#^"P__ 4O^&/_ 41M_\ @D/_ ,%; M]/U.\U_5;>:#P[J_B6VA&JZ9>Q6KW<4)&4D#XFTK M]KW_ ()G_'K_ (++?M$_M)?\%J+'Q-XI\.6_B#4-&^'7A?3K:[F@CBM[R2UM MUE^S2QNJP6L* *&"M),[D%AF@#^GWX'_ !Z^"O[2WPXL?B]^S]\4M"\8^&-2 MW"SUSP]J4=U;R,IPR;D)VNIX9#AE/! ->6_&S_@JC_P3G_9Q^-%O^SQ\<_VR M? ?ACQG1W5\&MY(RT\KWR89LA?*^4#<<@'[K_#']M#]E+XT?%CQ3\"OA1\?/ M#7B#QAX)5V\6>'M,U%9;G2@D@C8S*/N@.0OU->=7W_!8C_@EYIWPBZMX5_P#! MK!_P20_8^_X*-?##XQ>._P!L;P-=^+;+P]?6NC>%=(.M75K!ID]U;N]U>HL$ MB9G*QVRJQR%$?()VE0#]YO%/_!4G_@G=X+_9VTC]K'Q-^V)X%MOAYK]RUMHG MB;^VD>*^N%)#P1(F9'F3!WQ!2Z8.X+@UZ/\ ']HKX%_M4?#&Q^,_P"SG\5M M$\9>%M19UM-:T&^6>$NIP\;8Y213PR, RGJ!7\Y7_!K5_P $I?V5_P#@H:/C M7=?MG^$;SQEH'@":RTWPIX>DUN[MK2TO-06X%Y?*L$J$3^796J*V<8&2"40K MT/\ P0!_:4^(W[%__!,[_@H;K/@3Q%<>?\,K&TO/"3NF[= M;6K'U\D#M0!^W'Q3_P""P'_!,+X(_&B7]GKXK_MP?#[0_%]M=BUO])O=;4"Q MGSCRKF8 Q6S@]5E=2O<"O8/C!\?_ (*? #X17WQ\^,_Q.T?PYX+TR&WFOO$^ MI7BI9PQSRQPPN9!D;7DEC52."77UK^3_ /8X\8_\$$Y?^"=7C?P[^W';>.M3 M_:-\5_VK)!_"D2*, M4 ?M5\4/^"P__!+_ .#&F>%]7^)G[;_@'2X/&>F1:CX:+:OYK7EE(2([K;&& M:.%B& E<*AVM@\'''?\ !83_ (*<>%?V$_\ @F_XA_:E^#_Q4\'3^)M(? M">:_N5N[/7+F9HB'M_+<+<[;=WG7#%6$8)W+D'\F?@/_ ,$4?V,/'_\ P;/> M(OV[_B7X.U#6/C%F^,[K7;HR:7'IDDZ6=C#")/)\@6UHD;*Z,?WC M8(VQA*'@KX2^ ?VD_P#@SEF^('QCTJXU?6/@QXAU6X^'MX^I3Q_V;))K4<1) M5'"RJ(KR9 D@95!& -HP ?J#_P &[G_!0/1OVVO^">WA"V^(?[2-KXZ^,>F6 M^I7WQ*M9[Y9-0LFN-9OS;&>-0!$AA$8C10%5%55 50!]\5^7O_!J9^Q?^SI\ M(/\ @F?X*_:[^'_@:6R\?_%/2+R'QOK3:M+_P#@F=^T/X3\)Z%>:IJNI_ _Q7:: M;IFG6KSW%W<2:1=)'%%&@+2.S$*JJ"22 !DU[O10!^8/_!I-\)/BM\%O^"66 MH^#_ (Q_#+Q#X3U9OBOJ]PNE^)M%GL+DPM:V(6013HK;"58!L8)4^E?I]110 M!^+O_!J1\!_CC\&_VD_VRM5^+WP9\5^%;77?%FBR:)<^)/#MS8QZ@BWFO%F@ M:9%$H DC)*9 $B_WAG+_ ."6/[-G[16F?\'!7[)8=+>);=_*%NHN+DP%9-.1U^TK*DJQ. M)')=%(D'J'_!%#]FS]I;X,_\$?O^"@O[,OQ2_9X\;:)XME\&:JFD:;?^%KN- MM8E?1=0M?+LBT8%V?-AQ^ZW9\V/'WUS_ $*T4 ?FY_P:H_"OXG?!S_@DKI7@ MSXN?#C7O"NLKX\UN:32?$>CSV-R(VDCVN8IE5PI X.,'%>!?\$%O@/\ ''X< M_P#!=3]N/XA_$+X->*]!T#Q!XN\12:!KFL^';FUL]21_$\\J-;S2HJ3!HR'! M0D%2"..:_:"B@#\7_P#@C#\!_CCX#_X.-_VS?BCXX^#7BO1O#.NGQ'_8?B+5 M?#MS;V&H[_$-K(GD7$B".;<@+C8QRH)' K-_X)H_LY?M"Z5_PVZ7,$KH$NDAN88I&,98%60@X<&OWSHH _F8_9 M5_X*6?\ !7/_ () ?LG^,?\ @D9J7_!.7QAJ/C-;W5;3X>>++&WOQ+H\EZ6W MRVT=O;2)J:"9Y)X9(I4&Y^2X ^I_CE_P2$_X*;_ +8O_!N]IWP]_:H\?^)O M&_[0FC>-A\0-!\/^+-7^U:C;V:V[VBZ(T\A):8VTDMQM=BWGN(F88X_<"B@# M^=;P]_P6-_X*P_&'X-?#+]@_]D__ ()5:EX8^.N@W%AI7BWQ?K7@)+BWN[>V MB\AFFM;VR5+$2G9)--+(%BV-M(#Y3Z,_X.F?V"_VNOC?_P $]/@=\1/ G@YO M&OB[X0WF?'UKX%T-\,US9P+_91^/WQ9_X(R?LU>(/AS\*-?UF? MX?0:/_PENEZ=I4LUWIL,NB)$9I854NJ)+&L;DCY&D7..QL9#)';X\R6:UN;1"8 I?;-*<'9BOVSHH _GI\5?\ M%3_^"W__ 6P^+_PF_9M_9&_9P\??L[3:#K2S?$CQUH&IZA'9DE5CEGNGEMX M4AMHT\YULY&G:20HH+LJYN?\%7?#7Q\_X)X_\'$FC?\ !2GXF_L<>(OC=\+- M2T+3XO#J6NF->);S1:,FGN@D\J2.*\BN8WNT1U&_S=R%6.]/Z"J* /Y\?V;- M4_;U^.G_ /?AOX3\<:-=#0K6XT*ZNDT?3)-$U+2K/[ M?.L06VGDG42/'*(V59T.T(R,WMW_ 3?^!'QP\+?\'5W[3?QB\3_ :\5Z;X M1U;PCK$>E>*K_P .W,.FWKM=Z,56*Y=!%(2(W("L20C>AK]H** ,3XE> /#O MQ7^'.O\ PM\86[3:3XET2ZTK5(5."]M<0M#*H/;*.PK^;;]E[X^_\%9_^#7S MXL?$+]E[Q!^QGJ'Q0^&OB'Q U_HFHQ6-Y'87\ZIY4=_9WMO'*B-+ D(FMY%+ MKY48.PJ2W],E% 'X"_\ !)?X"_\ !0W_ (*S?\%I['_@L?\ MC? 2\^'/@OP M79,V@VEYI$]C#>.EG+:V5G9BY EN%0S/<2W&"A=&4%=ZHN#X_P!(_:>_X-X? M^"M7QG^/$O[">K?&;X&?&V]N=3TN[TG3VD2RDGNGNXHO/$$RP36\LUQ 8I I MEC99%/%?T,44 ?E[_P $/?'_ /P4G_;S;XO?&C]O/X#Z/\/O@[XMM[S3?ASX M.N/!$&F:K]FNY&WHLZPQ336L-OB(32IF=Y-ZG$9%? O[%$__ 7!_P"#?OXX M_$S]A/X&?\$_=9^,WA[QKXB^T^!_$$6A7TFER7(7R8=2%U;#RD1X1#]H@F>, MQF)1R.*_!SPE^P=_P '3/\ P2[^ M+GC3P7^PEX\A^-GP[UV81>'[[QIXXLKM;"V1Y#!(MKJ]Y";2Y"2%9!#OB<@9 MWA$V@'+?\&N?AGXQ>&O^"MG[8GAGX]ZI#J?CS3M+UBS\;7]DV^*ZUE=>*WO^#-GX%_&[X%_LU_&?2OC;\'/%7@ZZO_ !SI\MC;>*O# MUSI\EQ&MFP+QK<(A=0>"1D U[5_P;V?\$B?VD/V S\5?VI_VY/%NG:G\8OC3 MK"7FNVNFW27"Z?&)I[B5I9HP(WGGN+AW<1YC41Q[6.6 _2R@#\7_ /@SS^ _ MQQ^!_A/]HR'XT_!KQ7X0?5/%VC2:8GBCP[;M%CO\ "O]X5^^5% '\T/[*W[?7_!1;_@C_\ LK^+?^"6 MWCG_ ()3Z[KWQ0L-3U*#X7^-(O#+WL5O)=NQ\U(_L(V M"G/W'^V?\+/^"C'Q,_X->_B+H7[7?PTAU+XU>*QHU_)X/\"^#4AO(+;_ (2# M2VB@EM;%"'N5@B::78@V!BA \HFOU[HH _+K]GCX1?%C3/\ @T^U#X-:E\,/ M$5OXP;]G;Q19+X4GT6=-2-S(+_RX!:E/-\QMR[4V[CN&!R*^??V'OV.?VE/& M7_!I7\4?V9E^"?B>P\>W\NMW>G>$=5T.>UU&Z\C48+L)';RHLCO(D#!% R[$ M!M M3WFK75PUL8I;=%@DB$^-HDD9PA;"X(K]=Z** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "OFWQ-_P6(_X)7^#/$FH>#_ !9_P4"^ M%&G:KI-]+9ZEI]WXSM4EMKB)RDD3J7RK*RE2#T(-?25?S$_\$FO^"4W[*O\ MP56_X*D_M:^!/VJ$\2&Q\)^+]5O])/AS6!9N)I=;NHVWDQON&T# P.: /Z,/ M@!^V#^RC^U;;7EU^S+^TIX%\?KIP4ZDO@_Q5::B]GN^[YR02,T6>VX#->C5_ M,YXT_9"T/_@@_P#\')_[/?PB_8Y^+'B#4_#WC[4?#L6H:?K%Y'+=PZ?K&J2Z M7=V%R841)TQ']HCW("#Y1.6C$A_6C]L/_@X^_P"">_[#O[2_Q(_90^.6G^.X M/%/PTT&VU+4)++1;62TU1[BUL[F"SLG-T'DG=+Z(8>-$79*S.$0M0!]]T5\8 M?"G_ (+L?L2>.O\ @F\?^"H7Q!?Q'\/_ (??VM<:5;6?BK3XCJ.H7T3F/R+2 M*VEE%RSNKA=K#_5R,^Q8W8> ?LO_ /!W;_P2_P#VC?C;I_P9\0:!\0/AVFM7 MZVFD>)_&VF62::97;;&MQ);74K6VYB!O93&N./ACJ'QF\/?MT?#L^&-*U>UTK4]8O==6UCM;RYCGDMX)!.$97D2VN& M0$?,(),9VG'Y5_\ !Z+^W=\/;CP!X-_X)R:1%X@A\60:_IWCC5IQ;1KIL^FF MWU*TBB\P2^8THF.XH8PN &W$@"N,OM4_X-U/&_\ P0]M_B,OP*^./@OX=+\: M]#\/^,I_!+VAUS5_%EEX?N94N6%_=W$/V0PWMR24,;&1A\@ H _H)T?QIX1\ M0>#;7XB:+XEL;G0;[3$U&TUB.Y4VTMH\8E6<29V^68R'W9Q@YK1BECFC6:&1 M71U#(ZG(8'H0>]?SO_\ !T!_P4,\&>%?V./@'_P3O_9F\7_$'1M-U3X;Z#XF MU&*\DB@BU?PQ-9/;V%K>/!+F6<-;[Y8=GD[@K L0 O[0?\$ROV_O@G_P4F_9 M6T[]HSX!Z/XBL=!CU";1F@\46,-O<_:+9(Q(=D,TJ[#O&#NR><@4 ?05%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5_*'^Q)^QE_P %+_VRO^"F7[47AS_@ MFI^UQ!\)-:T7QSK%SXGU"?QKJNBC4+5]9NECB#Z=;S-+M<%MK@ 9R#FOZO*_ M*W_@AK_P2G_;&_86_P""A?[37[1'[0WA'2+#PQ\3M4NI_"5S8:]!=2SH^K7% MRI>.,EHOW4BGYNYQ0!P7_!+'_@V<_: ^!G[;^G_\%!O^"FG[65E\5/&_A^<7 MNB6EAJ>H:H;C41'Y<5W=W^H)'-+Y"\QQB/[ZQMO 38W@OC;]G;X5_M,_\'K' MBGP+\:?!.F^)/#VGV-AJ]UH6L6:7%I=RV_@FP: 2Q."LBK,8Y-I!!,8R",BO MZ":_+SP3_P $M_VO=$_X.DK\)-8\-Q6=CJJZ[";II5\-V5@0 M;;/F ?:()%R1T /0T ?)O_!TC\,O =M^U/\ L8_L%^&O"VF^#/A%K'BNZFO- M"\-V<>GV,O\ @ZE_86_9#\'?\$?9 M?'O@7X)>%?"VK_#'7=%@\%7&A:-!:20V\]S':2V0:-06B,4ID*'(W0*W5!M2U)WCMKE)UC%S92R M1@M")## ZR@-M>!01AF(_._QC_P2N_X.9?\ @JM/X)_94_X*=>/M)\)?"+PE MJD-UJGB'^U]&N+C4_*4Q?:?*TV226[NO*9PAN!$@+EF^8DD X3_@N/KU[\6? M^#6\&C:A''YDQ&]PXC64@G!9BV,F MOHO_ (.C? G@?P!_P09^$&G^!/!NE:);W?Q,\+W5U!I&G16R33MX>U(-*ZQJ M SD*H+'DX'/%>\?\'!'_ 2)^.7[8W_!/+X0?L<_L!^ =*EA^&GBFP^QZ7J6 MMQ6<=KI-KI5S91 22D!V&^(8ZGD^M;/_ 7K_P"":G[5G[?7_!+'X;_LJ_LW M^%]+U'QCX:\7:%J&JVFH:U#:0I!:Z3>VTQ660A6(EGC Z@D]J /@+_@Y[\( M^%(?^"1W[%_CF'PQIR:W/XRGUA;*,74ELF@0ND#2XWF-69F"$[06) R37 M[]?!;X=_#_X8_#;2_#7PU\#:/X>TTVLGBM M;73IM/D$>DI! MN';3V:$R;Q,3AF/(R>@ !]24444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 45\Y?M?_P#!2WX/?L@_M&?!C]E'6O".N^)_'/QN\2'3/#NC^'EA8V%LC(LV MH79DD7R[>/?DE0S,(Y2JG8U8^E?\%=?V8=7_ ."G^I?\$EK7PWXR'Q,TK35O MKG47TJV&CF,Z9%J0"S_:?-+>3,HP81\X(SCYB ?4M%%% !1110 444V:58(7 MG<':BECCT H =17QS^Q!_P %P/V0OV_/V;OBI^U)\%/"GCRS\.?""PFN_%%O MXBT:U@NYHXK.6[86Z174BR'RXF W.GS$#IR#X&?\%P/V0OV@O^"=_CO_ (*: M>"/"GCR'X??#R_N[37+#4=&M8]5DDMX[:20PPK=-&P(NH\;I5R0W3 R ?8U% M?',__!<#]D&W_P""7D/_ 5M?PIX\_X5E/?FT331HUK_ &SYG]J-IF3!]J\K M'GJ3_KON<]?EKZ&_96_:0\!?M@?LZ>#OVG?A=8ZG;>'O&^APZKI%OK5ND5W' M!(#M$J1NZJW'(#L/>@#T"BBB@ HHHH ***^7$+2A]/+^9YB7&(L@%-I\V)0VYP* M /HVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#\9?V0]?D_;M_P"#L_XS_&'7Y#=:)^SGX!N/#?A%'.X6 M=XC16$RCL-TMUJ[YZC)/V-X?V&_AO!XLM/#<=Q+\ M;H[4_P#"1W"'PU:W7E.^W&T1N+?K_JXU%>*_\&WBRVW_ 6=_P""A%GK^?[6 M_P"%CWY??]X@>(=5\P_3<4_,5D>!O^5WCQG_ -B9%_ZA=C0!W_Q5_P"#FG]H MWPG^W;\9_P!@/X1_L%M\1/&_A7Q'=Z#\+M)\+W-S)/K%S!,1)<7H"D1010(\ MK[.20!N1=TB=[_P1E_X+]_'S]MK]L?Q=_P $]_V\/V7K#X9?%'0;"ZO+"'28 MKJWC=K9D\^RGMKIY)(YA'()5D#E)$5SA?EW_ #S_ ,$:]'TZ^_X.M_VR-4N[ M5))K'1?%#6CNH)B9M>TI2R^AVEESZ,1WJ7PA;PVG_![UXG-M&$\_PBCRA1C< M?^$*M.3^0H _="OP\^'7_!TK^W9^T9J/C[X&?LG_ /!-!/'WQ5\/Z]<)I5AH M#WEWI]GI%L[QS7UZ%*N7:3RHTC5D!+GY\[$?]PZ_"O\ X,Y]*L)/V@OVT=;D MM4-U%XJT""*8K\R1O=Z^SJ#Z$HA/^Z/2@"Y\ /\ @ZU_; _:M^#)^$_[-?\ MP37N_&G[2EM>W+:GX>T2.ZET*STJ!4W:A(F[[0C>:X@^SM( &P?.RZQ'Z^_X M(/?\%LM;_P""MGPY^('A[XQ?!VR\%?$GX97=O%XDTG37F^QW<%QYXCECCG)E MA=9+>:.2)V?:0AW?/M7XQ_X-/- TE?\ @HE^VYK"V48N++Q-#:VL@49CADU? M5F=!Z F&/C_9'I4G_!LM%';?\%8?V];6W0)&GBJ]5(U& -=U( 8]A0!UO\ MP2-_;-^$O[97_!)3]LCQ%\)_V'OAQ\$(-$\#:Q;7FF?#FU,4.IN^@WC":8%1 MEU VCV)KY_\ ^"7_ /RJ%?M2_P#8TZ]_Z2:-1_P;)?\ *&K]NG_L5M2_]1V] MH_X)?_\ *H5^U+_V-.O?^DFC4 >G_LG_ !_\#_LQ?\&?7ACXR?$7]G/PG\5] M)T[Q%=QW'@CQM"9-.O3+XQN(E>10#DQLPD7C[R"OMKP[_P %8_V=/V)_^"&_ MPW_X* >.O@_I?A/1M4\'Z?'X2^%W@PB&"2_N%W_ (%0!]#Z'_P==?\ !2GX;P>'/VEOVI?^"51TCX!>+-12 M+2/$NF:=JEK++ ^2K07]R3:W3[ SHOEQ+-L;:RC++]Y?\%;/^"UEM^PS_P $ MX/A[_P %"_V7?!^A_$71OB)XITJQT==5NYK>%[&]TZ]O%F_=C)OV<;C_ (("_$S5M/O-&?P7J?@'2!X"^SLGD3,]Q:-IGV8# MK@B)EV]%4GH#7Y%?M@V/C.P_X,[/V:8_&:S*9/CS/+I:7&=XLF?Q.T77G:02 MR_[#+CC% 'U-^T3_ ,'4/_!0/X>Z#X?_ &K_ (;_ /!+UX_V=-4U&&PL_''B M^&_@D\02X/F/:W"$16J.R2B(O'-N$9));'8;_ .&NK>.M=@M;?5+CYH)[+RWD621& M$D&7A5WC98SM8$JP!U6@_P#!Q+_P55_92^/G@#PG_P %9/\ @F'9>!/ WQ&U M5;+2]<\+0W:W=HI9 TA1KBY6=XE=7>W_ '4NW) R-I[/_@[S\'Z_X(_9<^"W M[>/PSG^R^,?@M\9+*YT?4E'-M%&OB/\ \$&-:^(FG1R):^(M3\*ZCI"7*[9 )[N"901V;RF; M(^M 'Z.?!7XH:)\;_@WX2^-/AE2--\7^&;#6]/!;.(+NWCGCY[_+(*Z:OG;_ M ()#VVJVG_!*K]FZWUD,)U^!OA;(?JJ'2KB_\%RM:_P""QQ_:'@DMM7T5+ ?#[_A%V#Q%=$@TS?\ ;?M. M#S#YN/)'WMN>-Q]S_:N_X)T_ /\ :^^./PA_:/\ 'VH^(='\9_!3Q,=8\'ZW MX8OH;>23#7H/B]8ZG;Q^#4\+M;/I7VO4;2\#&Z-RXFV_9=F/*3._/&,$T MO_@C%J>G?\%RM2_X+'G]H>![:_T5; ?#[_A%F#H1HD6E[_MOVG!YC\W'D]]N M>-U?=M% !7PE_P $9?\ @C'J?_!)KQQ\;O&.H?M#P>.A\7]:TZ_CMX?"[:=_ M90M9=1?86-S-YV[[>!G"8\KH=W'W;10!\)?\$D_^",>I_P#!,+]H3X[_ !RO MOVAX/&B?&C6H;^+3(?"[:>=("7=]<;#(;F7S\_; N=J?ZO./FP&?\$Q?^"+N MI_\ !.W]KK]H#]J*]_:)@\6Q_&_5Y[V+18O"S61T<27]U=[#*;F7S\?:-F=J M9V9QS@?>%% 'YQ_\$O\ _@@AJW_!.C]B[X\?LDWO[45MXND^-&E7-G%KT7@Y MK%=(\W3I[+<83=R^?CSM^-Z9VXSSD'[+7_!!#5OVTVGVMC+M^R9SYJY\SH,<_HY10!^<=U_P $ M$-6N?^"&%M_P1L_X:BMA6V==?5=OV+[7D<-Y6?.[;L?PU MZMJ'_!&SX'_%'_@DQX5_X)4_M'>(YO$NE^%_#-G86?B_2[(65U;7]L&\G4;9 M':40R+N8;2SAD=T;*N17V-10!^%W@G_@SK^*FJ^(="^&'[1/_!4;Q-XH^"WA MG4S=:7X)T_2KF%PA8[DACGNY;:Q=@Q#2HDAY/R\Y'WG_ ,%8_P#@C)X4_P"" MB?[!'@?]@GX/?$FP^%'A_P !>)M,U#0WB\.-J4,-G9:?=V45FL7VB$CY;E3O M+D_N^02V1]O44 ?(W[(_A#I@B\'_$_2M$5)(+@@K*6M'E;?!*I0/#YH),4;!P5%?HE10! M^+_A3_@UC_:<^-7CGPCIG_!2G_@K#XR^+OPT\#WB3:3X&87Q-RB@+Y7FW5W( M+4,BA&9%>0IE5=.&'3_\'9USJGQ#_9Y_9\_X)O\ P>M(H_$OQA^,EC::)IEO M'A%M+2$VP78OW8UGO[0YX $9[ X_7FO!?B-_P3J^ GQ9_;S\#_\ !0WX@ZCX MAU+QE\.?#-QHW@[19[Z$Z/I_GF;S+Q;?R=YNBL[KO,A4!4(4%%8 'KWPQ^'^ M@?"?X;>'OA9X4B,>E^&M#M-*TV,]5M[>%(8Q_P!\H*W*** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ K\EOVR/^3I?'7_8Q3_SK]::_);]LC_DZ7QU M_P!C%/\ SH \THHHH **** "BBB@ HHHH _6K]CG_DUOP)_V+EO_ "KTJO-? MV.?^36_ G_8N6_\ *O2J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\EOVR/\ MDZ7QU_V,4_\ .OUIK\EOVR/^3I?'7_8Q3_SH \THHHH **** "BBB@ HHHH M_6K]CG_DUOP)_P!BY;_RKTJO-?V.?^36_ G_ &+EO_*O2J "J'B?6_\ A'-! MN=;^S>=]G3=Y6_;NY ZX..OI5^L+XF_\B'J7_7 ?^A"@#E/^&@_^I1_\G_\ M[71_PT'_ -2C_P"3_P#]KKS>B@#TC_AH/_J4?_)__P"UT?\ #0?_ %*/_D__ M /:Z\WHH ](_X:#_ .I1_P#)_P#^UT?\-!_]2C_Y/_\ VNO-Z* /2/\ AH/_ M *E'_P G_P#[71_PT'_U*/\ Y/\ _P!KKS>B@#U?PQ\:/^$CUZVT3_A&_)^T M/M\W[9NV\$]-@ST]:[FO#?AE_P CYIO_ %W/_H)KW*@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_);]LC_DZ7QU_V,4_\ MZ_6FOR6_;(_Y.E\=?]C%/_.@#S2BBB@ HHHH **** "BBB@#]:OV.?\ DUOP M)_V+EO\ RKTJO-?V.?\ DUOP)_V+EO\ RKTJ@ K"^)O_ "(>I?\ 7 ?^A"MV ML+XF_P#(AZE_UP'_ *$* /#**** "BBB@ HHHH **** -[X9?\CYIO\ UW/_ M *":]RKPWX9?\CYIO_7<_P#H)KW*@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH *_);]LC_DZ7QU_P!C%/\ SK]::_(K]NC7 M](\*_M#?$CQ1X@ODM;#3=6O+J^N9,[8H8P7=SCL%!/X4 N;&Q\.>)KF(B2*:>6YC2>X_@\J4PL%"G*?9Y3F3G M9]#?MC_MA?#G]C3X5O\ $+QHJW]]<3+#HOAZ&[6*XU&0L-^S(.U44EF<@@8 MZLH(!ZW161\/O%D?C[P%HGCJ&R:V36M(MK]+9GW&(31+($)P,XW8S@9Q7BO[ M7?[?OAK]E[QEI/PK\/\ PKU_QWXOU:P?4!X>\.QEI+>R3=F9RJNW\$A "GB- MBQ48) /H&BO!X_\ @HA\ 7_9"/[9!GOQH2_N&TH1+]M%]OV?8]N[;OW'.<[= MGSYQ7/?LQ?\ !2?0?CS\78/@=X_^!WB?X>>(M4TUM0\.6WB.(A=4MU5G+(61 M&!**[J=I5@CX;( (!],T5\?_ !H_X*[^#_A+\9/$OP>TS]G[Q7XDF\,:A]CO M-0TAT:-I-H)&,$K@[EYZ[37U-\-O&2?$7X=:!\08])GT]==T6UU%;"Z_UML) MX5E\M_\ :7=M/N#0!^PG['/_ ":WX$_[%RW_ )5Z57FO['/_ ":WX$_[%RW_ M )5Z50 5A?$W_D0]2_ZX#_T(5NUA?$W_ )$/4O\ K@/_ $(4 >&4444 %%%% M !1110 4444 ;WPR_P"1\TW_ *[G_P!!->Y5X;\,O^1\TW_KN?\ T$U[E0 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57UC5M/T'2;K7 M-6N/*M;*V>>YEV%MD:*69L*"3@ G !-6*YWXO?\ ))O%'_8NWO\ Z(>@#S3_ M (>+_L;?]%B_\M[4?_D>C_AXO^QM_P!%B_\ +>U'_P"1Z_+BB@#]1_\ AXO^ MQM_T6+_RWM1_^1Z/^'B_[&W_ $6+_P M[4?_ )'K\N** /U'_P"'B_[&W_18 MO_+>U'_Y'H_X>+_L;?\ 18O_ "WM1_\ D>ORXHH _4?_ (>+_L;?]%B_\M[4 M?_D>C_AXO^QM_P!%B_\ +>U'_P"1Z_+BB@#]4-'_ ."@/[(NOZO:Z%I/Q:\V MZO;E(+:+^P;]=\CL%5M"(OB5\7OBQ\/9M7N=/&N7>H6/\ :%E( M5FM3*A02H000RDAASU% 'Y#?!CXI?%[_ ()J_'B^^&7[3_PWL_%/A>VL]$TN M7Q/IX$B:39"?4&L;D?(1D^;=C8^Q\18!X^;VK_@KK^RC\+I_@A\1/VM=76\O M_%,>E:-I^D"XN/\ 1]-B&I6L;M$@'WW61P68D88@ 9)/C_@3]B']M+XE?%?6 M_P!DKXP>-="D\-:98^'F\5^(5F>6YO=(MKF_DLHH"1DNQ><'> 5$<>3QA_MK M_@H#\$?''[1/[(OBSX,_#.VM9-:U?[!]ACN[@0Q'R;^WG?+'@?)$V/? H [3 M]G3_ )-\\"?]B;I?_I)%7S+\-F;4O^"WGQ!&I#=_9_PGA&G[_P"$$Z;G;_W] MD_,UVG[6?B']H?\ 9V_8@\*R_!CQ+I^D^)]"&BZ=J33I!.)T\D6[P0K,C+)( MTQC"A1N(!(XS6)^UE^S-^U1H7[4%A^V+^Q?_ &!>:_<^&FT'Q#HGB"39')'G MY+A264-C"94L,&%#APS+0!YY_P $OOA=\*/BG\ _BGX#^+_A73=5\+:1\7+V M^M[;5.+>W=+>-?-SD!=J#KG !-:GP@\47/[>_P#P4>L_VC/ 6ERQ_#CX0Z;< MZ9INN21E1K-]*DJ'9GG;B8N!V2-"V#*%J/5OV!/VFOAQ_P $[)OV9_A%K6FW MWC+QEXF;4?'U\=1\B(PRI^]ACD8 L#Y-O&W W R\ -BM#]A[X+_\%+O@+K_A M'X7^.+/P38?#/2?,CU.TTD6YN&4QR$/N5=[R-,59FSDY- 'G.M?"#_@I9^R7 M%\7_ -JCP9XM\*Z-I=WXON_$>K>';F*&]GU:S\UY-V_RV\N-(Y&^19(WX?I\ MN?NO]GWXMV?QX^"/A;XQ6-@;1?$6BP7KVA;=Y$C*/,CSW"N&7/?&:^._B#^R ME_P4WL[#QO\ LS^"_B%HWB;X>>.]6DE7Q=XMUF:?4M+LY2H>W)D1<-,8T :1@.A9LL0.,M0 M!^R7['/_ ":WX$_[%RW_ )5Z57FO['/_ ":WX$_[%RW_ )5Z50 5A?$W_D0] M2_ZX#_T(5NUA?$W_ )$/4O\ K@/_ $(4 >&5R/QV^//P@_9E^%>K?&WX[^.[ M+PWX7T2%9-2U:^W%8]S!$550,\CLS*JHBLS,P !)Q775\I_\%=OA1\7?B#\# M? ?Q!^#OPOG\=W?PL^,>@^.-7\"697[1XAT^Q,PFM85;Y9)1YRS*ASN:$ !F MPI .G_8?_P""GG[)O[?TVLZ'\#/&-W'X@T&6X;4O"^NZ9-97Z6D=U);I>+'* MJ^9"Y13E23&9%20(_P M:?B+_@I=^P5X3_:$C_95\1_M3^$K/Q])>I9_\(_- M?';;Y,,OCW\+O! M/_!/3XR?\$XM<^#MSXB\2:G\8M3TV;X[QV*/X,DU&]UCSX=8O]:SMMKBV21( MV0AG5H44$ACM /V!_:=_;,_9<_8R\,67B_\ :?\ C7HO@ZQU.X,&FG4I6::[ M=0"PBAC5I) H*EBJD+N&XC(K9\+_ +1?P+\;?!!OVD_!_P 5=%U/P&FCSZK) MXJL;U9;-+2!6::5G7.WRPC[P?F4HP(!!%?'D$_P^\(?\%PM&C_:0\6:?/>6O M[-%A#\*-7\03(D%S=C4)AJ2Q_AS7S=XU^.&@77P)_P"" ME?PQ_9(L9-:\(QZSHT?A?3?"5JUS%+?:Y:)IVKM:I "'1KF&=SY8V\,W3)H M_0CX1?\ !5+_ ()X_'KXC:7\(_@]^UEX4\0>)=:E:+2M'T^XD,URZQM(P4% M,A$9NO0&OH"O@C]E_P#:D\(?";XY?#G]GO\ :%_X)>77P,;Q7:#3_A-XWU-M M(O3JEQ!;\6UTUD"VG7_\ HAZZ*N=^+W_))O%'_8NWO_HAZ /QMHHH MH **H^'?$_ASQ=IIUCPMKMIJ-H+B:W-S97"RH)8I&BE3%O^QCL?_1Z5 M^R- !1110!Y]\?\ _D':;_UWD_D*\PKT_P"/_P#R#M-_Z[R?R%>84 %%%% ! M1110 4444 %>A? #_D(ZE_UPC_F:\]KT+X ?\A'4O^N$?\S0!Z=1110 5^2W M[9'_ "=+XZ_[&*?^=?K37Y+?MD?\G2^.O^QBG_G0!YI1110!1USPQX;\3-9- MXCT"ROSIU\E[I_VRV67[-I?]I?]M])^%E_P#%J[\=?$:Y\.W%A!+%KVLZD=*TR.2=$:>9!<+> M&+I%D@[7WJ*OPY_:3\.? ?\ X)6:U_P2,^('[-/CBX^/,'A76O!EC\/=/\#7 MEQ;:]=7DERD.KP7RQ?96M&,ZW#3M(K#:Y . Q_5;X=_#?P7\*/#;^$? &C?8 M-.?5=0U)K?[3)+FZO;R:]NI-TC,WSW%Q,^W.U=^U0J@*-R@#\YOVGD^"'P"\ M#? _]FW_ (*E?LPV/CCX4:#\(=.LO^%G0^%[[69M,\7V<4,$]M+]C1Y8(;B% M%9' _>NI5@54E:G[/.B?M0_"#]FWX_\ [??[(G[+-OHNK>-_$^C3_#7X2ZOX M=>UGD\&Z+;P6,2I9Q-&UO(O!U[I5OX;&FV]P(]+D>ZC027< MTTXCV0EU 1CN*ABOZ)T44 ;WPR_Y'S3?^NY_]!->Y5X;\,O^1\TW_KN?_037 MN5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7._%[_DD MWBC_ +%V]_\ 1#UT5<[\7O\ DDWBC_L7;W_T0] 'XVU\O_\ !73Q]XT\ _LD M>;X2\0W^D6NK>*;#3?$FK:9N$UIILOF&5E*\C++&AP1N#E?XJ^H*\6_;N^._ MPW^ GP5CU?XR?"R;Q7X3UW6(-'UVU6-'CMH9@S>=*K Y52G&.=Y3!!(- '@? M_!)O]GN;PC/%+J0SF2>'4KA+6[!!41,;:.!N4W M-YCG@,H'SI'?_!K]HK]H_P"(^J?&;]O#7OAU<7OQ&O[/POI5L+EX);192L"OVYO!W_#-?C*>]L/$5MXJ/C?1;*[\ZVM- M/M[R]33F)/(W*EH5#DM\RMD"6MSXX?%7_@FQXW_8:^)B?#CX7Z1X/\5)K)AM M] UVV@37CJ0FBQ,@\R20)]\-L?8H60'&2" >U_\ !0SXA_M(_#'X#+^S]^S_ M .$+W4;>'X=3W7BWXAW$A5+'3K6!EE ;H+B98VP=Q;YCM&?G3+\,^-?BUX5_ MX(FVOC/X3WM^?$MOX-W0WEJS-<0Q-?%;B9&'S!DMS*X8B^(]/\6Z3 M_P $F-0TOQVLRZQ;_ >:/4$N,^:D@TE@5?/.\=&SW!KQ/7O%OQ"\$_\ !"O2 M-;^&U[=6MX=!MX+N\LF*RP6DNHF.8J5Y&58J2.BLQXZ@ XS]D"+0?AM^UM\' M+']E_P#:,U[QW%XU\+7%Y\5],NM4^U063"WWEY54#R&$I.%DS(K(H+'S<-^F M%?F=X2M?V:OA=^U#^S:_[!7BJ";5/$,7V;X@6ND:N]R;FQ*0F0WL9=A'*!]J ME?LC7XW?!_\ Y*UX6_[&.Q_] M'I7[(T %%%% 'GWQ_P#^0=IO_7>3^0KS"O3_ (__ /(.TW_KO)_(5YA0!^=_ M_!8?]H3]J#5_'/BW]DW]G?XUGX<:?X5_9QUGXF^,->L+".;4M8A2XDL[?3;6 M1^;0;XW>2>/]X R!2N>?IG]A%?VV/#WAOQ?\+_VU[N#Q!?>%O%IM*W%C/)&R-&>#F-VNC>(+.:Y M759K"UX%U:6]O<_:W8*/MJ2S-,@L;03$6 MZ21!W8J['' 'SC^R'^V9^R]X/_X*M?"KP!\#_@+\6-#\+V7[.:_#K0[#7/A_ M<6UU%(K.1;ZY5CD6QPS379X\QR3RU7_V O^";&G_MA?"+XPZ[\8_VA?B' MHNM^&OCEXRTGP3!X4\6W&F0>%+V/4))GOC# RB>Z:>8LSR[OW4<2KMQF@#]" M_#?[41\)?L5VG[6G[5'@ZY^'LVG>"EUKQMH%^O[W2ITBW3VZ@G+MY@*QK]Y] MR#&YL5Y3_P $?_VN_P!H']LWX*_$7XC?M(>'TT37-&^,NLZ'9^'!:I&^B64$ M-I)%8R%0#)+$9G5G;YF8'., #XI?_@I!XK^/?P=_94T[]KGX4_$;Q+X._P"$ M7'C?XCZAX'\$3ZJGBO5M/U*YL=+M)A" BQ&>R;49T;Y7(MU"A6./>/\ @A;^ MUMX%^,WC?]HCP%X?\">--/NM7^//BGQE!=:[X9EM+:*SN9;.-+621CA+Q3R] MN?F4I?\ 7 ?^A"MVL+XF_P#(AZE_UP'_ *$* /#**** "BBB@ HHHH **** M-[X9?\CYIO\ UW/_ *":]RKPWX9?\CYIO_7<_P#H)KW*@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ KG?B]_R2;Q1_V+M[_Z(>NBKG?B M]_R2;Q1_V+M[_P"B'H _&VLSQEX+\)?$3PO>^"O'?ARSU?2=1A\J^T[4+=98 MIDR#AE;C@@$'J" 1@BM.B@#R?]E3]C[X3?LF>&KW2? >@Z>=0U#4+J:\UF+3 MQ%<2P27,DL-LS%G8I"CI&/FP?+W8!)JQKW[%G[*?B?XH#XSZ_P# GP_=>)?M M(N'U*6T_UDP.1*\>?+>3(!WLI;(SG->H44 4/%/AC0/&OAK4/!WBO2XK[3-5 MLI;34;*<92>"12CQMCL5)!^M4/#?PN^'?A+X?1?"CP_X.L(/#4-F]HFB& /; M>0^=T11\AE.YL@Y!R:WJ* /-OA%^Q]^S)\!?$ESXQ^$7P8T;1-4ND9)+^VA9 MI51OO(C.6\I3QE4V@X''%>DT44 ='\'_ /DK7A;_ +&.Q_\ 1Z5^R-?C=\'_ M /DK7A;_ +&.Q_\ 1Z5^R- !1110!Y]\?_\ D':;_P!=Y/Y"O,*]/^/_ /R# MM-_Z[R?R%>84 ?&W_!5G_@FMKW[6GA36OC;^SSX_UWPQ\6;/X;:KX7@31WM? ML_BS2KA'+=$1B-I22DI=?*:0OR54KZ]^Q;^Q;HG[(FB^)]5U7XFZWX]\ M=>/=<&L>/O'WB-(DNM8NEC$42B*(".W@BC&R*%/E0$@'GCVNB@#RR?\ 9:T" M?]MFU_;8/BJ\&J6OPLG\$+H@A3[.UO+J4-^;C?\ >WAH0FWI@D]:\6^-G_!* MO6O&7Q/\;^,_V>_VT/'GPCT+XKR>;\5?"7A>QLKBWUF44 '?"VCP:9H]F'+&."% M B[F/+L0,LQY9B2>2:Y']ES]EG0/V7/^%B_V!XJO-4_X6+\4]7\;WOVR%$^Q MW%_Y6^W3;]Y$\H88\G)S7J=% !7H7P _Y".I?]<(_P"9KSVO0O@!_P A'4O^ MN$?\S0!Z=1110 5^2W[9'_)TOCK_ +&*?^=?K37Y+?MD?\G2^.O^QBG_ )T M>:4444 %%%% !1110 4444 ?K5^QS_R:WX$_[%RW_E7I5>:_L<_\FM^!/^Q< MM_Y5Z50 5A?$W_D0]2_ZX#_T(5NUA?$W_D0]2_ZX#_T(4 >&4444 %%%% !1 M110 4444 ;WPR_Y'S3?^NY_]!->Y5X;\,O\ D?--_P"NY_\ 037N5 !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7._%[_DDWBC_L7;W_ M -$/7FFJ?L$?!K5]3N=6N?%7C=9+J=YI%B\7W*J&9BQ / R>!VJ#_AWO\$_ M^AM\=_\ A97/^- 'Y?T5^H'_ [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H M;?'?_A97/^- 'Y?T5^H'_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A9 M7/\ C0!^7]%?J!_P[W^"?_0V^.__ LKG_&C_AWO\$_^AM\=_P#A97/^- 'Y M?T5^H'_#O?X)_P#0V^.__"RN?\:/^'>_P3_Z&WQW_P"%E<_XT ?G%\'_ /DK M7A;_ +&.Q_\ 1Z5^R->%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z&WQW_P"% ME<_XT >Z45X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQW_X65S_C M0!V?Q_\ ^0=IO_7>3^0KS"MS_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^._ M_"RN?\: ,.BMS_AWO\$_^AM\=_\ A97/^-'_ [W^"?_ $-OCO\ \+*Y_P : M ,.BMS_AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@##HK<_P"' M>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\: ,.O0O@!_R$=2_ZX1_ MS-_P3_Z&WQW_P"%E<_XT ?E M_17Z@?\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_ 3_ .AM\=_^%E<_XT ?E_17 MZ@?\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"- 'Y?T5^H'_#O M?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_ .%E<_XT ?E_17Z@?\.]_@G_ -#; MX[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C0!U7['/\ R:WX$_[%RW_E7I5>%_\ M#O?X)_\ 0V^._P#PLKG_ !H_X=[_ 3_ .AM\=_^%E<_XT >Z5A?$W_D0]2_ MZX#_ -"%>4?\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"- &'1 M6Y_P[W^"?_0V^.__ LKG_&C_AWO\$_^AM\=_P#A97/^- &'16Y_P[W^"?\ MT-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- &'16Y_P .]_@G_P!#;X[_ /"R MN?\ &C_AWO\ !/\ Z&WQW_X65S_C0!AT5N?\.]_@G_T-OCO_ ,+*Y_QH_P"' M>_P3_P"AM\=_^%E<_P"- #OAE_R/FF_]=S_Z":]RKPO_ (=[_!/_ *&WQW_X M65S_ (T?\.]_@G_T-OCO_P +*Y_QH ]THKS[X,_LU^ O@9J=[JWA#6?$-U)? MP+%,NM:Y+=JJAL@J'/RG/<5Z#0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !117D?[8'[>/[(/[ W@2V^)'[7WQYT7P1I5].T.G'43)+6C;0PSC(H ])/V.OVB-%\: MQ:2RC5;.UCGM;VR#9V--:74<5Q$C$$*[1A6*D G!QA_M*_\ !6;_ ()P_L>_ M%:U^!W[2G[7WA#PGXLNHXG.B7UU(\MLD@!C:X,2.MJK A@9B@*G=]WF@#Z(H MJMH^L:3XATFUU_0-4MKZPOK9+BRO;.=98;B%U#)(CJ2KJRD$,"00017S#^T? M_P %L?\ @EQ^R+\9]9_9Z_:,_:YT?POXR\/_ &?^V-"NM'U&62V\^WBN8LM# M;.AW0S1/PQX< X.0 #ZGHKY>^&O_ 6A_P""8OQ?\-Z=XR^'?[66D:AI&J^. M++P?9ZH=(U"&W.MW:,]M9/)+;JL3R*K%6^ M-7QE\96?A_PMX8TR74-=UF_8B*TMXQEG(4%F/8*H+,2%4$D @'245X%\?/\ M@J/^P%^RW\+_ E\8OVA/VF]"\):%X[TZ*_\(MJ\-REWJ=K)&DBS1V8B-SL" MR1EB8QLWJ&P2!7J7P2^.7P?_ &D?AAI7QH^ OQ(TCQ;X5UN$RZ7KNAWBSV\X M5BK ,O1E965D.&5E*L 010!U=%<5HG[17P3\2?'?7/V9- ^(EC=^//#.A6NL M:_X;@WM-865R[+!)*P78IT_9$_:5\.^-KK0E5]7T_3WEBNK:- MCA96@G1)#&3QY@4IGC.>*[?]H_\ :0^"7[(WP8UG]H7]HSQ];^%_!OA[[/\ MVSKMU;S2QVWGW$5M%E84=SNFFB3A3RX)P,D '<45\7>&/^#A[_@C-XR\2:?X M0\,_MT:#=ZEJM]%9Z?:IH.J@S3RN$C0%K0 $LP&20.:^DO@/^U'\!/VF_P#A M*4^!WQ&MM=E\$>*KGPWXMM4MIK>?2M5M\>=:S13HCJR[ASMVGG!.#@ [^BO/ MT_:F^ $O[06I_LL0_$NS?Q[HOA1/$NM:"D,K'3]+>3RTN)Y@GDP[FZ([AROS M!=O->9_ ;_@KG_P34_:?^-TO[.7P#_;)\&>)_&:&40:+I]ZX-Z8P6D%K*ZK% M=E55F/DN_P JLW0$T ?1E%>"?M0_\%1O^"?/[%OQ#TKX3_M2?M7^$_!OB/6H MDFLM'U2[=IEA=BJS3"-6^S1,0P$DNQ#M;!^4X]STG5M*U_2K;7="U.WO;&]M MTGL[RTF62*>)U#)(CJ2&5E((8$@@@B@"Q1110 4444 %%8'Q5^*'@;X)?#77 M?B_\3=:;3?#GAG2I]2UW45LYI_LEI"A>68I"CNRH@+':IP 3T!H^%7Q3^'GQ MP^&NA?&'X3>++37?#/B;2H-2T+6+%B8KNUF0/'(N0",J1D$!@<@@$$4 ;]%? M*?Q-_P""W_\ P2N^#FDPZ_\ $C]K_1]-T^Y\3:OX?M-0.C:C+!_MN:%J>O\ B76+ M72M#TV+0M45KN\N)5AAB#/:A06D=5RQ &>2!0!]CT5\>_$'_ (+\?\$@?A3\ M2]<^#WQ#_;/_$T7A_P=IYMIIY]5U&12RPQQPH[8 !+2$!$&-S+D9^7?^(D+ M_@B5_P!'[^'_ /PG]6_^1* /M^BOE,?\%O\ _@E:?V>V_:K'[7^C?\*^7QF/ M";>)?[&U'RAK)M#>"TV?9O,W?9P9-VW9@8W9XK8_9A_X+#?\$R_VR_B##\)_ MV;OVQO"7B/Q- M:XER)@ ZIN0'!-?H=7YO_&'QUXS_ ."/?_!1_P")_P"UIXO^#?B[Q7^S[^T1 M9Z1>^*-?\#Z%+J=QX%\3:=;FT,ES:P@R&SNH-CF90Q$J[=HXW &C_P %4O 7 MA?\ 9;_;[_9*_P""@OPCT:WT;Q=XM^.FF_"7Q[-IL(B/B31M=@G1%O N//-O M+;+)&6R5)!R=B[?1/BA\%_V)O^"7G[,O[27[2W[1-W#XHTGXG^)=7\3^.Y/% MEK;RW.LM>(L5KX>AP@,L(PMO;PG.WS23U9J^ O"G_!2KXE?\%,OV_OV<_ _[ M6_A"P\ _!SP/\;[_ ,1^!/BE+X9UG2])^(FN6]OLT#3+<:C;J+:]C-U(9!)) MMF96$6TE%>Q\2_\ @IG\$_C7_P %0/$GQ@_;]^!_QNU?P#\#?%LVG? /X<>& M_A9>7VDW%_;LTZM_%>D>"(1J-A?9\^PCEDDFM[20'E7@@DAA*G[IB*]J^'T_X M*#?L=_L.?\%MOVW;3]JGPAXAU23Q+>?#E]#.A_#ZYUP1K!X5B$N\P1/Y.3-' M@'&[!QG::_4+]E[]HOP;^UG\"/#_ .T+\/O#WB'2M'\1Q3R66G^*]'?3]0A$ M5Q) PFMW):,EHF(SU4J>]?,'[!?A;Q/I'_!8_P#;V\2ZKXZ9J]HX:VOE@D1) 89UC<'C>H9Z_9"^!7PV_; \7?\%)OB/XM5M33X;6 MOAV";Q";=-/\)Z/9O/+:(].CC:.68H^Z20^7A2BR)[GK'@SX ?\%Y_P!GWPG9?L]> M.?C+\!M,^"/C^SO_ ^$\&1Z'/%>V]D4M#!;W"LGEP)+^[90/+887&* /._^ M"1_P ^*GP$_X+ ?&*?\ :%\2G5OB?X[^ 7AOQ?\ $V[28O!%K5]JVH-):6XR M0MO:Q)!:1 <>7:J>]?JE7Y.?L+OV\OC5XQT[PS\ M(]!U*[U_Q-Y)C\4+)>7\7]D74JQ!'A@.)E1"/!%?K'0 5\6?\' GQ7^( M'PS_ ."8WB[PY\+?$,VCZY\0]=T3P/;:S;L0]E#JNHP6ES(",$$VSSH""""X M(.17VG7SG_P5@_8V\2?MX_L&^.?V>/A_K<.E^+KB&UU;P1J<[;4M]9L+J*\M M-S$'8CRP")FP=JRL<'&* .M\$_L%?LA^ OV3X/V(M&^ OAR3X91Z(-,N?"]U MID;PWD>P(TL_&9)W/SM.?WA<[]V[FO@[_@F5^R7H7[:7[$M[^P_\?O'VM:KX M8_9)_;)UCP]I=O<&.>/Q/IOAZY\VPT_4!*K":U"WL:F/CBUB7[JE3C?&7_@X MJ_:#\'^%O G@GP'^P=XT;X\6>LI8_%+X#^(? 6LB\U ;!'))HFH6<,UNR>:? M-264,KP]%R5)\@^%/[=GCS]C/_@AI&O"= MW>W'P\\1:G,UQJDEUI[1B5;FRM4@C6*0 /,\;KYD1&X ^PO%E]X/^.G_ <) M_#I?V;=(M6NO@;\)-?M_CUXGTF$+$8]46W31]"N)4X>>.2&2[6$YVH2>"I U M/^#FJY@L_P#@B3\9+NY4F.*\\*/(%7<2H\5:03QWX[5PW_!&#]M7_@GUX*/A M_P#8/_98^"?QUM->\0S7VK>(O'?Q)^'%S:2>(M6$#W-WJ.I7TKG=/-Y3 9R! M\D:X %>F_P#!QMX6\3^-/^"./Q9\->#O#E_JVHW&H>%3;Z?IEF\\\H3Q1I+L M51 6;"JS' X"DG@4 4?V>O\ @L=_P3"_:.^-?ASX(?"[X6>+XO$/B/45M=)E MU7X+7MC;I-@L"\\MN$B'RGYB0,XKS/\ ;\\=6?\ P18_X*#_ /#T:'1+^;X+ M?&W0V\.?'32='MC(UGXDLK:671M52-?XYUC>S8G"@N68EI!7Z<5\0?\ !Q#X M5\3>,_\ @ESXET'PAX;O]6OG\<>$)$LM-LWGE9$\1:>[L$0$D*H+$XX )/ H M YO]C#_@FOX\^,G[!WQ=\3?M<^)=7\+_ !A_:_MY]5^*6K:,5%]X=TZYA,5C MH4!E4A8[2Q?R"C D-+,N3A37-?\ !43X<_!C0?$?['G_ 3D_9=\%:9'\2]# M^+WAS7O!EMHUFB3^$?"^CR;]2U21HP#! \4?DE6P+AV8#>R''V7^WM^TYJ/[ M&O['?Q _:9T/X?7_ (KU/PIH#SZ-X;TVUDFEU&^D=(+:$K$"^QIY8][*"53< MW:OR[_X)-?\ !2+]D_X-^*9/B;^T!\+OV@?&?[2GQLU2SB^(_P 1-4^#UW': M6LLTB)#I-DS-BTTNU+*H #"/S& "HD8!];?MQ:7^RI_P3%^'?QW_:\\3_L[ M?$+XPZ_\>))!XLTO3_#(UO=!;Z7Y$-E,\<2BQTB..'YFF+A#*QRQ*J/2?^"* M/@N?X>?\$HO@/X-N?BCI7C)K+X?V@_M[0]1%W:.&+.((I1PZP!A;]L>1C QB MO+?'O_!7[6/V)?VB?BS\$/\ @H?\+?$]O:+K:W_P!UCP!\.=2U.W\9Z/-;1[ M=-1[=9D&I17"R))YS0H?,0C:NTMW'_!#']GGXM_LU?\ !.3PKX,^-G@F3PIK MFLZ[K?B3_A"I#SX;MM2U.XO+?3R.-C1Q2H63 V.[J0"IH ^O**** "BBB@"' M4=.T_6-/GTG5K&&ZM;J%H;FVN(@\"#7XP:E\4_P!IW_@E MOJ?Q,_X(2?L]:7JESK_Q3\0QS_L=^(2DCPZ)H.M33'51-*,^4NCE+N=6.6)8 M.1M*BOVEKX@_:Z\*^)M1_P""Y'['OBO3_#=_/I>F^!_B-'J.I0V;M;VKR65D M(UDD VH6((4,1G!QF@#Z"_94_8G^ W[)/[,7@?\ 97\">#+"]T+P-HJV5G/J M6GQR2W,S'?P KY:_P"#?#P+X(NOV/\ QGJUSX.TJ2ZM M_P!H?QR+>YDTZ(R1!-9EV;6*Y7;@8QTQQ7Z!5\0?\$"O"WB?PC^QYXUTWQ9X M$? MVJSXU\ Z+K&_]MOXCQO_ &II4-QN07D!"GS%.1DGCWJ+_@G5X&\-?L>?\%AO MVGOV)?@YI4.D?#CQ#X4\._$O0/"E@@CLM"U"Z\VSU!;:)?EB2=XHY-B@*HC5 M5 50*^?_ -@__@JM\)/^"=OC?]I?X%?'#]G+XY:IKFL_M;>/?$&DMX-^%MUJ M%M=V5S?*D+1R@J&+&%B,<8*G.#7U%_P2E^&WQX^,W[37QP_X*H?M&?!;7/AQ M-\6_[(T'X:^ ?%< AU;2?#.EPNJSWD628)KJ>1I3"W,>SNK*Q /NNBBB@ HH MHH **** "OAS_@MI^SU\25^'W@[_ (*2?LO:*;CXN_LS:M)XETRR@RK^(?#S M)MUG1W*C+++:AW4 %LQLJ -)FON.LOQQ&\W@K6(HHRS-I=P%51DDF-N,4 ?G M]_P3TUJU_P""LO[;FI?\%==4TJ^7X5?#_2IO!W[->FZO:F)III57^W-?,;?= MD>3-C&P.#'!(" 5!J_\ \%9/AW\/]/\ VR?V';:P\"Z-!'=?M!S1W4<.F1*L MR?V/=G:P"_,,\X-=W_P;W^&?$?@[_@C9\"O#/B[P_>Z5J5IX;NUNM/U*T>"> M%CJ5V0'C,)_A;X+_9 M?^-T_@?Q)K^E> OVMO#/B'Q#:>%-$EU"\CL+:QU1Y9%AC&3C@#.!E@,C->2_ MME?\%!/%_P#P6>^!EU_P3H_8,_9+^-.FO\3M0L]-\=_$WQ]X ET;1?"F@K*-HT@ !<.V"6 4@'Z=_!7Q[+\5?@YX2^*$UHMN_B3PS8:H\"Y MQ$;BWCF*C/IOQ^%=-6?X3\,:-X)\*Z9X,\.VWD:?I&GPV5C#G/EPQ((T7/LJ M@5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110!4UC0=#\0P16NOZ-:7T4%W#=01WENLJQSQ.)(I5# X='575ARK*"""*MT M44 %%%% !1110 4444 %%%% !1110 54TS0=#T6>]NM'T:TM)=1N_M6H26UN ML;74^Q(_-D*@;WV1QIN;)VHHS@"K=% !1110 4444 %%%% !1110 4444 %% M%% !17QA_P %1/VT?VXO@)^T/^S[^RQ^P=X+^%VJ^+/C;?>)X#/\53J"V-J- M)T^*^R'L9%="T?GCE'RP0?*,FF_!K6/^#@^\\1ZC#^T!X1_9(L=)_P"$$KKQ'<7 U86SFQ$D<[(K6YN/+$N&5Q&6*G.* /M&BOE3_ ()\?\%-?"W[ M4/["NK?M/_M!V5AX \2_#.75=*^.?A^5F2/PMJVE!C?*5=F=8MBB9 6W5Q<620:).)9;/ M4M;G:20G;:0274AMU0,DD(55+DJ ?HM17QI^RM^VG^V_X9_;4C_8(_X*0_#C MX9VGB7Q-X'N/%7PZ\:?"*ZOSI&JP6L\<-[830:@3/%='(&R4=">AX,/[= MG_!5V7]F7]O/X _L(_"WPE8:[K7Q,\:65KX^U"]CE>+PYI5T+A;508W4)=W+ MV]P\0?[/&C? MM3_ 7X4?L?6GA/Q'?:G!I$'B>\\307RBRU"YL9#*D+R("9+9R-KG*E3P20 # M]3Z*^'/%/[>_[;7[(?[0O[/'P\_;^\#?#&U\(?&:"X\,>(/%G@!=0^S^'_&Y MED>PMO.NY3NL[N )&@:,2"82DOL4 ^@?M4_MO_%+PC^W'\'?V!/V6_"V@ZWX MO\8--XE^)=]KT,\UOX5\&6Q,ZNVX*!N /N2BOF'_@G M9^VC\:_V@_%?Q7_9G_:R^''AWPW\7_@EXAL-.\9+X+OIKC1-4M=0M!>:?J%D MUP/.C26'=F*3+H4Y.6VK]/4 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 ?F?_ ,%MO"_[2/C/_@I#^PQX:_9& M^)^A^#/B'\2^(]'^WV5GM\/PM/YD'_+3?;K-&/1G5NU?2?["WPB M_P""J?PZ\<:UJ/[?G[77P^^(N@W&E+'H>G>#_ _]E36MYYJDRR/CYT\L,NWU M(-;_ .T;^Q9J?QV_;;_9T_:XM/B!!IMO\"[WQ5/=Z')IS2OJXU?2?[/4)*' MA\H_O#E6W#CCK7OU 'Y%?\%*_P!A:XUK_@L!\._V=_ WQ%D\/_##]MF&>Z^/ M/A2SB9?[5E\'QPZ@S1NI'DF]AEAMI2O)"R,Q8OBOU%^+/Q,^"_[,WP:U3XK_ M !8\0:1X5\%>"M)-W?:A=HL5MIUM"NU0BJ.#C"(B LQ944$D ^8_M _L5ZG\ M;/V\?V>?VRK7X@0:?;? ^U\80W6@2:G>%/&T/B76['7_"']LVFN MSVP!LX9[W'F6NG02VMHJH7R_FR+D2$U^M/[)'[-7_!5_P"'7Q>@UW]L3_@HOX/^)_@8 M:=<0W7A'2O@[::-)+,RXBD^T1R,0J'DIC#=*[+]LO]ABP_:G\7_!/Q-H^O:9 MH*?";XQV'C:]@?1A-_:L-O:7EN;,%67RRQN@V\[@-F-ISD 'N?A;Q/H7C;PQ MIOC+POJ*W>F:O80WNG7:*RB:"5 \;@, 0"K X(!YJ_2(B1H(XT"JHPJ@8 'I M2T %%%% !1110 5^)'_!%;X#_P#!;7QI_P $WO WB7]D+]O#X6>"_AY)/AM_:%[9[?$&HK/YD^/WF^X6:1?175>U?MO7@/_ 3 _8LU/_@G MI^Q)X1_9'UCX@0>*+CPS>ZS/)KEMIS6J7 OM6O-0 $3.Y78+H1GYCDH3QG M#]M#]B.V_;N_8)UK]DOX[>(K:7Q!J_ABW"^*]/MC$+#Q#;HDD&IVZC#1A+I! M)M4@E"R9PQKYJ_X-R_"?B_XS?LGW/_!43]H3Q:OB?XL_'^53KFMM;[!8Z5I$ MDFEV=A"O(12X)(.T&OT3(R"/45X#_P2Z_8LU/\ X)W_ +!_P_\ MV-M9^($'BFY\%6M]%+KUKI[6D=W]HU"YNP1$SN4VBX"_>.=N>^* /&_^"G?[ M7'C_ ,9>)9/^"4/[!-O!J?QP^)FBR+XGUJ-";'X;>';@>7"MR=T%T5F9974E49VVD@-7Q+\'O^"/_ /P5Y_9T^)7Q,^)WP+_X*N^! M-)U+XK>-;CQ)XKU#4?@5;ZA>74SDB*$W%Q<-)Y$,?R10@B.,%MJC<<^V?'/_ M ()S_M?_ !#@^#G[2_@;]L/0]/\ VE_A-I%]I=]X[OO!"G0?%]A>D?:;*\TZ M&53%%E(WC:-\QNK$ E@R ' ?\$A=%^)?[,W[=7[2G[&G[47B>V\>_%C4Y='^ M(5_\:(+=K67QCI-U&]G;Q3V6YH[ V9@,"00L8]CG:!C+?HI7R_\ L#?L$_$K M]G?XE_$/]JW]JKXZ6_Q)^,_Q3-C!XBUW2]$_LW2])TRR1UM-,T^V+NT<*&1V M9V;=*Q#,-P);Z@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9 end GRAPHIC 17 cah-20231231_g6.jpg begin 644 cah-20231231_g6.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@! MX (4 P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_D ML_X.*/BS^T)X6_X+H7VFV^W)EO;' MPWHU];*/_'H^%$TFZTN[:* M>&&YA76)=C(0RCR[5HF.>DFT]:\&_P"#++Q)\5M1\4_M3^%?BQXMUK4;[0KG MPE:R6^LZG+<&TF5]=255\QCM.Y #CKM'I7Q=\//VA/\ AY!\)O\ @FQ_P37: M^^VS>&OB!J%MX[M-V[_04UB)+9BO;R],CN.#UR>@KZ-_X(2_'C7_ -E_P1_P M5/\ VB/"6W^V/!EH-6T8N@91>POXH>W+ ]5\T)GVS0!^RGQI_P""N_\ P3+_ M &=?C"_P"^-G[;/@'P[XNAF6*]T>^UD;K&1L82YD4&.U;!!(E9" 03@$&OH3 M2]:T;7-&M_$6BZM;7FGWELES:7]K.LD,\+J&61'4E60J0P8'!!!%?R/?L$_$ M#_@A!J?[&?Q$B_X*8?\ ">ZY\>_'&I:E-I_BVSL[ZX.BEXP;:XC>.98YIFN# M)-*TJOOW!2,9W?17[*G_ 45^-VA?\&FOQK\ 6GB^^75?"OQ!M_ N@:H+AO- MM-"U1[2:6W#9SC9)?PCGY4F51@*!0!^P7[5?_!6+_@GA\9OV>_CI^SW\#/VU M_ ^M>/[/X2^*?LFD:-KZF::>'2KEF%K*,)<2)M+8A=V 0G^$D?GU_P $7;'4 M?VA?^#9'XZ>&?BM^U2? *:C\1-3MI_B7XHU&>6/0XEAT9Q(\@<.%SE0 PYD] MS67\$?\ @WQ_8;\3?\&Z\O[4=_X-NV^,^H?!Z^^(=AX^CUJY26UN8[66^M[) M(5D$(@\E$@<%"Q+N^=P3;Y]_P3H_Y4]_VH/^QZU/_P!!T*@#]BO^"+'@'PE\ M#_\ @ES\-_!6B?M4:/\ %[2-'AUJ0?%#3+B0V>J(VL7\SL'F=F A+M Q9C@P M-T' T_!G_!9W_@E5\0_B_#\!_!?[>7PYU#Q1_ /_@S'^!OA'X?ZU<6$GQ,\>ZKX6UFXM9"C MG36USQ#>3QAAR!(;..)A_%'(ZG@D5]0:'_P:<_L/?M _\$POA?H_PTU&?P5\ M7]4\.:)KNL_%::6[U$W4US!%->0O8FYCA,.V1EB5/+9#'&2YS(7 /UU^.G[0 M'P1_9C^'%[\7_P!H7XK:#X,\,:>56ZUOQ%J4=K;J[<)&& ":\ MG_9D_P""L?\ P3@_;)\>?\*M_9I_;"\&^*?$K0O+!H-M?-!>7"(I9S#%.J-- MM4%FV!MH!)P!FOBK_@ME^Q7^P[!^QG\ /#__ 5?_P""D/BK2-$^$[06;26N MG!I_B)?&["$W6XBM=?N$U>T7S+59KF=BHBD:.7++N#J& M09)8 _1#_@HUX\\'7CDN8KI=/GAM9I(K%9X5N[J:61YC M([9CA&!E4"GJOV0?V)/^"K?_ 0:_P""N'PY^ /P=U;XD_&K]G_QW\A0SPZ?[\9>$+K7&A!OD3RX[Z"YM-\EE,ZQ %7CVO(K/ MYB$MGYT_8^_X*D_\%J/^"-?[._V4?CYX;\=Z983K!J,N@Z@))+*1@2J3Q'$D)8 E0ZKN )&17\_G_!;3 M]J#]ECXK?\''"?#C_@IEJ?B&Z^ GP:T6SL/^$*?" MFKPW$*07DT%P?)C6X=W:-;B"SN%9F;:9)47:O /WW_:L_X*,_L-?L.ZAI6C M?M8_M/>%/ ]_K:&32]-U>_\ ]*GB#%3,(8PT@BW KYA4)D$;LBK7A3_@H%^Q M+X\^,'AWX ^!_P!J/P7K/C'Q=HJZOX7T#2MHR6%A&YA='\N"UM6_=J5#2,&;/(:K^RA^QA\._V!/^#P3PA^S5\&;B]7P5 MING:O?\ A+3+Z_DN6TJTO/"FH736:O(Q8QQSRS[!+"Z^%[%/B!;WNO1Q-H;B;R/+G#$8?\%2?^"=WQ5^!'B#]IOP)^V)X%O? GA298?$WB)]:2"+2Y'_ -7'.DNU MXVD/$:E09#P@8U^'?[$?_!/_ . ?_!1#_@Y@_:M^&?[47A^XU_P3X6\2^*/$ M=QX7&HSV]OJ=]'K$5I;B?R71F2,7DT@ 8?,H!RK,IY'_ ()Y_P#!)_\ 9:^, MO_!Q9\)&YP[A5;!P3@U^/?_ 1>^'/@C]A/_@YC_:<_9G^# M-O.YTN[A0&1BSF(2R1HSDMM8@DEB3\1_L!_M6_ M\$A_CE\;OC?^U/\ \%S=)\6>,_&'Q"ULS^&[#2X+Z2WL(YC*T\H>UFC8,@,$ M,*D[8HXL*O3: ?U8^'OC?\'?%WPA3X_^$OB=H>K>")-'DU6+Q7I>I1W%@]E& MK/).LT9*,BJC$D'C:>XKQ;Q'_P %@_\ @F#X3^#=E^T!KO[<'P_B\(:GJT^F M:9K$>M"47EW"J--%#&@,DIC$L9?:I""1=Q&X5^./_!N!^T3;7/[)_P"W;^QY MX'\8:IK7PY\.>#]8\0_#:75T*31V<]KJ-O([H?\ 5M+'%92,@P%?S#C+&LW_ M (-B?^",/[%O_!1G]B/XC_&O]L3P7J'BNYA\97?A#PG;OKMU;Q^'XTL;2[EN M[9(9%7SGDO5.7#*/('R_,^X _<#XA?\ !0G]E7P_^Q/K?[=7@[X_>#]3\ V6 MCRSZ=XK355DTZ6Z+>3!;NZ'*NURT<)C.'#MM(!KX)_X-FO\ @L%XF_;X\-_$ M72/VP_VD](U+XO>)/B1=WOA?P0)5@-KHD6FV9V6-J/\ 5VT;K-SDLS!V=GV5;^*WN)UF5H M75U_?:9:,0#AA$%;()!])_X,POV+_P!G3Q=\)?%O[<^O^!I9OB;X4^(-]X=T M+Q -6N52WTZ72K-I(3;K(('),\OSLA8;N#P, '[1?M@W5S9?LD_%*]LKAX9H M?ASK;Q2Q.59&%A,0P(Y!!YS7\RO_ 1O_P"",W[6W_!8#]GWQ5\=_"?_ 42 MUOP./#/BU]!_LO45O[TW,BVD%P)?,2[38I\\+C:Q&TGG.*_IG_;+_P"30/BM M_P!DVUW_ --\]?S"_P#!$3]L3_@N/^SQ^SEXM\&?\$N?V3;?Q[X1U'QF]SKN MLR>#9M2:TU,V=NAB$B7$:+B%86VLI^]DG!Q0!]H_\&__ .TS^W=^Q)_P6#\< M?\$6_P!L3XSZCXYTY;.^_LM]0UF>_CL+^VM4OXKFTEN,R1V]Q9EV:$X&YD.% M8/N_6;Q7_P %=?\ @F;X'T7Q?K_BG]M;P':6W@/7(=&\79U,_\ @KI_P5/TJ31O M&FL6=Y'H.CWUQ;-?7=Y=JL4MW)%;,R6L$5LK6\<)PV'^ZBQKO^-_^"5'_!+/ MX _\%1_^"Q7[67@S]J*36[KP9X0\8>(=0;1=&U=[/[7J,VN7,%O)(Z#/V=[+]K7Q;^T5X0TWX::E9176G>-;[7(HM/ MNHY03'Y4C$"1VP0L:Y$?&FJ:=" M9KS1]-U#9>QP@@&7[/*$E:,$@%PI4$@$Y(K\5_\ @I1^SOH'[:'_ 7>_9P_ MX(6#7]6T7X(_"CP)IVG6FD6EWMDEAM]'EU"XFW@8-Q+:6L%L)=IVD,P&6;.+ M_P %[/\ @GK\$/\ @@[\;_V?_P#@H;_P30TO4/ UQ;>*I+34O#AUZ[O()I[> M-)58/=222[)X3<03QERC*5PHW/N .K_X.P/VR_!7Q[_:O^"G_!/7PS^UG:Z# MX*M_$36_QGCTW428M&N)[NUA6;4(P0'^S6[33*C' #N?0CJOB-_P3=_8X^'? MPJ_9"\/_ "_X+3Z/HG@S2_&VLZOX5U#Q/J,ID\>>;JFG*]M;&VD2,K"]M]G MP5(W3=.3GR;_ (.%OV)_V4;[_@LC^R_K&@_#JXCM/VC?%6DW7Q.236;O=JRW M.K65JV,RG[,3;R%/W.S!.1SS77?\'%O[,OP8_8X^._\ P3Y_9J_9Z\*R:)X- M\+^+=5BT32Y=0GNV@276]'G<&6X=Y'S)*[?,QQG X % 'O7_ 69_P""X?B3 MX ?\%7/@#^QI\*_VE- \-_#G3/'&A7WQYU&QF"W=HJZJAFL+R_#^9],^/.N:#-\4;?^V;L'5G MN-9-A*582[K;-M&B?N2F,;AAB37[^? ;X&_#/]FCX->&O@#\&M ?2O"OA'28 MM,T#3I+R6X:WMHQA$,DS-(^!_$S$GN: .MHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\8O@/ M^SY\8C_P=Y?&?XM^)/@EXG7P'JW@-K6'Q1>>'+D:3>%M!TF)HENF3R7)9)$V MACRK#J#7[.T4 ?S8?\&\G_!*GX]? [_@O+KM[\4O@;XMTCPO\&T\5-HOB77/ M#ES;Z?J4J2MI5N8+B5!'.7CNGF0HQW*A<<#->^_\$!_V%/BG\0KW_@HQ\!?C M[\*?%?@W1OBY+%HNE:KX@\-W-FES#)(FN+8S(HG\L7$4F4) W(?XAG]TJ M* /YH_V2OVU?^"@__!#WX$_$#_@FA\5?^"66K^,?'":WJ$GPN\;6V@275M'< M7*"-98\6DJZE;"51<1A&4L7:)]O\'Z$3?L(_\%%?^"C7_!OWXR^!W[<6D>'= M'^-_C/;KWA31[+P[:Z,]F;2:WN+&TOD@"Q1W,_D2JYPOE+=JKJK1N*_52B@# M^;O]G'_@H/\ \%@]?_X)RZU_P0U\)_\ !-'Q8OC?2_".I>%;_P"(FK6MY:1Z M)X=9)1.+BV:UV^:MLTD$4JS#?F+9'))@2>A?L!?LV?M%^&_^#3_]I'X->(O@ M%XUL/&&J^--1ETOPI>^%;R+4KR-ET7:\5JT8ED4^7)@JI!V-Z&OZ J* /PT\ M*_\ !*[X]?MH_P#!I9\-?V:-.^&VK:3\5/ VLZOXJ\.^$O$%@]A=W%U#K^L@ MVK).$:-YK.[F,>X ,SQ9(5MP^=W_ ."PW_!;/XW?L6^"_P#@DE\"/V$/B9X. M^+FA1Z3X?N_B3H!U/3]4^QZ>\2Q*T1MXO[/=EAA6XN)+CRVC\[P7MT M+I4C8K:W8!MQ,T97; JR,["U\.6W_".7%[>SK!?V5W>W;P00!H;;RTBCB.SRV\F3:['J>*K'P[2V5FL;FVG9TBD<%7B)P'W.J84DO\ MP4O_ .#F[_@HM\'_ !A\4OV1;_X8?"#X7:HL]_J$VFW26=E:&XAGO1]LN43[ M7>3_ &:&%(XU 3",4"B20_TET4 ?AC_P66_9Y_:I_P""T#_@M=\ _ MV7+SXO\ @+Q%I$-G\1/#FGZ>]P;::.P&G2),(XI6MT>WCMY8K@HR":-E<T336/]G>)O ]N+RXNU M@,<<=IJ#6\,LL[W#":0H&BABC\LX=E9_UZHH _GT^.WPB_X*=?\ !!__ (+* M_$W]KW]C?]CG7_C-\,?CA=WMV=-T'1+R\BWWMT+Q[21K..1[.X@NBXB+HRR0 MN0 26\O@OV!]5_;+\:?\':'@+XG_ +>/A"R\.?$?Q5H>I:UJ?A73W)CT"RF\ M(WJV5B02=KQVRP!P26WEMQWEJ^I?VSO^">W_ <"?LE?\%'O&'[9?_!*3XHR M_$+P5XZU&ZU*3X=^(_&\26>G3W>'N89;'4;F&V9%F+20RQ.'53MP,'?UW_!' M?_@DO_P4>/\ P4A\4_\ !7O_ (*X:KHEE\0[_19-.\.^%='O;6=X))+>.T\Y MS9E[>&**T0PI&CNSF1G<@KF0 Y3_ ((T_ ?XX^!?^#D#]LKXI^-_@UXKT;PQ MKL?B/^Q/$>J^';FWL-0W^(+.1/(N)$$E^$M9\(Z]'I'BC4?#MS!IU\[ZKHKHL-RZ"*4LL+_!>LP?#+PEI_@"'2-8-H M=/N]S3P01J[+(\D4<$,O"?QH^%GB/P MAJL_QOU.[@TSQ1H=QI]Q);MI&CHLJQSHK%"R.H8#!*,,Y!K]5J* /P]_X-4O MV7/C[X,^"'[7'@+XL?!WQ1X-NO%UY8VNB'Q9X>NM/%UOMM4C+Q^?&OF*ID3) M7.-P]17G_P#P:C_'K]JW]D+XZZ__ ,$K/BY^Q#XNTJ'7_&&IZ]XA\;ZI97=N MF@3V^F+']FEC-N8RLCVD:I,9E4F0!0^Y37] 5% 'GO[7&F:EK?[*7Q.T;1M/ MGN[R[^'NM0VEI:Q-)+-*]C,JHBJ"68D@ 9).*_,[_@SL^"OQD^!W["'Q+\. M_&KX2^)O!^H7?Q^$+*"S\;^&M,L)+NXC,"S0F9X8?WLEM/93O;2-&"8?+#$@-E?G; MXK^+?^"A'_!U'^UG\)_AIXD_8HUSX.? _P"'>J->>,M3U&6YGA42-%]K?[9- M;6ZS7#11"&"WCC+(97=R4W,G]&5% 'XN_P#!P5^S_P#&GX@?\%B/V'/%WPM^ M"GBG7/#_ (:\6:0VM:IH'ARYNK/2XD\063DSRQ1LD"K&I;+D *I/04[_ (.B M?@1\2V M;W=OI%I,\;7NGZN+];2>6&.0VWGI)M1V4Y*N0&*$5^OO[$O[0'B_]JG]D_P) M^T3X]^$=_P" ]8\7:%'J%_X/U02^?I3LS#R6,L<3MP 0Q1=P(( !%>IT4 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YY\(8]"\$:;="1Y]8U!V15@ACC5F8[I(P6("@NN2-PS M%;?M@_LLWG[1=Q^R):_'_P *2?%"TMQ/<^ DUF(ZK%$;=;D.UOG>!Y#I)G'W M6!Z&ORZL?%-Q_P %$O\ @[//AS4)C>>"_P!DKX>7,VF6K'-N^KR1P1S2X[3" MZU%1G_J&(?X>?0_"W_#L/_B)^\2?V7_PN7_AIG_A&X_[1\[^SO\ A#OLW_"- M6N/+Q_I6_P"Q>5UX\[=_#B@#]2J*_//XU_\ !S7_ ,$TOV>_BI\7?@S\5Y?' M&F:]\'[^2PU.V?0[9AKUZL_D_9M-"W1:9R=SYE6%%1&9F7@'JO\ @E1_P7X_ M8J_X*U>,]=^%?P7TGQ5X6\8Z%IYU%O#?C*SMXY;ZQ$BQO<6\EO-*CA&DC#H2 MKC>" RY8 'W%117Y>^-/^#MW_@EGX,\">*?$]UI7Q'?6/#?B4Z'#X0;0;-=0 MU29=_F3P 7C1K;1E &DE>,Y=0JN<@ 'ZA4CNL:&1V 51DD]A7YA2_P#!VQ_P M2GB_90A_:4;4/&)UF?67TI?A8NE6Y\0+.B*[3%?/\@6NUU(G\W!R5 +JR#Z9 M_P""8?\ P5L_92_X*V?!K7?B9^SJ^N:?<^&KI+/Q5X7\26D4.H:8TJ.T3D12 M21O%*$DV.KG/EN"%*D ]/\ @]^W1^QQ^T'X \2?%7X'_M,^"_%?AKP="\WB MK7-"UZ&YMM*C2)IF:>1&(C C1G)/\*D]J/!O[='[''Q#^!.M?M/^!?VF?!>K M?#OPY-+#KWC2PUZ&33;"2-8VD66<-L0J)8R03P'7UK\K?^"1O_#LC_ATI^V1 M_P .S/\ A2GCXZ M]#_932?:3:[1<;MF?/!BQG[XQUKNOAK\2_A_\8_ 6E?%+X5>,=.\0^'-=LUN M]&UO2;I9K:]@;[LDZYX:^!WAGX=VESH^K?$#RCJB6!.V%)TM05DN7=E18X@2[LJJ"3 MB@#ZWHK\F_AA_P 'CG_!++Q_\8(/AQXB\'?$_P )Z+>7HMK?QKKV@VAL8LMM M$LZ6]U)/%$>NX1N0.65>DL$T:R1N/8JP M/XUHT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 ?B7_P;C2R^)_\ @M3_ ,%!?&FNDMJ:_$&_A4O]Y(W\0:F6 M0>@'DQC'^R*R/ W_ "N\>,_^Q,B_]0NQKKO^";^@2?L=_P#!U-^U+^S]KR?9 M;'XO^%;CQ?XZ5_P)/\ M@I[>>%-)'PDU+PW'9VNJC783=-*/#=K8$&VSY@'VB)USCH >AH ^2O\ @E3\ M$OAK\7?^#L;]J?7OB/X0L-9;P7_PE&L^'X]1M5E6TU ZO86JW"JP(WK#"O#'PI_X/7?&/ACX>:':Z/INI>')KNYL-/@6*)IKCPG;74[; M5 &9+@M,WJ[$]Z^GO^";?_!+?]KW]FO_ (+N_M*?MY_%7PGI-K\.?B7IFM0> M%-0M==AFN)WN=7L+J(/ IWQYBMY"=PX( [TFB?\ !+;]KVQ_X.<=8_X*?7'A M/21\)+SPXMG!JHUV$W1E'AJ#3\&VSY@'VA&7..G/2@#]1*_ ?_@T/^!_PO\ M'7[7'[7?Q8\9>"=,U36?#NL:=I>BW=_9),UI;WUYK#72IO!V^9]D@!(ZA2.A M(/[\5^7G_!NC_P $M_VO?^"&> M*WFU=Y2XB)\L@7D& W7*M0\ Z5!-0 M;1O"Z7-BDBZ?;76J7ZR")6!"$I9QQY&#L++T8@]3_P &N&AZ5X%_X*:_MT_# MSPI91V.C:9XAFMK'3[=0D4,4&M:G%"BJ. %0E0.P-?37_! __@EO^U[^P'^U MG^U%\6_VD?"FDZ=HOQ2\26]YX0FT[78;MYXDO]3F8R)&28CLNHCANY([&HO^ M"*7_ 2R_; _8E_;^_:N_:!^/OA/2;'PU\6=?NKKP9T?\$O_ /E4*_:E_P"Q MIU[_ -)-&KZD_P"")7_!'7]N/]B'_@G%^U)^S=^T!X+T6P\5?%/0KVU\'VMA MXBM[J*>231[FU4221DK$/-E09;L<]J/V'O\ @CK^W'\#?^#>OXZ?\$\/B%X+ MT6W^)WCO7=5NO#NFV_B*WEMI8Y[?3DC+W"G8A+6TN03Q@>HH ^6M4_Y4?=._ M[&IO_4XEKS__ (+)_$+QGI/_ ;J?L&?"O3=1EM] \1:>+W6MC$))-:6:K;A M\=0!=3MM/&5!ZJ,??L[!L9Z_+UKTGXS_\$,/%W[8?_!!_X5?\$]_BSJVF^%?B MM\-/#MA*6)X)I(02]O+'*\;,F2I*2!7,81@"+_ (+??\$U M_P!AWX=?\$(/&O@KP-\%_"^D0?"GPA9ZAX&UZRTN".[M[J"6!/-^T*NZ1[E2 MR2LQ/FF8L) M+:V4$_PQQ1I"/:$"O4?$G_!,+_@ZA_;%^#GAW_@FC^U'XQ\/Z'\%]&N+2VOO M&%[XATBX%[96C(;<3&S=K^\$016CCEC3>Z1F5@5#K]F?\%C_ /@BE\4_BQ_P M1Q^$O_!-O_@GSX7LM3E^&OC72KM5UO5X;$W%K!IVI17%V[N0AFEN;L2LJ]6E M8@ "@#R'_@KO^RA\ _A;_P &I/A"S\'_ MT2RN/#'A/P+J^GWMOIT:SC4;N M:QCO+LR ;C+,+JX+MG+>8<\8KAOVE_\ @FQ^U#_P4F_X-P_V1]9_99LDU[QC M\,M!M]23PM/=11MJEFT+P,(3,1&\T7EQ%8W(#IY@!+;4;[J_X*=?\$__ -I/ M]J#_ ((36_[!WPC\.Z==_$6/PAX.T]M/N]6B@M_/T^XT][D>>YV8"V\N#GYL M#'6O"OVC?^"*G[>7Q:_X(O\ P!_9S^"_QSO?A]\:?@MHP%WH6G^,9[;2M<+$ M&2VFEMF\MI4:.)X975D4^8AVB5G4 ^$M6_X+B>(M3^+'@/X0?\'$O_!)+1?$ M2^#KQHM)\1WO@^[T75=+C?8DMP;"?_1[^/Y4)BC\J,[5902!G])O^#KB?PQX MW_X(>^)O%^E7L-Y:-XC\-ZAH]W$%_-D<_-) MC2K=0Y]20 <^]?0]<7^S?\(K+]G[]G?P%\!=-E22W\$>"]+T""1!A62SM(K= M2/8B,5VE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% 'Q_^VE_P2_U?]H+_@H+\ /^"C'P9^)UCX2\:?""_ELO M$:WFG/,OB/P_-O$MCN1E,3A)[Q4M\\Q;:J(8K)U0*6WV@YPQ ^P** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBOR6_;(_P"3I?'7_8Q3_P Z M /UIHK\2Z* /VTHK\2Z* /VTHK\2Z* /VTHK\2Z* /VTHKS7]CG_ )-;\"?] MBY;_ ,J]*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR6_;(_Y.E\=?\ 8Q3_ M ,Z_6FOR6_;(_P"3I?'7_8Q3_P Z /-**** "BBB@ HHHH **** /UJ_8Y_Y M-;\"?]BY;_RKTJO-?V.?^36_ G_8N6_\J]*H **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "OR6_;(_Y.E\=?]C%/_.OUIK\EOVR/^3I?'7_8Q3_SH \THHJC:^)_ M#E[XAN_"=GKMI+JFGV\-Q?:='<*9K>*4N(G= E5YK^QS_R:WX$_[%RW_E7I5 !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !117._%[_DDWBC_L7;W_T0] '145^)=% '[:45^)=% '[: M45^)=% '[:45^)=% '[:45^-WP?_ .2M>%O^QCL?_1Z5^R- !1110 4444 % M%%% !1110 4444 %%%% !1110 5^2W[9'_)TOCK_ +&*?^=?K37Y+?MD?\G2 M^.O^QBG_ )T >'?&G7O$WA;X.>+/$_@JW,VLZ=X9O[K2(A'OWW4=N[Q+M_BR MX48[U^8O_!/3X-ZI\?/C#;_%[X7_ +4VIV7CO2+?2-8\27&KW#SMJ+2W.H"^ MLWC+*\J[(K09+%=LK$_?7;^HGQ.\9R_#GX%/"NCS!9 M)=6GNKY+V(Q*."OE6S93:F)%!'[X4 ?4?_!8'XT_M+OX#\3_ O^&G@&ZTOP M1H-AI]YXP\;M,T?VLSW,4<-E;G Y$CQM)M+,5'.U=V(51W9@.]>>_\%=MW_#O#Q_O !_X ME.0/7^UK.O./VPOA%^T_\;OV1O@GX+_9_P#AS;^*=+@T_3-1\6:+=ZI;VL-V MD%I;M;PRF6>)GB9C)N5&SE5.00IH X__ ()A_$SXS?$_]MGXL^.OBM;SQ:QK M/A&TU6UT>XN6\NV@N?(GLXES]U1;R0@'&<=>T4ERB+!&NW=D(9) @(01Q[#&1DUL_L>^.OV MP3_P5"\;:E\1_@WX=T?4[W1["/XEV=M?Q>1H>GQV=OY$T!%TP8LJ6Y(5I<;V M^5F M&)&/:MRJGA_7=(\4:#9>)O#]\ES8:C:1W5C_P"23>*/^Q=O?_1#UT5<[\7O^23>*/\ L7;W_P!$/0!^-M%% M% %+Q'XD\/\ @_0;OQ3XKUNUTW3;"!I[Z_OIUBAMXU&6=W8@*H'4FKB.LB"1 M&!5AD$'@BOSF_P""U/C'4+SXIZ#\*_&_C34M'\'GX?:EJVFV]F[+#J>MIYRQ M0RX!# ;(<9''FD KOS7M_P -/V%/&-W^R7KO[.LO[5.IWGA[6-:BU#P7KVG$ MR7>EZ>)$D6V$PD E4A!]W:H+O@8. ?5=%?FG\*/V._$_AS_ (*-Z%\&? _[ M3'C'Q'I_@&&T\1^.;V_NW2*&194EM[ *)&#F3]WN!_@=L_&[]I MOQCX]T?0AX$O/"_PT\.?$RRTFWU22=DE\1:B1(_FKPI,"(D@ 7*[FY9C@( ? MI#1110!T?P?_ .2M>%O^QCL?_1Z5^R-?C=\'_P#DK7A;_L8['_T>E?LC0 44 M44 %%%% !6+IOQ'\ :QX\U3X7:5XRTVX\1Z)86M]J^APWB-=6=M"/ 'PO M\8:U\1QJMSJNI7.O7%YK_P#PE-AJEN]RAD-UY4,4L;D!56 KF-_W@!^[M%?F M;_P/_ /@H4?V0_B)\/OV9_#^G^$OA?I/PS;7?B5\5;G5O]-OE:XEA_P"$ M>T^V3YTD<)&\UPQ""&?8#N.'^KOVA_V&?A'^WS^SEX'^'7QH\5>--,LM)BLM M3M[CP5XMN-(N9)OL9BQ)+ 0SIMD8[3QD ]J /H2BOR=_X)=?L%_#&T_X*T_$ MGXP?LX?%/XG7'PJ_9]\WP5'_ ,)3\0[[5HO$WC*:W8:EE9F*""P@G6 IMR;A MPX8A *_6*@ HHHH **** "OR6_;(_P"3I?'7_8Q3_P Z_6FOR6_;(_Y.E\=? M]C%/_.@#S0@$8(KQ3X?_ +!7[/7PW_:&UC]H/P[\/M#AN[^UMAIEA%HZJFE7 M2-,9KJ$[BJO*)(P=J+M\K@_,:]KHH P_B/\ #;P+\7?!MY\/?B5X9MM8T34/ M+^VZ=>*3'-YBZ-I?AW1K3P_HEDEM96%M';V=M&/EBB10 MJ(/8* /PJS10!R:? SX21^-/$/Q$C\"6*ZYXKT];'Q%J:JPEOK=8UC$;G/0( MBKQCA17GO_#M_P#89_Z-G\-?]^'_ /BJ]NHH JZ%H>D^&=$L_#>@V*6MCI]K M';65M$/EABC4*B#V"@#\*M444 ?K5^QS_P FM^!/^QE5YK^QS_P F MM^!/^QE4 %%%% !1110 5BZ;\1_ &L>/-4^%VE>,M-N/$>B6%K?:O MH<-XC75G;7+2K!+)&#N1)&@F"DC!\MO2N1_;'\0?%;PG^R'\5/%/P(LYKCQQ MIGPWUR[\&V]O#YDDFJQZ?.]HJI@[F,XC &.2<5^-7_!*K]@#]D7]K7X@Z#\> M_P!AO]H^70/BIX(\ ?"_QAK7Q'&JW.JZE '[NT5^9L_[+_A'_ (*U_P#!3W]H_P *_M>^./&%SX&^ __9R^,WPN,NHW?@B\UKP1XMNR!%!J*"15@C9? MG60F, C.UMT8(.X5+_P2/CTKP=KOQI\!_#KQO=:Y\,O#WB2T'A+5+F?S(O,: M*9KL1N %8#$.64 -\KC[]?1?[5?[+7PX_:Q^%=[\.O'.E60NVMI1HFN3V GF MTF=UQYT7S*<\#*[@&P,]*ZGX??"/X;_"OP%%\,_A_P"#=/TG1(H63^S["V$4 M;[AAV8#EF;NQ))[F@#YI_P""1D$WCOX?_$+]J'6XR=5^)'Q"O;II7'(M(CB& M/Z(\DP Z 8':J?\ P6>_Y(Q\-O\ LL&E_P#I-=U]3?#/X6_#WX-^$8/ 7PO\ M*6FBZ/;22/!I]DI$:,[%G(R3U8D_C4/Q.^#WPQ^,VF6.C?%+P99ZW:Z;J4>H M6,%ZI*PW**RI*N"/F =A^)H Z6BBB@#H_@__ ,E:\+?]C'8_^CTK]D:_&[X/ M_P#)6O"W_8QV/_H]*_9&@ HHHH **S_$'BK0?"T<?]#!_P"2DW_Q% &;^TI\8Y?V=_V>O&_Q\B\#ZAXE_P"$*\*7^N/H M&DLHNM02U@>=H8MW&]E0@#N<#FOQ%_;W?]COQ=KGBO\ X*J_L01:5X-^+)\' M_"'Q+\%KGP/>I:3ZUX@UK7-<@U'3+BWMBJ7TT\$ CN4=#)FT8/@"16_[U&V!8Q))<+<6R@)#'Y/V/*-F5L '0_\%]O^4-W M[0O_ &3Z;_T;%7L7Q4^-5I^S;^PEXA_:'OH4EB\"?">Z\0/#(>)/L>FM<;/^ M!>7C\:U/B\O[./Q\^&FL_!SXQZ=9^(?"_B&S-IK6BZA93F&[A)!*. H)&0._ M:E\?G]G/XI_"S5/@E\0K"TU7PGK6CR:5JNA75E.8+FR>/RW@8!0=I3Y2,]* M/%O^"'OP/NO@7_P2U^$-CKTLEQXA\7>&D\9^++^XYGO-4UECJ4[S-_%(#RF$=O;Q($CC4;>%55 M 'L*O?\ "W/AY_T,'_DI-_\ $4 =)17-_P#"W/AY_P!#!_Y*3?\ Q%:'A_QE MX;\4R20Z%J7GM"H,@\EUP#T^\!0!J4444 %?DM^V1_R=+XZ_[&*?^=?K37Y+ M?MD?\G2^.O\ L8I_YT >:4444 %%%% !1110 4444 ?K5^QS_P FM^!/^QE5YK^QS_P FM^!/^QE4 %%%% !1110!Q/[2GQCE_9W_9Z\;_ M !\B\#ZAXE_X0KPI?ZX^@:2RBZU!+6!YVABW<;V5" .YP.:_$7]O=_V._%VN M>*_^"JO[$$6E>#?BR?!_PA\2_!:Y\#WJ6D^M>(-:US7(-1TRXM[8JE]-/! ( M[E'0R9M&#X D5OWO=$D0QR(&5AAE89!'I7R+\%?^"(__ 3Y^ W[:^N_MJ_# M_P#9S\&V.JWMAIW_ C6E6OA_9#X=U*&6]>[U&V!E,227"W%LH"0Q^3]CRC9 ME; !Y'\?OV=?V??C[_P4J^*VO_L__M[?$C]G/XL^%?!>B#XWR>'WL;>Q\6:# M);N]I?I]M5T\RVB#6YO57_1R F 3EM;_ (-Q/A3X1^'W[&'Q!\;_ NL[^/P M+\0_V@/%?B+X>3ZK9-/\TNW+^9NR=V3]'?M8?\ M!,_]@S]N7Q+HOC/]K']E[PQXVU?P_'Y6E:IJENZ7$<.\N(&DB9&EAW%F\J0L M@+,=OS'/LOACPQX;\$^&[#P=X-\/V6DZ1I5G%::7I>FVJ06]I;QJ$CABC0!8 MT50%55 H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !7._%[_DDWBC_L7;W_T0]>::I^P1\&M7U.YU:Y\5>-UDNIWF MD6+Q?_P3_Z&WQW_P"%E<_XT ?E_17Z@?\ #O?X)_\ 0V^._P#PLKG_ M !H_X=[_ 3_ .AM\=_^%E<_XT ?E_17Z@?\.]_@G_T-OCO_ ,+*Y_QH_P"' M>_P3_P"AM\=_^%E<_P"- 'YQ?!__ )*UX6_[&.Q_]'I7[(UX7_P[W^"?_0V^ M._\ PLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__ LK MG_&C_AWO\$_^AM\=_P#A97/^- '9_'__ )!VF_\ 7>3^0KS"MS_AWO\ !/\ MZ&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@##HK<_P"'>_P3_P"AM\=_^%E< M_P"-'_#O?X)_]#;X[_\ "RN?\: ,.BMS_AWO\$_^AM\=_P#A97/^-'_#O?X) M_P#0V^.__"RN?\: ,.BMS_AWO\$_^AM\=_\ A97/^-'_ [W^"?_ $-OCO\ M\+*Y_P : ,.O0O@!_P A'4O^N$?\S7,_\.]_@G_T-OCO_P +*Y_QH_X=[_!/ M_H;?'?\ X65S_C0![I17A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ MA97/^- 'NE?DM^V1_P G2^.O^QBG_G7WK_P[W^"?_0V^._\ PLKG_&C_ (=[ M_!/_ *&WQW_X65S_ (T ?E_17Z@?\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;? M'?\ X65S_C0!^7]%?J!_P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/ M^- 'Y?T5^H'_ [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^- M'Y?T5^H'_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C0!U7['/ M_)K?@3_L7+?^5>E5X7_P[W^"?_0V^.__ LKG_&C_AWO\$_^AM\=_P#A97/^ M- 'NE4/$^M_\(YH-SK?V;SOLZ;O*W[=W('7!QU]*\:_X=[_!/_H;?'?_ (65 MS_C1_P .]_@G_P!#;X[_ /"RN?\ &@#K/^&@_P#J4?\ R?\ _M='_#0?_4H_ M^3__ -KKD_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__ LKG_&@#K/^ M&@_^I1_\G_\ [71_PT'_ -2C_P"3_P#]KKD_^'>_P3_Z&WQW_P"%E<_XT?\ M#O?X)_\ 0V^._P#PLKG_ !H ZS_AH/\ ZE'_ ,G_ /[71_PT'_U*/_D__P#: MZY/_ (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO_P +*Y_QH ZS_AH/_J4? M_)__ .UT?\-!_P#4H_\ D_\ _:ZY/_AWO\$_^AM\=_\ A97/^-'_ [W^"?_ M $-OCO\ \+*Y_P : .[\,?&C_A(]>MM$_P"$;\G[0^WS?MF[;P3TV#/3UKN: M\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &@#W2BO/O@S^ MS7X"^!FIWNK>$-9\0W4E_ L4RZUKDMVJJ&R"H<_*<]Q7H- !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%>1_M@?MX_L@_L#>!+;XD?M??'G1 M?!&E7T[0Z<=1,DMS?2* 76WMH$>>X*@@MY:-M##.,B@#URBO$_V,O^"C?[$? M_!0GP_J'B3]CK]HC1?&L6DLHU6SM8Y[6]L@V=C36EU'%<1(Q!"NT85BI )P< M8?[2O_!6;_@G#^Q[\5K7X'?M*?M?>$/"?BRZCB: /HBBJVCZQI/B'2;77] U2VOK"^MDN+*]LYUEAN(74,DB.I* MNK*00P)!!!%?,/[1_P#P6Q_X)OVC/VN='\+^,O#_V?^V-"NM' MU&62V\^WBN8LM#;.AW0S1/PQX< X.0 #ZGHKY>^&O_!:'_@F+\7_ WIWC+X M=_M9:1J&D:KXXLO!]GJATC4(;^_&'X MO_#/X ?"[7OC5\9?&5GX?\+>&-,EU#7=9OV(BM+>,99R%!9CV"J"S$A5!) ( M!TE%>!?'S_@J/^P%^RW\+_"7QB_:$_:;T+PEH7CO3HK_ ,(MJ\-REWJ=K)&D MBS1V8B-SL"R1EB8QLWJ&P2!7J7P2^.7P?_:1^&&E?&CX"_$C2/%OA76X3+I> MNZ'>+/;SA6*L R]&5E960X964JP!!% '5T5Q6B?M%?!/Q)\=]<_9DT#XB6-W MX\\,Z%:ZQK_AN#>TUA97+LL$DK!=BERA(3=OVE6*A64GM: "BB@D*"S' '4F M@ HKX\UW_@O_ /\ !'+PU\:7^ .L_MZ^#X_$4=]]CE=(+R33(YMVTJVII ;% M<'@DS@#!R17T[\2_C/\ "7X-?"[4?C;\5?B1HOA_PAI-@+W4?$FJZC'#900' M&V0RL=I#%E"X)+%E"Y) (!TU%>(?LA?\%)/V&/V]I=7M/V1/VE?#OC:ZT)5? M5]/T]Y8KJVC8X65H)T20QD\>8%*9XSGBNW_:/_:0^"7[(WP8UG]H7]HSQ];^ M%_!OA[[/_;.NW5O-+';>?<16T65A1W.Z::).%/+@G R0 =Q17Q=X8_X.'O\ M@C-XR\2:?X0\,_MT:#=ZEJM]%9Z?:IH.J@S3RN$C0%K0 $LP&20.:^DO@/\ MM1_ 3]IO_A*4^!WQ&MM=E\$>*KGPWXMM4MIK>?2M5M\>=:S13HCJR[ASMVGG M!.#@ [^BO/T_:F^ $O[06I_LL0_$NS?Q[HOA1/$NM:"D,K'3]+>3RTN)Y@GD MP[FZ([AROS!=O->9_ ;_ (*Y_P#!-3]I_P"-TO[.7P#_ &R?!GB?QFAE$&BZ M?>N#>F,%I!:RNJQ79559CY+O\JLW0$T ?1E%>"?M0_\ !4;_ ()\_L6_$/2O MA/\ M2?M7^$_!OB/6HDFLM'U2[=IEA=BJS3"-6^S1,0P$DNQ#M;!^4X]STG5 MM*U_2K;7="U.WO;&]MTGL[RTF62*>)U#)(CJ2&5E((8$@@@B@"Q1110 4444 M %%8'Q5^*'@;X)?#77?B_P#$W6FTWPYX9TJ?4M=U%;.:?[):0H7EF*0H[LJ( M"QVJ< $] :/A5\4_AY\2!0!]CT5 M\>_$'_@OQ_P2!^%/Q+USX/?$/]MS0-*\1^&M/\ Q-%X?\':>;::>?5=1D4LL,<<*.V 2TA M 1!C O"O[7?_!:']I[]J+XS:';:Y=_ ^_T+X??"6TU.$31 M^'8OL/VS4+J%&!5)YKB7(F #JFY <$U^AU?F_P#&'QUXS_X(]_\ !1_XG_M: M>+_@WXN\5_L^_M$6>D7OBC7_ /H4NIW'@7Q-IUN;0R7-K"#(;.Z@V.9E#$2 MKMVCC< :/_!5+P%X7_9;_;[_ &2O^"@OPCT:WT;Q=XM^.FF_"7Q[-IL(B/B3 M1M=@G1%O N//-O+;+)&6R5)!R=B[?1/BA\%_V)O^"7G[,O[27[2W[1-W#XHT MGXG^)=7\3^.Y/%EK;RW.LM>(L5KX>AP@,L(PMO;PG.WS23U9J^ O"G_!2KXE M?\%,OV_OV<_ _P"UOX0L/ /P<\#_ !OO_$?@3XI2^&=9TO2?B)KEO;[- TRW M&HVZBVO8S=2&022;9F5A%M)17L?$O_@IG\$_C7_P5 \2?&#]OWX'_&[5_ /P M-\6S:=\ _AQX;^%EY?:3<7]NS1R^*;YCM6XN6=3]E0@K!'AL;_F8 _1__@BQ M\'?C'\ ?^"5GP/\ A)\?;>ZM_%>D>"(1J-A?9\^PCEDDFM[20'E7@@DAA*G[ MIB*]J^'T_P""@W['?[#G_!;;]MVT_:I\(>(=4D\2WGPY?0SH?P^N=<$:P>%8 MA+O,$3^3DS1X!QNP<9VFOU"_9>_:+\&_M9_ CP_^T+\/O#WB'2M'\1Q3R66G M^*]'?3]0A$5Q) PFMW):,EHF(SU4J>]?,'[!?A;Q/I'_ 6/_;V\2ZKX'+_1/"_C6.XL]+U'4_",ND7NF:O:.&MKY8)$20&&=8W!XWJ&7.&-?% MOP6^,_[07_!9O4OA?_P2N_:3\(ZC82_ W53?_MI3W,+BWUR[T>[-OI&EK(0% MG34IH!?2XP"D1*'"C/[)5\0?\$Y?"OB;1/\ @J-^W;KVL>&[^TL=6\<>"Y-* MO;FS>.*]1/#J([1.P D"M\I*DX/!YH ]GNOV0O@5\-OVP/%W_!2;XC^+5;4T M^&UKX=@F\0FW33_">CV;SW-R]O(R@P+*9"\S,V,1]AD5\9_\$V?VE? G[)W[ M#O[3?_!1.W\"W>F?";QS\=M;\1_ [P7:636\VO6\XM;"S%E;;#]*M-=^)MM\-O!%Y?3> M/M6D\NXM-&EGBVB/3HXVCEF*/NDD/EX4HLB>YZQX,^ '_!>?]GWPG9?L]>.? MC+\!M,^"/C^SO_#X3P9'H<\5[;V12T,%O<*R>7 DO[ME \MAA<8H \[_ ."1 M_P /BI\!/\ @L!\8I_VA?$IU;XG^._@%X;\7_$V[28O!%K5]JVH-):6XR0M MO:Q)!:1 <>7:J>]?JE7Y.?L& XF5$(8-)D\$5^L= !7Q9_P ' GQ7^('P MS_X)C>+O#GPM\0S:/KGQ#UW1/ ]MK-NQ#V4.JZC!:7,@(P03;/.@(((+@@Y% M?:=?.?\ P5@_8V\2?MX_L&^.?V>/A_K<.E^+KB&UU;P1J<[;4M]9L+J*\M-S M$'8CRP")FP=JRL<'&* .M\$_L%?LA^ OV3X/V(M&^ OAR3X91Z(-,N?"]UID M;PWD>P(TL_&9)W/SM.?WA<[]V[FO@[_@F5^R7H7[:7[$M[^P_P#'[Q]K6J^& M/V2?VR=8\/:7;W!CGC\3Z;X>N?-L-/U 2JPFM0M[&ICXXM8E^ZI4XWQE_P"# MBK]H/P?X6\">"? ?[!WC1OCQ9ZREC\4O@/XA\!:R+S4!L$//V,_\ @AI&O M"=W>W'P\\1:G,UQJDEUI[1B5;FRM4@C6*0 /,\;KYD1&X ^PO%E]X/\ CI_P M<)_#I?V;=(M6NO@;\)-?M_CUXGTF$+$8]46W31]"N)4X>>.2&2[6$YVH2>"I M U/^#FJY@L_^")/QDN[E28XKSPH\@5=Q*CQ5I!/'?CM7#?\ !&#]M7_@GUX* M/A_]@_\ 98^"?QUM->\0S7VK>(O'?Q)^'%S:2>(M6$#W-WJ.I7TKG=/-Y3 9 MR!\D:X %>F_\'&WA;Q/XT_X(X_%GPUX.\.7^K:C<:AX5-OI^F6;SSRA/%&DN MQ5$!9L*K,<#@*2>!0!1_9Z_X+'?\$POVCOC7X<^"'PN^%GB^+Q#XCU%;729= M5^"U[8VZ38+ O/+;A(A\I^8D#.*\S_;\\=6?_!%C_@H/_P /1H=$OYO@M\;= M#;PY\=-)T>V,C6?B2RMI9=&U5(U_CG6-[-B<*"Y9B6D%?IQ7Q!_P<0^%?$WC M/_@ESXET'PAX;O\ 5KY_''A"1++3;-YY61/$6GN[!$!)"J"Q.. "3P* .;_8 MP_X)K^//C)^P=\7?$W[7/B75_"_QA_:_MY]5^*6K:,5%]X=TZYA,5CH4!E4A M8[2Q?R"C D-+,N3A37-?\%1/AS\&-!\1_L>?\$Y/V7?!6F1_$O0_B]X+-+T_P ,C6]T%OI?D0V4SQQ*+'2(XX?F:8N$,K'+$JH])_X(H^"Y_AY_ MP2B^ _@VY^*.E>,FLOA_:#^WM#U$7=HX8LX@BE'#K &%OVQY&,#&*\M\>_\ M!7[6/V)?VB?BS\$/^"A_PM\3V]HNMK?_ !UCP!\.=2U.W\9Z/-;1[=-1[=9 MD&I17"R))YS0H?,0C:NTMW'_ 0Q_9Y^+?[-7_!.3PKX,^-G@F3PIKFLZ[K? MB3_A"I#SX;MM2U.XO+?3R.-C1Q2H63 V.[J0"IH ^O**** "BBB@"'4=.T_6 M-/GTG5K&&ZM;J%H;FVN(@\"#7XP:E\4_VG?\ @EOJ?Q,_ MX(2?L]:7JESK_P 4_$,<_P"QWXA*2/#HF@ZU-,=5$THSY2Z.4NYU8Y8E@Y&T MJ*_:6OB#]KKPKXFU'_@N1^Q[XKT_PW?SZ7IO@?XC1ZCJ4-F[6]J\EE9"-9) M-J%B"%#$9P<9H ^@OV5/V)_@-^R3^S%X'_97\">#+"]T+P-HJV5G/J6GQR2W M,S'?P KY:_X-\/ O@BZ_8_\9ZM<^#M*DNK?]H?QR+>Y MDTZ(R1!-9EV;6*Y7;@8QTQQ7Z!5\0?\ ! KPMXG\(_L>>-=-\6>'+_2[F7X_ M^.+B*WU&S>!WADU>5DD"N 2K Y#=".10!RW_ 1%^&WPZ\<>$?VJSXU\ Z+K M&_\ ;;^(\;_VII4-QN07D!"GS%.1DGCWJ+_@G5X&\-?L>?\ !8;]I[]B7X.: M5#I'PX\0^%/#OQ+T#PI8(([+0M0NO-L]06VB7Y8DG>*.38H"J(U50%4"OG_] M@_\ X*K?"3_@G;XW_:7^!7QP_9R^.6J:YK/[6WCWQ!I+>#?A;=:A;7=E/C-^TU\19)@FNIY&E,+#O^"DG[+VBFX^+O[,VK2>)=,LH,J_B'P\R;=9T=RHR MRRVH=U !;,;*@#29K[CK+\<1O-X*UB**,LS:7FZO:F)III57^W-?,;?=D>3-C&P.#' M!(" 5!J__P %9/AW\/\ 3_VR?V';:P\"Z-!'=?M!S1W4<.F1*LR?V/=G:P"_ M,,\X-=W_ ,&]_AGQ'X._X(V? KPSXN\/WNE:E:>&[M;K3]2M'@GA8ZE=D!XW M 93@@\CH167_ ,%6/"WB?Q!^V'^Q)J6@^'+^^MM+^/\ -<:G<6=F\J6D/]D7 M2^9*R@B-,)_A;X+_9?^ M-T_@?Q)K^E> OVMO#/B'Q#:>%-$EU"\CL+:QU1Y9%AC&3C@#.!E@,C->2_ME M?\%!/%__ 6>^!EU_P $Z/V#/V2_C3IK_$[4+/3?'?Q-\?> )=&T7PIH*W,< MM[.TTKGSIWBC:-( 7#M@E@%(!^G?P5\>R_%7X.>$OBA-:+;OXD\,V&J/ N< M1&XMXYBHSZ;\?A735G^$_#&C>"?"NF>#/#MMY&GZ1I\-E8PYSY<,2"-%S[*H M%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 5-8T'0_$,$5KK^C6E]%!=PW4$=Y;K*L<\3B2*50P.'1U5U8)X#/\53J"V-J-)T M^*^R'L9%="T?GCE'RP0?*,FF_!K6/^#@^\\1ZC#^T!X1_9(L=)_X1S43I=QX M2NO$=Q<#5A;.;$21SLBM;FX\L2X97$98JW5Q<620:).)9;/4M M;G:20G;:0274AMU0,DD(55+DJ ?HM17QI^RM^VG^V_X9_;4C_8(_X*0_#CX9 MVGB7Q-X'N/%7PZ\:?"*ZOSI&JP6L\<-[830:@3/%='(&R4=">AX,/[=G_ M 5=E_9E_;S^ /["/PM\)6&NZU\3/&EE:^/M0O8Y7B\.:5="X6U4&-U"7=R] MO$_$=]J<&D0>)[SQ-!?*++4+FQD,J0O(@)DMG(VN %U#[/X?\ M&YED>PMO.NY3NL[N )&@:,2"82DOL4 ^@?M4_MO_ !2\(_MQ_!W]@3]EOPMH M.M^+_>)?B7?:]#/-;^%?!EL3'+=E(98V%Q<3D06Y8E-ZMO4@@T ?4=%?G M3KO_ 47_P""J/Q^/Q5^/?[ /[.GP=U/X/\ PF\4ZMH4=O\ $#6M2C\0>.IM M)8KJ$FFM:_Z/:1F1)(H3.'WLF3M!('9?$7_@J-\%Y_$MAJ7Q*DNH]"\'Z5;6\4ES)J#68\R:82S+;I%$PWNKMN"@;@#[D MHKYA_P""=G[:/QK_ &@_%?Q7_9G_ &LOAQX=\-_%_P""7B&PT[QDO@N^FN-$ MU2UU"T%YI^H637 \Z-)8=V8I,NA3DY;:OT]0 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^9__!;;PO\ M(^, M_P#@I#^PQX:_9&^)^A^#/B'G>#_ _P#94UK> M>:I,LCX^=/+#+M]2#6_^T;^Q9J?QV_;;_9T_:XM/B!!IMO\ N]\53W>AR:< MTKZN-7TG^SU"2AP(?*/[PY5MPXXZU[]0!^17_!2O]A:XUK_@L!\._P!G?P-\ M19/#_P ,/VV89[KX\^%+.)E_M67P?'#J#-&ZD>2;V&6&VE*\D+(S%B^*_47X ML_$SX+_LS?!K5/BO\6/$&D>%?!7@K23=WVH7:+%;:=;0KM4(JC@XPB(@+,65 M%!) /F/[0/[%>I_&S]O']GG]LJU^($&GVWP/M?&$-UH$FG-))J_]MZ?;VBE) M0X$/E& LW,L:2P)(7=H9 \*? ?XF>+OB5XX M^(__ <,?M9> M9\*?#GP1\)-2L/@/\ #Z[M\:H?#4>;VZUNZCSB.ZOS#&L, M>0$AV[BP*R-\'3_\%+O^">EW9_L\?M$?$/\ :Y\/ZS\7_%7[6>D_$[X^W%GI M>H,GAVP32M1MK;3D=[<>9:Z=!+:VBJA?+^;(N1(37ZT_LD?LU?\ !5_X=?%Z M#7?VQ/\ @HOX/^)_@8:=<0W7A'2O@[::-)+,RXBD^T1R,0J'DIC#=*[+]LO] MABP_:G\7_!/Q-H^O:9H*?";XQV'C:]@?1A-_:L-O:7EN;,%67RRQN@V\[@-F M-ISD 'N?A;Q/H7C;PQIOC+POJ*W>F:O80WNG7:*RB:"5 \;@, 0"K X(!YJ_ M2(B1H(XT"JHPJ@8 'I2T %%%% !1110 5^)'_!%;X#_\%M?&G_!-[P-XE_9" M_;P^%G@OX>7.K^)/^$?\->)/AM_:%[9[?$&HK/YD^/WF^X6:1?175>U?MO7@ M/_!,#]BS4_\ @GI^Q)X1_9'UCX@0>*+CPS>ZS/)KEMIS6J7 OM6O-0 $3.Y7 M8+H1GYCDH3QG #]M#]B.V_;N_8)UK]DOX[>(K:7Q!J_ABW"^*]/MC$+#Q#; MHDD&IVZC#1A+I!)M4@E"R9PQKYJ_X-R_"?B_XS?LGW/_ 5$_:$\6KXG^+/Q M_E4ZYK;6^P6.E:1))I=G80KR$7-M+ _P#!+K]B MS4_^"=_[!_P__8VUGX@0>*;GP5:WT4NO6NGM:1W?VC4+F[!$3.Y3:+@+]XYV MY[XH \;_ ."G?[7'C_QEXED_X)0_L$V\&I_'#XF:+(OB?6HT)L?AMX=N!Y=S MK>H.GW9VC1T;O&LOO?PT_9\T;]F[]D/0OV&OV:/BW:>%-<\-_#@:- MX*US4K&'4+JT:&!8%U1[)W07169EE=251G;:2 U?$OP>_P""/_\ P5Y_9T^) M7Q,^)WP+_P""KO@32=2^*WC6X\2>*]0U'X%6^H7EU,Y(BA-Q<7#2>1#'\D4( M(CC!;:HW'/MGQS_X)S_M?_$.#X.?M+^!OVP]#T_]I?X3:1?:7?>.[[P0IT'Q M?87I'VFRO-.AE4Q192-XVC?,;JQ )8,@!P'_ 2%T7XE_LS?MU?M*?L:?M1> M)[;Q[\6-3ET?XA7_ ,:(+=K67QCI-U&]G;Q3V6YH[ V9@,"00L8]CG:!C+?H MI7R_^P-^P3\2OV=_B7\0_P!JW]JKXZ6_Q)^,_P 4S8P>(M=TO1/[-TO2=,LD M=;33-/MB[M'"AD=F=FW2L0S#<"6^H* "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** )** "BBB@#__9 end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - shares
 6 Months Ended
Dec. 31, 2023
Jan. 26, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Dec. 31, 2023  
Document Transition Report false  
Entity File Number 1-11373  
Entity Registrant Name Cardinal Health, Inc.  
Entity Central Index Key 0000721371  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Incorporation, State or Country Code OH  
Entity Tax Identification Number 31-0958666  
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code 614  
Local Phone Number 757-5000  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   243,233,153
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]        
Revenue $ 57,445 $ 51,469 $ 112,208 $ 101,072
Cost of products sold 55,599 49,806 108,594 97,795
Gross margin 1,846 1,663 3,614 3,277
Operating expenses:        
Distribution, selling, general and administrative expenses 1,283 1,191 2,480 2,388
Restructuring and employee severance 28 17 53 46
Amortization and other acquisition-related costs 63 71 127 142
Impairments and (gain)/loss on disposal of assets, net 1 710 538 863
Litigation (recoveries)/charges, net (11) (207) (52) (180)
Operating earnings/(loss) 482 (119) 468 18
Other (income)/expense, net (16) (7) (18) (5)
Interest expense, net 8 25 22 50
Earnings/(loss) before income taxes 490 (137) 464 (27)
Provision for/(benefit from) income taxes 136 (7) 104 (8)
Net earnings/(loss) 354 (130) 360 (19)
Less: Net earnings attributable to noncontrolling interests (1) 0 (2) (1)
Net earnings/(loss) attributable to Cardinal Health, Inc. $ 353 $ (130) $ 358 $ (20)
Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:        
Basic (in shares) $ 1.44 $ (0.50) $ 1.45 $ (0.08)
Diluted (in shares) $ 1.43 $ (0.50) $ 1.44 $ (0.08)
Weighted-average number of common shares outstanding:        
Basic (in shares) 245 261 247 266
Diluted (in shares) 246 261 248 266
Cash dividends declared per common share $ 0.5006 $ 0.4957 $ 1.0012 $ 0.9914
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]        
Net earnings/(loss) $ 354 $ (130) $ 360 $ (19)
Other comprehensive income/(loss):        
Foreign currency translation adjustments and other 6 20 (5) (38)
Net unrealized gain on derivative instruments, net of tax 4 10 1 6
Total other comprehensive income/(loss), net of tax 10 30 (4) (32)
Total comprehensive income/(loss) 364 (100) 356 (51)
Less: Net earnings attributable to noncontrolling interests (1) 0 (2) (1)
Total comprehensive income attributable to Cardinal Health, Inc. $ 363 $ (100) $ 354 $ (52)
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Millions
Dec. 31, 2023
Jun. 30, 2023
Current assets:    
Cash and equivalents $ 4,591 $ 4,043
Trade receivables, net 11,788 11,344
Inventories, net 18,451 15,940
Prepaid expenses and other 2,816 2,362
Assets held for sale 12 144
Total current assets 37,658 33,833
Property and equipment, net 2,446 2,462
Goodwill and other intangibles, net 5,371 6,081
Other assets 1,098 1,041
Total assets 46,573 43,417
Current liabilities:    
Accounts payable 34,259 29,813
Current portion of long-term obligations and other short-term borrowings 1,188 792
Other accrued liabilities 2,839 3,059
Liabilities related to assets held for sale 0 42
Total current liabilities 38,286 33,706
Long-term obligations, less current portion 3,535 3,909
Deferred income taxes and other liabilities 8,199 8,653
Preferred shares, without par value:    
Authorized—500 thousand shares, Issued—none $ 0 $ 0
Preferred shares, authorized 500 500
Preferred shares, issued 0 0
Common shares, without par value:    
Authorized—755 million shares, Issued—327 million shares at December 31, 2023 and June 30, 2023 $ 2,855 $ 2,747
Common shares, authorized 755,000 755,000
Common shares, issued 327,000 327,000
Accumulated deficit $ (425) $ (534)
Common shares in treasury, at cost: 83 million shares and 76 million shares at December 31, 2023 and June 30, 2023, respectively $ (5,724) $ (4,914)
Common shares in treasury 83,000 76,000
Accumulated other comprehensive loss $ (155) $ (151)
Total Cardinal Health, Inc. shareholders' deficit (3,449) (2,852)
Noncontrolling interests 2 1
Total shareholders’ deficit (3,447) (2,851)
Total liabilities and shareholders’ deficit $ 46,573 $ 43,417
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - shares
shares in Thousands
Dec. 31, 2023
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred shares, authorized 500 500
Preferred shares, issued 0 0
Common shares, authorized 755,000 755,000
Common shares, issued 327,000 327,000
Common shares in treasury 83,000 76,000
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Retained Earnings
Treasury Stock, Common
Accumulated Other Comprehensive Income/(Loss)
Noncontrolling Interest
Common shares in treasury       54,000    
Balance at beginning of period (in shares) at Jun. 30, 2022   327,000        
Balance at beginning of period at Jun. 30, 2022 $ (706) $ 2,813 $ (280)   $ (114) $ 3
Treasury, balance at beginning of period (in shares) at Jun. 30, 2022       (54,000)    
Treasury, balance at beginning of period at Jun. 30, 2022       $ (3,128)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (19)         1
Net Income (Loss) Attributable to Parent (20)          
Other Comprehensive Income (Loss), Net of Tax (32)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (32)       (32)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   2,000    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 58 $ (16)   $ 74    
Purchase of treasury shares (1,250) $ 50   $ (1,300)    
Treasury shares acquired (in shares)       (16,000)    
Dividends (260)   (260)      
Stockholders' Equity, Other Shares          
Other 1       1
Balance at end of period (in shares) at Dec. 31, 2022   327,000        
Balance at end of period at Dec. 31, 2022 (2,212) $ 2,747 (560)   (146) 1
Treasury, balance at end of period (in shares) at Dec. 31, 2022       (68,000)    
Treasury, balance at end of period at Dec. 31, 2022       $ (4,254)    
Treasury Stock, Value, Acquired, Cost Method (1,250)     $ (1,200)    
Purchase of noncontrolling interests 2         2
Common shares in treasury       65,000    
Balance at beginning of period (in shares) at Sep. 30, 2022   327,000        
Balance at beginning of period at Sep. 30, 2022 (1,780) $ 2,576 (301)   (176) 1
Treasury, balance at beginning of period (in shares) at Sep. 30, 2022       (65,000)    
Treasury, balance at beginning of period at Sep. 30, 2022       $ (3,880)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (130)         0
Net Income (Loss) Attributable to Parent (130)          
Other Comprehensive Income (Loss), Net of Tax 30          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 30       30  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   1,000    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 47 $ 21   $ 26    
Purchase of treasury shares   $ (150)        
Treasury shares acquired (in shares)       (4,000)    
Dividends (129)   (129)      
Balance at end of period (in shares) at Dec. 31, 2022   327,000        
Balance at end of period at Dec. 31, 2022 (2,212) $ 2,747 (560)   (146) 1
Treasury, balance at end of period (in shares) at Dec. 31, 2022       (68,000)    
Treasury, balance at end of period at Dec. 31, 2022       $ (4,254)    
Treasury Stock, Value, Acquired, Cost Method $ (250)     $ (400)    
Common shares in treasury       68,000    
Common shares in treasury 76,000     (76,000)    
Balance at beginning of period (in shares) at Jun. 30, 2023 327,000 327,000        
Balance at beginning of period at Jun. 30, 2023 $ (2,851) $ 2,747 (534)   (151) 1
Treasury, balance at beginning of period (in shares) at Jun. 30, 2023 (76,000)     76,000    
Treasury, balance at beginning of period at Jun. 30, 2023 $ (4,914)     $ 4,914    
Balance at end of period (in shares) at Sep. 30, 2023   327,000        
Balance at end of period at Sep. 30, 2023 $ (3,490) $ 2,728 (654)   (165) 1
Treasury, balance at end of period (in shares) at Sep. 30, 2023       80,000    
Treasury, balance at end of period at Sep. 30, 2023       $ 5,400    
Balance at beginning of period (in shares) at Jun. 30, 2023 327,000 327,000        
Balance at beginning of period at Jun. 30, 2023 $ (2,851) $ 2,747 (534)   (151) 1
Treasury, balance at beginning of period (in shares) at Jun. 30, 2023 (76,000)     76,000    
Treasury, balance at beginning of period at Jun. 30, 2023 $ (4,914)     $ 4,914    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 360         2
Net Income (Loss) Attributable to Parent 358          
Other Comprehensive Income (Loss), Net of Tax (4)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent $ (4)       (4)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 1,000        
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture $ 57 $ 8   49    
Purchase of treasury shares (750) $ (100)   $ (750)    
Treasury shares acquired (in shares)       (9,000)    
Dividends (249)   (249)      
Stockholders' Equity, Other Shares       (1,000)    
Other $ 1   0     1
Balance at end of period (in shares) at Dec. 31, 2023 327,000 327,000        
Balance at end of period at Dec. 31, 2023 $ (3,447) $ 2,855 (425)   (155) 2
Treasury, balance at end of period (in shares) at Dec. 31, 2023 (83,000)     (83,000)    
Treasury, balance at end of period at Dec. 31, 2023 $ (5,724)     $ (5,724)    
Treasury Stock, Value, Acquired, Cost Method (759)     $ (859)    
Common shares in treasury       (80,000)    
Balance at beginning of period (in shares) at Sep. 30, 2023   327,000        
Balance at beginning of period at Sep. 30, 2023 (3,490) $ 2,728 (654)   (165) 1
Treasury, balance at beginning of period (in shares) at Sep. 30, 2023       80,000    
Treasury, balance at beginning of period at Sep. 30, 2023       $ 5,400    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 354         1
Net Income (Loss) Attributable to Parent 353          
Other Comprehensive Income (Loss), Net of Tax 10          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 10          
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   0    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 57 $ 27   $ 30    
Purchase of treasury shares   (100)        
Treasury shares acquired (in shares)       (4,000)    
Dividends (123)   (123)      
Stockholders' Equity, Other Shares       (1,000)    
Other $ 1 (1)     0
Balance at end of period (in shares) at Dec. 31, 2023 327,000 327,000        
Balance at end of period at Dec. 31, 2023 $ (3,447) $ 2,855 $ (425)   $ (155) $ 2
Treasury, balance at end of period (in shares) at Dec. 31, 2023 (83,000)     (83,000)    
Treasury, balance at end of period at Dec. 31, 2023 $ (5,724)     $ (5,724)    
Treasury Stock, Value, Acquired, Cost Method $ (254)     $ (354)    
Common shares in treasury 83,000     83,000    
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net earnings/(loss) $ 360 $ (19)
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:    
Depreciation and amortization 347 341
Impairments and (gain)/loss on disposal of assets, net 538 863
Share-based compensation 57 48
Provision for bad debts 43 59
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in trade receivables (487) (919)
Increase in inventories (2,536) (1,643)
Increase in accounts payable 4,446 2,954
Other accrued liabilities and operating items, net (1,034) (1,064)
Net cash provided by operating activities 1,734 620
Cash flows from investing activities:    
Proceeds from divestitures, net of cash sold 9 0
Additions to property and equipment (206) (155)
Proceeds from disposal of property and equipment 2 2
Purchases of investments (2) (5)
Proceeds from investments 1 1
Proceeds from net investment hedge terminations 28 0
Net cash used in investing activities (168) (157)
Cash flows from financing activities:    
Reduction of long-term obligations (15) (13)
Net tax proceeds from share-based compensation 1 9
Dividends on common shares (255) (271)
Purchase of treasury shares (750) (1,250)
Net cash used in financing activities (1,019) (1,525)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations 1 (1)
Net increase/(decrease) in cash and equivalents 548 (1,063)
Cash and equivalents at beginning of period 4,043 4,717
Cash and equivalents at end of period $ 4,591 $ 3,654
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies
 6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
Recently Issued Financial Accounting Standards
Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the six months ended December 31, 2023.
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Divestitures
 6 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations, Disclosure
2. Divestitures
On June 5, 2023, we signed a definitive agreement to contribute the OutcomesTM business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the six months ended December 31, 2023, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.
We determined that the divestiture of the OutcomesTM business does not meet the criteria to be classified as discontinued operations. The OutcomesTM business operated within our Pharmaceutical segment.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Employee Severance
 6 Months Ended
Dec. 31, 2023
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
3. Restructuring and Employee Severance
The following tables summarize restructuring and employee severance costs:
Three Months Ended December 31,
(in millions)20232022
Employee-related$8 $10 
Facility exit and other20 7 
Total restructuring and employee severance$28 $17 
Six Months Ended December 31,
(in millions)20232022
Employee-related$15 $29 
Facility exit and other38 17 
Total restructuring and employee severance$53 $46 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.
Restructuring and employee severance costs during the three and six months ended December 31, 2023 were primarily related to certain projects resulting from review of our strategy portfolio, capital-allocation framework and operation and the implementation of certain enterprise-wide cost-savings measures. During the three and six months ended December 31, 2022, restructuring and employee severance costs were primarily related to implementation of certain enterprise-wide cost-saving measures.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions8 4 12 
Payments and other adjustments(18)(1)(19)
Balance at December 31, 2023$34 $5 $39 
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets
 6 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2023$2,649 $1,960 $4,609 
Goodwill acquired, net of purchase price adjustments— (3)(3)
Foreign currency translation adjustments and other— (1)(1)
Goodwill impairment— (581)(581)
Balance at December 31, 2023$2,649 $1,375 $4,024 
(1) At December 31, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.
We have not identified any indicators of impairment during the three months ended December 31, 2023 within our reporting units, including the Medical Unit.
During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit due to an increase in the risk-free interest rate used in the discount rate. Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the six months ended December 31, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively.

Other Intangible Assets
The following tables summarize other intangible assets by class at:
December 31, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 N/A
Total indefinite-life intangibles12 — 12 N/A
Definite-life intangibles:
Customer relationships3,175 2,357 818 9
Trademarks, trade names and patents546 394 152 7
Developed technology and other1,022 657 365 8
Total definite-life intangibles4,743 3,408 1,335 8
Total other intangible assets$4,755 $3,408 $1,347 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
Total amortization of intangible assets was $63 million and $71 million for the three months ended December 31, 2023 and 2022, respectively, and $127 million and $142 million for the six months ended December 31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $127 million, $226 million, $206 million, $174 million and $148 million.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Obligations and Other Short-Term Borrowings
 6 Months Ended
Dec. 31, 2023
Long-Term Obligations and Other Short-Term Borrowings [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both December 31, 2023 and June 30, 2023. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $34.3 billion and $29.8 billion at December 31, 2023 and June 30, 2023, respectively.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December 31, 2023, we were in compliance with this financial covenant.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments, Contingent Liabilities and Litigation
 6 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingent Liabilities and Litigation
6. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation ("CVS Health") for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during first quarter of fiscal year 2024.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or
relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital
system and other healthcare providers, businesses and Individuals.
We have also received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil request for information, subpoenas and other request from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations.
In total, as of December 31, 2023, we have $5.47 billion accrued for these matters, of which $420 million is included in other accrued liabilities and remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrong doing. Please see below for additional description of these matters.
States & Political Subdivisions
In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities").
In November 2023, we reached an agreement in principle with the Alabama Attorney General, under which we would pay approximately $123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the three and six months ended December 31, 2023, we recognized a
$22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to this agreement.
Through January 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.9 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
Prepayment of Future Payment Years
In January 2024, we made payments of approximately $238 million to prepay at a pre-negotiated discount certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we expect to recognize income of approximately $100 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings/(loss) during the three months ended March 31, 2024.
Private Plaintiffs
The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of January 26, 2023 were 395. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs; however, we are vigorously defending ourselves in all these matters.
A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.
Cordis IVC Filter Matters
We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle 2,798 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits.
Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in
the product liability lawsuits. We intend to vigorously defend ourselves against these claims.
We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At December 31, 2023, we had a total of $300 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $31 million and $71 million during the three and six months ended December 31, 2023, respectively, and $66 million during the three and six months ended December 31, 2022.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 6 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
7. Income Taxes
Fluctuations in our provision for income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three and six months ended December 31, 2023, the effective tax rate was 27.7 percent and 22.4 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2023.
During the three and six months ended December 31, 2022, the effective tax rate was 5.4 percent and 30.0 percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2022.
Tax Effects of Goodwill Impairment Charge
During the six months ended December 31, 2023, we recognized a $581 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to these charges is $45 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the six months ended December 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the six months ended December 31, 2023 resulted in recognizing an incremental interim tax benefit of approximately $65 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended December 31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at December 31, 2023. This interim tax benefit will reverse in future quarters of fiscal 2024.
Unrecognized Tax Benefits
We had $959 million and $1.0 billion of unrecognized tax benefits at December 31, 2023 and June 30, 2023, respectively. The December 31, 2023 and June 30, 2023 balances include $864 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At December 31, 2023 and June 30, 2023, we had $52 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $30 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. As a result, the indemnification receivable was reduced. The indemnification receivable was $20 million and $82 million at December 31, 2023 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements
 6 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Disclosures
8. Fair Value Measurements
Assets and Liabilities Measured on a Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
December 31, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,708 $— $— $1,708 
Other investments (1)102 — — 102 
Liabilities:
Forward contracts (2)— (73)— (73)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
Assets Measured on a Nonrecurring Basis
As discussed further in Note 2, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment during the six months ended December 31, 2023.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments
 6 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative
instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December 31, 2023 and 2022, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the six months ended December 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million each. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains and losses recognized in other comprehensive income/(loss) were immaterial and a $2 million loss for the three months ended December 31, 2023 and 2022, respectively, and a $1 million gain and a $2 million gain for the six months ended December 31, 2023 and 2022, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $1 million and immaterial for the three months ended December 31, 2023 and 2022, respectively, and $2 million and immaterial for the six months ended December 31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
During the six months ended December 31, 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.
During the six months ended December 31, 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $16 million and $43 million during the three months ended December 31, 2023 and 2022, respectively, and $5 million and $21 million during the six months ended December 31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million during both the three months ended December 31, 2023 and 2022, and $7 million and $8 million during the six months ended December 31, 2023 and 2022, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $3 million gain during the three months ended December 31, 2023 and 2022, respectively, and an immaterial loss and a $3 million loss during the six months ended December 31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are the Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December 31, 2023 and June 30, 2023 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)December 31, 2023June 30, 2023
Estimated fair value$4,527 $4,417 
Carrying amount4,723 4,701 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Equity
 6 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Shareholders' Equity
10. Shareholders' Deficit
We repurchased $750 million and $1.3 billion of our common shares, in the aggregate, through share repurchase programs during the six months ended December 31, 2023 and 2022, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.
During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.
During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.
During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.
During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial
delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(5)5 — 
Amounts reclassified to earnings— (4)(4)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $1 million
(5)1 (4)
Balance at December 31, 2023$(142)$(13)$(155)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(38)11 (27)
Amounts reclassified to earnings— (5)(5)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(38)6 (32)
Balance at December 31, 2022$(140)$(6)$(146)
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share Attributable to Cardinal Health, Inc.
 6 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.
The following tables reconcile the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:
Three Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic245 261 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted246 261 
Six Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic247 266 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted248 266 
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and six months ended December 31, 2023, respectively.
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million and 5 million for the three and six months ended December 31, 2022, respectively. For both the three and six months ended December 31, 2022, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information
 6 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Information
12. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in
the United States through our Cardinal Health at-Home Solutions division.
In January 2024, we announced a change in our organizational structure and have re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other. The following indicates the changes in our reporting structure effective January 1, 2024:
•Pharmaceutical and Specialty Solutions segment: This reportable segment will comprise all businesses formerly within our Pharmaceutical segment except Nuclear and Precision Health Solutions.
•Global Medical Products and Distribution segment: This reportable segment will comprise all businesses formerly within our Medical segment except at-Home Solutions and OptiFreight Logistics.
•Other: This will consist of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics.
Revenue
The following tables present revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$53,190 $47,391 
Nuclear and Precision Health Solutions330 282 
Pharmaceutical segment revenue
53,520 47,673 
Medical Products and Distribution (2)
3,167 3,099 
Cardinal Health at-Home Solutions761 698 
Medical segment revenue
3,928 3,797 
  Total segment revenue57,448 51,470 
Corporate (3)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$103,872 $92,938 
Nuclear and Precision Health Solutions654 563 
Pharmaceutical segment revenue
104,526 93,501 
Medical Products and Distribution (2)
6,243 6,239 
Cardinal Health at-Home Solutions1,445 1,336 
Medical segment revenue
7,688 7,575 
  Total segment revenue112,214 101,076 
Corporate (3)(6)(4)
Total revenue$112,208 $101,072 

(1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(2)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following tables present revenue by geographic area:
Three Months Ended December 31,
(in millions)20232022
United States$56,241 $50,333 
International1,207 1,137 
  Total segment revenue57,448 51,470 
Corporate (1)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
United States$109,798 $98,810 
International2,416 2,266 
  Total segment revenue112,214 101,076 
Corporate (1)(6)(4)
Total revenue$112,208 $101,072 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation
methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income);
•state opioid assessment related to prior fiscal years;
•shareholder cooperation agreement costs;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in Note 4, we recognized cumulative pre-tax goodwill impairment charges of $581 million and $863 million during the six months ended December 31, 2023 and $709 million during the three months ended December 31, 2022;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $14 million and $5 million for the three months ended December 31, 2023 and 2022, respectively, and $20 million and $11 million for the six months ended December 31, 2023 and 2022, respectively.
The following tables present segment profit by reportable segment and Corporate:
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical
$518 $464 
Medical71 17 
Total segment profit589 481 
Corporate(107)(600)
Total operating earnings/(loss)$482 $(119)

Six Months Ended December 31,
(in millions)20232022
Pharmaceutical
$1,025 $895 
Medical142 9 
Total segment profit1,167 904 
Corporate(699)(886)
Total operating earnings/(loss)$468 $18 
The following table presents total assets for each reportable segment and Corporate at:
(in millions)December 31,
2023		June 30,
2023
Pharmaceutical$31,018 $28,077 
Medical
9,817 10,130 
Corporate 5,738 5,210 
Total assets$46,573 $43,417 
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation
 3 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
13. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following tables provide total share-based compensation expense by type of award:
Three Months Ended December 31,
(in millions)20232022
Restricted share unit expense$17 $15 
Performance share unit expense11 10 
Total share-based compensation
$28 $25 
Six Months Ended December 31,
(in millions)20232022
Restricted share unit expense$38 $32 
Performance share unit expense19 16 
Total share-based compensation
$57 $48 
The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended December 31, 2023 and 2022, respectively, and $8 million and $6 million for the six months ended December 31, 2023 and 2022, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.69 
Vested(1.0)60.80 
Canceled and forfeited(0.1)69.55 
Nonvested at December 31, 20232.0 $69.44 
At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.6 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at December 31, 20231.4 $96.55 
At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $60 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure        
Net Income (Loss) Attributable to Parent $ 353 $ (130) $ 358 $ (20)
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Recent Financial Accounting Standards
Recently Issued Financial Accounting Standards
Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the six months ended December 31, 2023.
Basis of Presentation
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Employee Severance (Tables)
 6 Months Ended
Dec. 31, 2023
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following tables summarize restructuring and employee severance costs:
Three Months Ended December 31,
(in millions)20232022
Employee-related$8 $10 
Facility exit and other20 7 
Total restructuring and employee severance$28 $17 
Six Months Ended December 31,
(in millions)20232022
Employee-related$15 $29 
Facility exit and other38 17 
Total restructuring and employee severance$53 $46 
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions8 4 12 
Payments and other adjustments(18)(1)(19)
Balance at December 31, 2023$34 $5 $39 
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets (Tables)
 6 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2023$2,649 $1,960 $4,609 
Goodwill acquired, net of purchase price adjustments— (3)(3)
Foreign currency translation adjustments and other— (1)(1)
Goodwill impairment— (581)(581)
Balance at December 31, 2023$2,649 $1,375 $4,024 
(1) At December 31, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.
Schedule of Finite-Lived Intangible Assets
The following tables summarize other intangible assets by class at:
December 31, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 N/A
Total indefinite-life intangibles12 — 12 N/A
Definite-life intangibles:
Customer relationships3,175 2,357 818 9
Trademarks, trade names and patents546 394 152 7
Developed technology and other1,022 657 365 8
Total definite-life intangibles4,743 3,408 1,335 8
Total other intangible assets$4,755 $3,408 $1,347 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements (Tables)
 6 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
December 31, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,708 $— $— $1,708 
Other investments (1)102 — — 102 
Liabilities:
Forward contracts (2)— (73)— (73)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments (Tables)
 6 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)December 31, 2023June 30, 2023
Estimated fair value$4,527 $4,417 
Carrying amount4,723 4,701 
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Equity (Tables)
 6 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(5)5 — 
Amounts reclassified to earnings— (4)(4)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $1 million
(5)1 (4)
Balance at December 31, 2023$(142)$(13)$(155)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(38)11 (27)
Amounts reclassified to earnings— (5)(5)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(38)6 (32)
Balance at December 31, 2022$(140)$(6)$(146)
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 6 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following tables reconcile the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:
Three Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic245 261 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted246 261 
Six Months Ended December 31,
(in millions)20232022
Weighted-average common shares–basic247 266 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units1 — 
Weighted-average common shares–diluted248 266 
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Disaggregation of Revenue [Table Text Block]
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$53,190 $47,391 
Nuclear and Precision Health Solutions330 282 
Pharmaceutical segment revenue
53,520 47,673 
Medical Products and Distribution (2)
3,167 3,099 
Cardinal Health at-Home Solutions761 698 
Medical segment revenue
3,928 3,797 
  Total segment revenue57,448 51,470 
Corporate (3)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$103,872 $92,938 
Nuclear and Precision Health Solutions654 563 
Pharmaceutical segment revenue
104,526 93,501 
Medical Products and Distribution (2)
6,243 6,239 
Cardinal Health at-Home Solutions1,445 1,336 
Medical segment revenue
7,688 7,575 
  Total segment revenue112,214 101,076 
Corporate (3)(6)(4)
Total revenue$112,208 $101,072 

(1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(2)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following tables present revenue by geographic area:
Three Months Ended December 31,
(in millions)20232022
United States$56,241 $50,333 
International1,207 1,137 
  Total segment revenue57,448 51,470 
Corporate (1)(3)(1)
Total revenue$57,445 $51,469 
Six Months Ended December 31,
(in millions)20232022
United States$109,798 $98,810 
International2,416 2,266 
  Total segment revenue112,214 101,076 
Corporate (1)(6)(4)
Total revenue$112,208 $101,072 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and Corporate:
Three Months Ended December 31,
(in millions)20232022
Pharmaceutical
$518 $464 
Medical71 17 
Total segment profit589 481 
Corporate(107)(600)
Total operating earnings/(loss)$482 $(119)
Six Months Ended December 31,
(in millions)20232022
Pharmaceutical
$1,025 $895 
Medical142 9 
Total segment profit1,167 904 
Corporate(699)(886)
Total operating earnings/(loss)$468 $18 
Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at:
(in millions)December 31,
2023		June 30,
2023
Pharmaceutical$31,018 $28,077 
Medical
9,817 10,130 
Corporate 5,738 5,210 
Total assets$46,573 $43,417 
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Tables)
 6 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following tables provide total share-based compensation expense by type of award:
Three Months Ended December 31,
(in millions)20232022
Restricted share unit expense$17 $15 
Performance share unit expense11 10 
Total share-based compensation
$28 $25 
Six Months Ended December 31,
(in millions)20232022
Restricted share unit expense$38 $32 
Performance share unit expense19 16 
Total share-based compensation
$57 $48 
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.69 
Vested(1.0)60.80 
Canceled and forfeited(0.1)69.55 
Nonvested at December 31, 20232.0 $69.44 
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.6 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at December 31, 20231.4 $96.55 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Discontinued Operations and Disposal Groups (Details)
$ in Millions
 6 Months Ended
Dec. 31, 2023
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Gain (Loss) on Sale of Assets and Asset Impairment Charges
Outcomes Divestiture [Member]  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $ 53
Transaction Data System Investment  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Equity Method Investment, Ownership Percentage 16.00%
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Restructuring Charges [Abstract]        
Employee-related costs $ 8 $ 10 $ 15 $ 29
Facility Exit and Other Costs 20 7 38 17
Total restructuring and employee severance $ 28 $ 17 $ 53 $ 46
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)
$ in Millions
 6 Months Ended
Dec. 31, 2023
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 46
Additions 12
Payments and other adjustments (19)
Ending Balance 39
Employee- Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 44
Additions 8
Payments and other adjustments (18)
Ending Balance 34
Facility Exit and Other Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 2
Additions 4
Payments and other adjustments (1)
Ending Balance $ 5
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Employee Severance Narative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]        
Employee-related costs $ 8 $ 10 $ 15 $ 29
Facility Exit and Other Costs $ 20 $ 7 $ 38 $ 17
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2023
Jun. 30, 2023
Goodwill [Roll Forward]        
Beginning balance     $ 4,609  
Goodwill, Purchase Accounting Adjustments     (3)  
Foreign currency translation adjustments and other     1  
Goodwill impairment     581  
Ending balance     4,024  
Pharmaceutical        
Goodwill [Roll Forward]        
Beginning balance     2,649  
Goodwill, Purchase Accounting Adjustments     0  
Foreign currency translation adjustments and other     0  
Goodwill impairment     0  
Ending balance     2,649  
Medical        
Goodwill [Roll Forward]        
Beginning balance     1,960  
Goodwill, Purchase Accounting Adjustments     (3)  
Foreign currency translation adjustments and other     1  
Goodwill impairment $ 709 $ 154 581  
Ending balance     1,375  
Goodwill, Impaired, Accumulated Impairment Loss     $ 5,300 $ 4,700
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Jun. 30, 2023
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible $ 12 $ 11
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 4,743 4,741
Accumulated Amortization 3,408 3,280
Net Intangible $ 1,335 1,461
Weighted- Average Remaining Amortization Period (Years) 8 years  
Gross Intangible, Total other intangible assets $ 4,755 4,752
Net Intangible, Total other intangible assets 1,347 1,472
Trademarks and patents    
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible 12 11
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 3,175 3,174
Accumulated Amortization 2,357 2,274
Net Intangible $ 818 900
Weighted- Average Remaining Amortization Period (Years) 9 years  
Trademarks, trade names and patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 546 546
Accumulated Amortization 394 380
Net Intangible $ 152 166
Weighted- Average Remaining Amortization Period (Years) 7 years  
Developed technology and other    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 1,022 1,021
Accumulated Amortization 657 626
Net Intangible $ 365 $ 395
Weighted- Average Remaining Amortization Period (Years) 8 years  
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]              
Amortization of intangible assets $ 63     $ 71   $ 127 $ 142
Estimated annual amortization of intangible assets - Remainder of Fiscal Year 127         127  
Estimated annual amortization of intangible assets - Year One 226         226  
Estimated annual amortization of intangible assets - Year Two 206         206  
Estimated annual amortization of intangible assets - Year Three 174         174  
Estimated annual amortization of intangible assets - Year Four 148         148  
Goodwill [Line Items]              
Goodwill 4,024   $ 4,609     4,024  
Goodwill impairment           581  
Medical              
Goodwill [Line Items]              
Goodwill $ 1,375   $ 1,960     1,375  
Goodwill impairment       $ 709 $ 154 581  
Medical Unit              
Goodwill [Line Items]              
Goodwill impairment           $ 581 $ 863
Discount Rate, Fair Value Input   11.00% 10.00%        
Terminal Growth Rate, Fair Value Input 2.00% 2.00% 2.00%     2.00%  
Change in Discount Rate, Fair Value Input           1.00%  
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Jun. 30, 2023
Debt Instrument [Line Items]    
Accounts Payable $ 34,300 $ 29,800
Debt, Long-Term and Short-Term, Combined Amount 4,700 $ 4,700
Commercial Paper [Member]    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity 2,000  
Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity 2,000  
Short Term Credit Facilities Member    
Debt Instrument [Line Items]    
Other Short-term Borrowings 0  
Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity $ 1,000  
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments, Contingent Liabilities and Litigation (Details)
$ in Thousands
 3 Months Ended 5 Months Ended 6 Months Ended 12 Months Ended 31 Months Ended 53 Months Ended
Jul. 01, 2024
plaintiff
Jan. 26, 2024
plaintiff
lawsuit
Apr. 30, 2023
USD ($)
lawsuit
Jul. 31, 2014
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
states
numberOfUSTerritories
Mar. 31, 2023
plaintiff
Dec. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
states
numberOfUSTerritories
Dec. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2024
USD ($)
Jan. 26, 2024
lawsuit
Jun. 30, 2028
USD ($)
Nov. 30, 2023
USD ($)
Oct. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
Apr. 30, 2018
USD ($)
Loss Contingencies [Line Items]                                      
Income from Settlements of Class Action Lawsuits           $ 31,000   $ 66,000   $ 71,000 $ 66,000                
Product Liability Lawsuits | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Pending Claims, Number | lawsuit   400                       400          
Product Liability Lawsuits | IVC April 2023 Agreement                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Claims Settled, Number | lawsuit     4,375                                
Product Liability Lawsuits | Subsequent Event | Other Agreements [Member]                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Claims Settled, Number | lawsuit                           2,798          
Product Liability Lawsuits | Minimum                                      
Loss Contingencies [Line Items]                                      
Loss Contingency Accrual           300,000       300,000                  
Total Opioid Litigation [Member]                                      
Loss Contingencies [Line Items]                                      
Estimated Litigation Liability           5,470,000       5,470,000                  
Estimated Litigation Liability, Current           $ 420,000       $ 420,000                  
Total Opioid Litigation [Member] | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency Accrual, Period Increase (Decrease)         $ 344,000                            
Income As A Result Of Prepayments         100,000                            
New York Opioid Stewardship Act [Member]                                      
Loss Contingencies [Line Items]                                      
Aggregate Annual Assessment                                     $ 100,000
Loss Contingency Accrual, Period Increase (Decrease)                       $ 6,000              
Loss Contingency Accrual                       3,000              
Opioid Lawsuits [Member]                                      
Loss Contingencies [Line Items]                                      
Settling States | states           48       48                  
Settling U.S Territories | numberOfUSTerritories           5       5                  
Insurance Recoveries                       10,000              
Opioid Lawsuits [Member] | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Payments for Legal Settlements         $ 238,000               $ 1,500,000   $ 4,900,000        
Opioid Lawsuits [Member] | WEST VIRGINIA                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Estimate of Possible Loss                                   $ 124,000  
Opioid Lawsuits [Member] | ALABAMA                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Estimate of Possible Loss                               $ 123,000      
Litigation Settlement, Expense           $ 22,000                          
Opioid Lawsuits [Member] | Native American tribes                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Estimate of Possible Loss                                 $ 136,000    
Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Lawsuits, Number | lawsuit   395                       395          
Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Number of Plaintiffs | plaintiff             21                        
Opioid Lawsuits [Member] | Private Parties [Member] | ALABAMA | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Number of Plaintiffs | plaintiff 8                                    
Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Lawsuits, Number | lawsuit   103                       103          
Product Liability Lawsuits                                      
Loss Contingencies [Line Items]                                      
Product Liability Accrual, Period Expense                       $ (103,000)              
Product Liability Lawsuits | IVC April 2023 Agreement                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Estimate of Possible Loss     $ 275,000                                
Payments for Legal Settlements                 $ 275,000                    
Product Liability Lawsuits | Alameda County [Member] | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Loss Contingency, Number of Plaintiffs | plaintiff   4,500                                  
CVS Health                                      
Loss Contingencies [Line Items]                                      
Long-term Purchase Commitment, Period       10 years                              
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Jun. 30, 2023
Income Taxes              
Effective Income Tax Rate Reconciliation, Percent 27.70% 5.40%   22.40% 30.00%    
Goodwill impairment       $ 581      
Income Tax Expense (Benefit) $ 136 $ (7)   104 $ (8)    
Unrecognized tax benefits 959     959     $ 1,000
Unrecognized tax benefits that would impact effective tax rate 864     864     873
Unrecognized tax benefits, interest and penalties accrued 52     52     65
Medical Unit              
Income Taxes              
Goodwill impairment       581 $ 863    
Medical Unit Goodwill Impairment [Member] | Subsequent Event              
Income Taxes              
Income Tax Expense (Benefit)     $ 65        
Forecast [Member] | Medical Unit Goodwill Impairment [Member]              
Income Taxes              
Income Tax Expense (Benefit)           $ (45)  
Minimum              
Income Taxes              
Estimated range of decrease in unrecognized tax benefits within the next 12 months 0     0      
Maximum              
Income Taxes              
Estimated range of decrease in unrecognized tax benefits within the next 12 months 30     30      
CareFusion [Member]              
Income Taxes              
Indemnification Receivable $ 20     $ 20     $ 82
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Transaction Data System Investment      
Assets:      
Equity Method Investment, Ownership Percentage 16.00%    
Recurring      
Assets:      
Cash equivalents $ 1,708   $ 1,253
Other investments 102   101
Forward Contract (73)   (73)
Liabilities:      
Forward Contract (73)   (73)
Level 1 | Recurring      
Assets:      
Cash equivalents 1,708   1,253
Other investments 102   101
Forward Contract 0   0
Liabilities:      
Forward Contract 0   0
Level 2 | Recurring      
Assets:      
Cash equivalents 0   0
Other investments 0   0
Forward Contract (73)   (73)
Liabilities:      
Forward Contract (73)   (73)
Level 3 | Recurring      
Assets:      
Cash equivalents 0   0
Other investments 0   0
Forward Contract 0   0
Liabilities:      
Forward Contract $ 0   $ 0
Level 3 | Fair Value, Nonrecurring | Transaction Data System Investment      
Assets:      
Equity Method Investments, Fair Value Disclosure   $ 147  
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments (Narrative) (Details)
¥ in Millions, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
JPY (¥)
Derivative [Line Items]            
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0 $ 0 $ 0 $ 0    
Proceeds from net investment hedge terminations     28 0    
January 2023            
Derivative [Line Items]            
Proceeds from net investment hedge terminations     28      
Cash Flow Hedging [Member]            
Derivative [Line Items]            
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax   2 (1) (2)    
Foreign Exchange Contract [Member]            
Derivative [Line Items]            
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 16 43 5 21    
Interest Income (Expense), Nonoperating, Net 4 4 7 8    
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]            
Derivative [Line Items]            
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 1   2      
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Subsequent Event | Forecast [Member]            
Derivative [Line Items]            
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net         $ 3  
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap            
Derivative [Line Items]            
Derivative Liability, Notional Amount 200 200 200 200    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | January 2023            
Derivative [Line Items]            
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount 300   300     ¥ 38,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025            
Derivative [Line Items]            
Derivative Asset, Notional Amount 120   120     18,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027            
Derivative [Line Items]            
Derivative Asset, Notional Amount $ 120   $ 120     ¥ 18,000
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]            
Derivative [Line Items]            
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net   $ (3)   $ 3    
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Amount of Long-Term and other Short-Term Borrowings $ 4,723 $ 4,701
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 4,527 $ 4,417
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 13, 2023
Nov. 02, 2023
Oct. 31, 2023
Aug. 16, 2023
Jan. 13, 2023
Dec. 23, 2022
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]                              
Purchase of treasury shares                       $ 750     $ 1,250
$250 million share repurchase program [Member]                              
Class of Stock [Line Items]                              
Purchase of treasury shares             $ 250     $ 250          
$1 billion share repurchase program                              
Class of Stock [Line Items]                              
Purchase of treasury shares                     $ 1,000        
$500 million share repurchase program                              
Class of Stock [Line Items]                              
Purchase of treasury shares               $ 500 $ 500            
Treasury Stock, Common                              
Class of Stock [Line Items]                              
Purchase of treasury shares                       $ 750     $ 1,300
Treasury Stock, Shares, Acquired             (4.0)     (4.0)   (9.0)     (16.0)
Treasury Stock, Common | $250 million share repurchase program [Member]                              
Class of Stock [Line Items]                              
Treasury Stock, Shares, Acquired (0.4) (2.0)     (0.6)         (2.6)          
Treasury shares acquired, average price per share (in usd per share)   $ 101.66         $ 103.67     $ 76.58       $ 77.50  
Treasury Stock, Common | $1 billion share repurchase program                              
Class of Stock [Line Items]                              
Treasury Stock, Shares, Acquired           (1.6)         (12.0)        
Treasury shares acquired, average price per share (in usd per share)                     $ 66.74       $ 73.36
Treasury Stock, Common | $500 million share repurchase program                              
Class of Stock [Line Items]                              
Treasury Stock, Shares, Acquired     (1.3) (0.9)       (4.4) (4.6)            
Treasury shares acquired, average price per share (in usd per share)               $ 90.57 $ 87.18     $ 88.22 $ 91.15    
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period $ (3,490) $ (1,780) $ (2,851) $ (706)
Total other comprehensive income/(loss), net of tax 10 30 (4) (32)
Balance at end of period (3,447) (2,212) (3,447) (2,212)
Other Comprehensive Income (Loss), Tax     1 5
Foreign Currency Translation Adjustments        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (137) (102)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     (5) (38)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     0 0
Total other comprehensive income/(loss), net of tax     (5) (38)
Balance at end of period (142) (140) (142) (140)
Unrealized Gain/(Loss) on Derivatives, net of tax        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (14) (12)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     5 11
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     (4) (5)
Total other comprehensive income/(loss), net of tax     1 6
Balance at end of period (13) (6) (13) (6)
Accumulated Other Comprehensive Loss        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (151) (114)
Total other comprehensive income/(loss), net of tax     (4) (32)
Balance at end of period (155) (146) (155) (146)
AOCI Attributable to Parent        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period (165) (176) (151) (114)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     0 (27)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     (4) (5)
Balance at end of period $ (155) $ (146) $ (155) $ (146)
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)
shares in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2022
shares
Dec. 31, 2023
shares
Dec. 31, 2022
shares
Earnings Per Share [Abstract]        
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) 1,000   1,000  
Shares that would be antidilutive as a result of net loss   2,000   2,000
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]        
Weighted-average common shares–basic (in shares) 245 261 247 266
Effect of dilutive securities:        
Employee stock options, restricted share units, and performance share units (in shares) 1 0 1 0
Weighted-average common shares–diluted (in shares) 246 261 248 266
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Narrative) (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Segment Reporting Information [Line Items]          
Project costs on investment and other spending $ 14 $ 5   $ 20 $ 11
Number of reportable segments | segment       2  
Number of operating segments | segment       2  
Goodwill impairment       $ 581  
Number of operating segments | segment       2  
Number of reportable segments | segment       2  
Project costs on investment and other spending $ 14 5   $ 20 11
Medical Unit          
Segment Reporting Information [Line Items]          
Goodwill impairment       581 $ 863
Medical          
Segment Reporting Information [Line Items]          
Goodwill impairment   $ 709 $ 154 $ 581  
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]        
Total revenue $ 57,445 $ 51,469 $ 112,208 $ 101,072
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue 57,448 51,470 112,214 101,076
Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 53,520 47,673 104,526 93,501
Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue 3,928 3,797 7,688 7,575
Corporate        
Segment Reporting Information [Line Items]        
Total revenue (3) (1) (6) (4)
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 53,190 47,391 103,872 92,938
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 330 282 654 563
Medical distribution and products [Member] | Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue 3,167 3,099 6,243 6,239
Cardinal Health At Home [Member] | Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue $ 761 $ 698 $ 1,445 $ 1,336
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ 482 $ (119) $ 468 $ 18
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 589 481 1,167 904
Operating Segments | Pharmaceutical        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 518 464 1,025 895
Operating Segments | Medical        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 71 17 142 9
Corporate        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ (107) $ (600) $ (699) $ (886)
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ 57,445 $ 51,469 $ 112,208 $ 101,072
UNITED STATES        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 56,241 50,333 109,798 98,810
Non-US [Member]        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 1,207 1,137 2,416 2,266
Operating Segments        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 57,448 51,470 112,214 101,076
Corporate        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ (3) $ (1) $ (6) $ (4)
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Jun. 30, 2023
Segment Reporting Information [Line Items]    
Total assets $ 46,573 $ 43,417
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total assets 31,018 28,077
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total assets 9,817 10,130
Corporate    
Segment Reporting Information [Line Items]    
Total assets $ 5,738 $ 5,210
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Narrative) (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Tax benefit related to share-based compensation $ 4 $ 3 $ 8 $ 6
Restricted Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)     3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 103   $ 103  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Performance Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting Period in years for Shares     3  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 60   $ 60  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Performance Share Units | Minimum | Fiscal 2022 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Minimum | Fiscal 2023 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Minimum | Fiscal 2024 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Maximum | Fiscal 2022 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     234.00%  
Performance Share Units | Maximum | Fiscal 2023 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     234.00%  
Performance Share Units | Maximum | Fiscal 2024 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     240.00%  
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 28 $ 25 $ 57 $ 48
Restricted Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation 17 15 38 32
Performance Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 11 $ 10 $ 19 $ 16
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 103
Restricted Share Units  
Nonvested at beginning of period (in shares) | shares 2.2
Granted (in shares) | shares 0.9
Vested (in shares) | shares (1.0)
Canceled and forfeited (in shares) | shares (0.1)
Nonvested at end of period (in shares) | shares 2.0
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 57.37
Granted (in usd per share) | $ / shares 90.69
Vested (in usd per share) | $ / shares 60.80
Canceled and forfeited (in usd per share) | $ / shares 69.55
Nonvested at end of period (in usd per share) | $ / shares $ 69.44
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Performance Share Units  
Nonvested at beginning of period (in shares) | shares 1.2
Granted (in shares) | shares 0.6
Vested (in shares) | shares (0.4)
Canceled and forfeited (in shares) | shares 0.0
Nonvested at end of period (in shares) | shares 1.4
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 82.17
Granted (in usd per share) | $ / shares 94.66
Vested (in usd per share) | $ / shares 62.26
Canceled and forfeited (in usd per share) | $ / shares 0
Nonvested at end of period (in usd per share) | $ / shares $ 96.55
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 60
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events (Details)
$ in Millions
 5 Months Ended
Jun. 30, 2024
USD ($)
Subsequent Event  
Subsequent Event [Line Items]  
Payments to Acquire Businesses, Gross $ 1,200
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,E&05@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #)1D%83$IO_>\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:95D=#E9<,G!<&!XEM(;EM8TX3DI-VW-ZU;A^@'$/*2NW]^ M]SM(JX/0/N)+] $C64PWH^OZ)'18L0-1$ !)']"I5.9$GYL['YVB?(U["$H? MU1ZAKJI[<$C**%(P 8NP$)ELC18ZHB(?SWBC%WSXC-T,,QJP0X<])> E!R:G MB>$T=BU< 1.,,+KT74"S$.?JG]BY ^R<')-=4L,PE$,SY_(.'-Z?GU[G=0O; M)U*]QOPJ64&G@"MVF?S6K#?;1R;KJKXMJKJH^)8WXBZ?AX_)]8??5=AY8W?V M'QM?!&4+O_Z%_ )02P,$% @ R49!6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #)1D%8J]-5N,(% #!'@ & 'AL+W=O2+;DK=2P(=3[$NIU7?'1(GE?B>"?5ES000I/G.$K2ZTZ@]>9-KY=Z@8AY M>BDW(H$S*ZEBKF%7K7OI1@GNYT%QU&..,^S%/$PZDW%^;*XF8YGI*$S$7)$T MBV.N7FY$)'?7'=HY''@,UX$V!WJ3\8:OQ4+HWS=S!7N]4L4/8Y&DH4R($JOK MSI2^F;G,!.17_!&*77JT30S*4LHO9N?!O^XXID4B$IXV$AQ^MF(FHL@H03O^ MW8MVRGN:P./M@_I]#@\P2YZ*F8S^#'T=7'>N.L07*YY%^E'NWHH]T,#H>3)* M\_]D5US;[W>(EZ5:QOM@:$$<)L4O?]X_B*, MRZ [0/8_P)H78"[#W!ST*)E M.=8MUWPR5G)'E+D:U,Q&_FSR:* )$Y/&A59P-H0X/9G)K5!D#ADC79(&7(ET MW-,@;$[WO+W(32'":D2&Y+U,=)"2N\07_M?Q/6A0V2IV:-4-0P5OA7=)7'I! MF,-<2WMF>/BO/+DD;)B']Y'FN.5#!^CSB6BL>I=9$ MHF$M :]*P"NT47>)#O4+N0\C03YD\5(H&QBN0;N4NB-K[M# EFBO2[373= > MQ3HTDR@D\0./K3T4UYEQY8<)C\A;P2,=7)"'Q+NTP:(R+6&I4U55IPGN#'JK M@L8^0%U\)K^)%VMMQ:4<^!LQR"FU8>+!;3F/W /%TY$I94;D?9AZP/E9<(5. M/R?DNEUGV'4=*R@:V1:45:"LV=QS3'H/!^UV"1?[UI;L&=&PMHR5RZ&HK_B& M<5].ZBEQN4_,RG@.;T,KS(%0+^ C/C:2H4+U!8./*XM6&5Q*&Y,]C,. M3(=204GDICI>D(6&@4BD(C.9P50$,Y+T[0,35__XUHI\#M=#*]M#<;>R1W[B MS^3!AY2&J]#+N9'B>4+2I5WG]>!J.!Q:><_A?FAE?RCN6?:\4]\']?3BL$'> MP77D8V+/*RXY@N)"RIHZCZ#Q5O!SN"):V2+:R!>5X#.S!YWZ2>X2*S0N=YLM MX9"5\QP6B58>B38R225G.7KG2F[#Q)J;FQ.:-2/W'/:(5?:(-;)')>A2=S@Q#(!'M3.2$R&HRZ YB K'SGL$*LLD(,]RY/H89W,+DBE+U:_D06PLL4 M9-(*B2O-9!Q#12H^K9%7NU ',M-D _9QRZ-,_&2E/X=)8I5)8KC'@?=K* AK MLGB)ES*R0N,"LZEUUL&CVF)5%HGA)N:017+W[ 4\68O:=] 30A\^+^ZL?.?P M0ZSR0ZR1'SJ\DQ6?1O(\0AVQ6_@3BI^M7X-G>%1;SLH'L48^Z"'10A7+ .9] MDQ_ K9RX8AWG.6P/JVP/:_PY" P\6(&U5/8I"-=YQQ7T]:GG"1 "&;^0M!*? MPP"QR@"Q1@9H$?,H(C=9"J=3>[_%=6I?TO"XEGQNY7O<1K[G+A9J;0;F+Z"@ M [ &\88GUM2>$*P%Q>/:@E:VQ\5=RR&1@8!$8GBX3#W>.>R/6]D?%WTQ M9.]HD=#TOWSM-"6>^3!0K!>61\OUV6F^*MFK+B\6=]]STWU3$HD5A#J7([B_ M*M9+BQTM-_F2XU)J+>-\,Q#<%\I< .=74NK#CKE!N6H]^0]02P,$% @ MR49!6&^91C[_!@ ;" !@ !X;"]W;W)K@0=>'80^R1=M")=$C:2?=K]^5 MY%@R>:6DF_L06_+A$<^]EY='4J^?A/RFUIQK\IREN;KIK;7>7#F.6JQY%JF^ MV/ S=B@&% B_DCXDVI\)X64N1#?BH/[^*;G%C/B*5_H@B*"CQV?\#0MF& > M?^])>X=K%@.;WU_8?RW%@YAYI/A$I%^36*]O>L,>B?DRVJ;ZLWAZS_>"@H)O M(5)5_B5/>ZS;(XNMTB+;#X899$E>?4;/^T T!@ //H#M!S!S@-\RP-L/\-YZ M!7\_P'_K%8+]@%*Z4VDO S>-=#2^EN*)R (-;,67,OKE:(A7DA>%\J@E_)K M.#V>B#R&M/.8P#M"*B"6913)/\I4BE^3+XY2^.? M?Z*A^PL6YU.234])-CL1V5%&_$-&_"[V\6>^X_F68]&O!H;EP&*KV(V#@>\' MU\ZN&58$1?UP=(R:VBA*&7.'Q[ 9 G.I.V 'V)'&X* QZ-0X$4H7'6@C1;Q= M0#>"%H6UAKN*)FAJ"8*1H65BH_S1T T-Q3:*NL-@Y!N*;=AH,!@%N.#P(#CL M%/R;%$I!@Y>K),=TAO;$/V^*O4==84H'I^P@IR2;GI)L=B*RHTP,#YD8=A;;-($.GLRWA66[ M(.#> +"Z("N>0X92$N4QB6(P'04L*@S=(6-8PH9VU;&A4743!$1'U"A-&\3\ MH6N4)@+RAD.\-$>'@(Q>::F@%/K,5A;E6>CGV285WSF'Z.P@*/D"[;RY& M?YS8$#HP9-N0P C?S(8T%O^19.K6#M#M%'V;":F3?Z+*N(-FH==<@H7_>YNH MI#A[*7E:VL(%M&/S9BW+(3,TV M" )C>BV,*K0R;H-H2]^CM9>DW6;R4[GFSY+2Y9\[^S[?GF[+=[O7+^IA]ENR@M\4ZD-@F1;NQ9"%9KF#:4:M8BMW1OMMF\?N%)7I"F9 M1+IRN-$\A40+D@O(>:ZE*+TN5$#5!/#TVV[KTMK+;(P5$(3&6OB=ESI^>E4; M.]9M[)#<6_&81#).M>^*$,!^SS8&JS#/I#^43S;?%![U=9I[W\T1O6D[)-3\HV M.Q7;<0YK;\JZO>E=I))%857V#Z'1AK;G�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 260 251 1 false 79 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Divestitures Sheet http://www.cardinal.com/role/Divestitures Divestitures Notes 9 false false R10.htm 0000010 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeverance Restructuring and Employee Severance Notes 10 false false R11.htm 0000011 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 11 false false R12.htm 0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 12 false false R13.htm 0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation Commitments, Contingent Liabilities and Litigation Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 0000016 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 16 false false R17.htm 0000017 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 18 false false R19.htm 0000019 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 19 false false R20.htm 0000020 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 9954473 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringandEmployeeSeverance 24 false false R25.htm 9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets 25 false false R26.htm 9954476 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 26 false false R27.htm 9954477 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 27 false false R28.htm 9954478 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 28 false false R29.htm 9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc 29 false false R30.htm 9954480 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 30 false false R31.htm 9954481 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 31 false false R32.htm 9954484 - Disclosure - Discontinued Operations and Disposal Groups (Details) Sheet http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails Discontinued Operations and Disposal Groups (Details) Details 32 false false R33.htm 9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 33 false false R34.htm 9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 34 false false R35.htm 9954487 - Disclosure - Restructuring and Employee Severance Narative (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails Restructuring and Employee Severance Narative (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 35 false false R36.htm 9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 36 false false R37.htm 9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 37 false false R38.htm 9954490 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets (Narrative) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 38 false false R39.htm 9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails Long-Term Obligations and Other Short-Term Borrowings (Details) Details http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings 39 false false R40.htm 9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails Commitments, Contingent Liabilities and Litigation (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation 40 false false R41.htm 9954493 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.cardinal.com/role/IncomeTaxes 41 false false R42.htm 9954494 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 42 false false R43.htm 9954495 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 43 false false R44.htm 9954496 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Details 44 false false R45.htm 9954497 - Disclosure - Shareholders' Equity (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity (Narrative) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 45 false false R46.htm 9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 46 false false R47.htm 9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 47 false false R48.htm 9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 48 false false R49.htm 9954501 - Disclosure - Segment Information (Narrative) (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information (Narrative) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 49 false false R50.htm 9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 50 false false R51.htm 9954503 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 51 false false R52.htm 9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails Segment Information Revenue From External Customers By Geographic Areas (Details) Details 52 false false R53.htm 9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 53 false false R54.htm 9954506 - Disclosure - Share-Based Compensation (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation (Narrative) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 54 false false R55.htm 9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 55 false false R56.htm 9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 56 false false R57.htm 9954511 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 57 false false R58.htm 9954512 - Disclosure - Subsequent Events (Details) Sheet http://www.cardinal.com/role/SubsequentEventsDetails Subsequent Events (Details) Details 58 false false All Reports Book All Reports cah-20231231.htm cah-20231231.xsd cah-20231231_cal.xml cah-20231231_def.xml cah-20231231_lab.xml cah-20231231_pre.xml cah-20231231_g1.jpg cah-20231231_g2.jpg cah-20231231_g3.jpg cah-20231231_g4.jpg cah-20231231_g5.jpg cah-20231231_g6.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cah-20231231.htm": { "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20231231", "dts": { "inline": { "local": [ "cah-20231231.htm" ] }, "schema": { "local": [ "cah-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "cah-20231231_cal.xml" ] }, "definitionLink": { "local": [ "cah-20231231_def.xml" ] }, "labelLink": { "local": [ "cah-20231231_lab.xml" ] }, "presentationLink": { "local": [ "cah-20231231_pre.xml" ] } }, "keyStandard": 231, "keyCustom": 20, "axisStandard": 27, "axisCustom": 9, "memberStandard": 41, "memberCustom": 35, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 1 }, "contextCount": 260, "entityCount": 1, "segmentCount": 79, "elementCount": 578, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 798, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.cardinal.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings", "shortName": "Condensed Consolidated Statements of Earnings", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R3": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R4": { "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "longName": "0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-52", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R7": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R8": { "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.cardinal.com/role/Divestitures", "longName": "0000009 - Disclosure - Divestitures", "shortName": "Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance", "longName": "0000010 - Disclosure - Restructuring and Employee Severance", "shortName": "Restructuring and Employee Severance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000011 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings", "longName": "0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation", "longName": "0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.cardinal.com/role/IncomeTaxes", "longName": "0000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.cardinal.com/role/FairValueMeasurements", "longName": "0000015 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.cardinal.com/role/FinancialInstruments", "longName": "0000016 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.cardinal.com/role/ShareholdersEquity", "longName": "0000017 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc", "longName": "0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.cardinal.com/role/SegmentInformation", "longName": "0000019 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.cardinal.com/role/ShareBasedCompensation", "longName": "0000020 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables", "longName": "9954473 - Disclosure - Restructuring and Employee Severance (Tables)", "shortName": "Restructuring and Employee Severance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "longName": "9954477 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "longName": "9954478 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables", "longName": "9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.cardinal.com/role/SegmentInformationTables", "longName": "9954480 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "longName": "9954484 - Disclosure - Discontinued Operations and Disposal Groups (Details)", "shortName": "Discontinued Operations and Disposal Groups (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-62", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "longName": "9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "longName": "9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails", "longName": "9954487 - Disclosure - Restructuring and Employee Severance Narative (Details)", "shortName": "Restructuring and Employee Severance Narative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "longName": "9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R37": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9954490 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)", "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails", "longName": "9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "longName": "9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)", "shortName": "Commitments, Contingent Liabilities and Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "longName": "9954493 - Disclosure - Income Taxes (Narrative) (Details)", "shortName": "Income Taxes (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "longName": "9954494 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R43": { "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9954495 - Disclosure - Financial Instruments (Narrative) (Details)", "shortName": "Financial Instruments (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "span", "div", "div", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "span", "div", "div", "div", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "longName": "9954496 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "longName": "9954497 - Disclosure - Shareholders' Equity (Narrative) (Details)", "shortName": "Shareholders' Equity (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R46": { "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R47": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails", "longName": "9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails", "longName": "9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R49": { "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "longName": "9954501 - Disclosure - Segment Information (Narrative) (Details)", "shortName": "Segment Information (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "cah:ProjectCostsOnInvestmentAndOtherSpending", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "longName": "9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R51": { "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "longName": "9954503 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R52": { "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "longName": "9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)", "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-227", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R53": { "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "longName": "9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R54": { "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "longName": "9954506 - Disclosure - Share-Based Compensation (Narrative) (Details)", "shortName": "Share-Based Compensation (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "longName": "9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "longName": "9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-246", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-250", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "unique": true } }, "R57": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "longName": "9954511 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-258", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-258", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.cardinal.com/role/SubsequentEventsDetails", "longName": "9954512 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20231231.htm", "first": true, "unique": true } } }, "tag": { "cah_A1BillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "A1BillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1 billion share repurchase program", "label": "$1 billion share repurchase program [Member]", "documentation": "$1 billion share repurchase program" } } }, "auth_ref": [] }, "cah_A250MillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "A250MillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$250 million share repurchase program [Member]", "label": "$250 million share repurchase program [Member]", "documentation": "$250 million share repurchase program" } } }, "auth_ref": [] }, "cah_A500MillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "A500MillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million share repurchase program", "label": "$500 million share repurchase program [Member]", "documentation": "$500 million share repurchase program" } } }, "auth_ref": [] }, "stpr_AL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "AL", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ALABAMA", "label": "ALABAMA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r685" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r113", "r865" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r6", "r18", "r40", "r207", "r784", "r785" ] }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r7", "r18", "r40" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r39", "r40", "r134", "r196", "r527", "r556", "r557" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income/(Loss)", "verboseLabel": "AOCI Attributable to Parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r18", "r40", "r476", "r479", "r506", "r552", "r553", "r783", "r784", "r785", "r791", "r792", "r793" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r737" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r743" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r743" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r743" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "cah_AggregateAnnualAssessment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "AggregateAnnualAssessment", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Annual Assessment", "label": "Aggregate Annual Assessment", "documentation": "Aggregate Annual Assessment" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "cah_AgreementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "AgreementsAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements [Axis]", "label": "Agreements [Axis]", "documentation": "Agreement" } } }, "auth_ref": [] }, "cah_AgreementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "AgreementsDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements [Domain]", "label": "Agreements [Domain]", "documentation": "Agreements [Domain]" } } }, "auth_ref": [] }, "cah_AlamedaCountyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "AlamedaCountyMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alameda County [Member]", "label": "Alameda County [Member]", "documentation": "Alameda County [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r743" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r750" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r715", "r723", "r733", "r750", "r758", "r762", "r770" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r768" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r433", "r441" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r13", "r57", "r62" ] }, "cah_Amortizationandotheracquisitionrelatedcosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Amortizationandotheracquisitionrelatedcosts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization and other acquisition-related costs", "label": "Amortization and other acquisition-related costs", "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r247" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r18", "r40", "r783", "r784", "r785" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r169", "r192", "r223", "r256", "r271", "r277", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r464", "r468", "r494", "r523", "r594", "r685", "r699", "r817", "r818", "r857" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r186", "r199", "r223", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r464", "r468", "r494", "r685", "r817", "r818", "r857" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r116", "r122", "r155", "r184", "r185" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r765" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r766" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r764" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r763" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r762" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r148" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r461", "r678", "r679" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r83", "r84", "r461", "r678", "r679" ] }, "cah_CARESActDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CARESActDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Operating Loss Carryback [Domain]", "label": "CARES Act [Domain]", "documentation": "CARES Act" } } }, "auth_ref": [] }, "cah_CVSHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CVSHealthMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CVS Health", "label": "CVS Health [Member]", "documentation": "CVS Health [Member]" } } }, "auth_ref": [] }, "cah_CardinalHealthAtHomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CardinalHealthAtHomeMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardinal Health At Home [Member]", "label": "Cardinal Health At Home [Member]", "documentation": "Cardinal Health At Home [Member]" } } }, "auth_ref": [] }, "cah_CareFusionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CareFusionMember", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CareFusion [Member]", "label": "CareFusion [Member]", "documentation": "CareFusion [Member]" } } }, "auth_ref": [] }, "cah_CarryingAmountofLongTermandotherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CarryingAmountofLongTermandotherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings", "label": "Carrying Amount of Long-Term and other Short-Term Borrowings", "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r46", "r188", "r661" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and equivalents at beginning of period", "periodEndLabel": "Cash and equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r46", "r145", "r220" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase/(decrease) in cash and equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r145" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging [Member]", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r96" ] }, "cah_ChangeInDiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "ChangeInDiscountRateFairValueInput", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Discount Rate, Fair Value Input", "label": "Change in Discount Rate, Fair Value Input", "documentation": "Change in Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r168" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r741" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "cah_ClassActionLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "ClassActionLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "documentation": "Class Action Lawsuits [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r193", "r194", "r195", "r251", "r378", "r379", "r380", "r382", "r385", "r390", "r392", "r559", "r560", "r561", "r562", "r672", "r776", "r788" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r742" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r742" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r159", "r691", "r692", "r693", "r696" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments, Contingent Liabilities and Litigation", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r157", "r328", "r329", "r647", "r813" ] }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "CommittedReceivablesSalesFacilityProgramMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Committed Receivables Sales Facility Program [Member]", "label": "Committed Receivables Sales Facility Program [Member]", "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables." } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per common share", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r163" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r687", "r688", "r689", "r691", "r692", "r693", "r696", "r791", "r792", "r850", "r869", "r871" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, without par value:", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r129", "r582" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r129" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at December\u00a031, 2023 and June 30, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r129", "r526", "r685" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r747" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r748" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r41", "r204", "r206", "r214", "r519", "r538" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income/(loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r91", "r165", "r204", "r206", "r213", "r518", "r537" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r225", "r258", "r269", "r270", "r271", "r272", "r273", "r275", "r279", "r337", "r338", "r339", "r340", "r342", "r343", "r345", "r347", "r348", "r817", "r818" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r225", "r258", "r269", "r270", "r271", "r272", "r273", "r275", "r279", "r337", "r338", "r339", "r340", "r342", "r343", "r345", "r347", "r348", "r817", "r818" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r23", "r270", "r271", "r272", "r273", "r279", "r797" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r139", "r513" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap [Member]", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r85" ] }, "cah_DateInitiatedAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "DateInitiatedAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Date [Axis]", "label": "Date Initiated [Axis]", "documentation": "Date Initiated" } } }, "auth_ref": [] }, "cah_DateInitiatedDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "DateInitiatedDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date Initiated [Domain]", "label": "Date Initiated [Domain]", "documentation": "Date Initiated [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r158", "r221", "r350", "r356", "r357", "r358", "r359", "r360", "r361", "r366", "r373", "r374", "r376" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r27", "r126", "r127", "r170", "r171", "r225", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r505", "r667", "r668", "r669", "r670", "r671", "r789" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r364", "r493", "r668", "r669" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r505", "r667", "r668", "r669", "r670", "r671", "r789" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r34", "r225", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r505", "r667", "r668", "r669", "r670", "r671", "r789" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r34", "r71", "r74", "r109", "r110", "r112", "r114", "r161", "r162", "r225", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r505", "r667", "r668", "r669", "r670", "r671", "r789" ] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, Long-Term and Short-Term, Combined Amount", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r81" ] }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other liabilities", "label": "Deferred Tax and Other Liabilities, Noncurrent", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r13", "r261" ] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNotionalAmount", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Notional Amount", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": [ "r633", "r636", "r638", "r640", "r847", "r848", "r849" ] }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Contract", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Name [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r572", "r574", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r609", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r633", "r635", "r639", "r641", "r687", "r689" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r99", "r101", "r102", "r105", "r572", "r574", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r609", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r633", "r635", "r639", "r641", "r663", "r687", "r689" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r20", "r99", "r102" ] }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments." } } }, "auth_ref": [ "r25", "r103" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r104", "r780" ] }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNotionalAmount", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Notional Amount", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": [ "r634", "r636", "r637", "r640", "r847", "r848", "r849" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r481" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r20", "r92", "r93", "r94", "r98", "r100", "r102", "r106", "r107", "r108", "r481" ] }, "cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount", "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount", "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Developed technology and other", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r164" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table Text Block]", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r820" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r403", "r406", "r434", "r435", "r437", "r681" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "cah_DiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "DiscountRateFairValueInput", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "documentation": "Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r312", "r787", "r810" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": [ "r313" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/Divestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r115", "r154" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r678", "r679" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r9", "r163" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r703" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r736" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Text Block]", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r239", "r247", "r248", "r249" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r495" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r445" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r436" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r436" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit related to share-based compensation", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r433" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee- Related Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r701" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r701" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r701" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r775" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r701" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r701" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r701" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r701" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r19", "r181", "r207", "r208", "r209", "r226", "r227", "r228", "r230", "r235", "r237", "r250", "r290", "r291", "r393", "r438", "r439", "r440", "r452", "r453", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r496", "r498", "r499", "r500", "r501", "r502", "r506", "r552", "r553", "r554", "r567", "r621" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r286", "r287", "r288" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Ownership Percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r286" ] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments, Fair Value Disclosure", "label": "Equity Method Investments, Fair Value Disclosure", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": [ "r782", "r851", "r852", "r853" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r750" ] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FacilityClosingMember", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Exit and Other Costs", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "cah_FacilityExitAndOtherCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "FacilityExitAndOtherCosts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Exit and Other Costs", "label": "Facility Exit and Other Costs", "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r486", "r487", "r491" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r486", "r487", "r491" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r364", "r395", "r396", "r397", "r398", "r399", "r400", "r487", "r508", "r509", "r510", "r668", "r669", "r675", "r676", "r677" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r486", "r487", "r488", "r489", "r492" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r485" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r95" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r364", "r395", "r400", "r487", "r508", "r675", "r676", "r677" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level\u00a02", "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r364", "r395", "r400", "r487", "r509", "r668", "r669", "r675", "r676", "r677" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r364", "r395", "r396", "r397", "r398", "r399", "r400", "r487", "r510", "r668", "r669", "r675", "r676", "r677" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r364", "r395", "r396", "r397", "r398", "r399", "r400", "r508", "r509", "r510", "r668", "r669", "r675", "r676", "r677" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Nonrecurring", "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r486", "r487", "r488", "r489", "r490", "r492" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r485", "r492" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r190", "r309" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year One", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r306", "r308", "r309", "r311", "r514", "r515" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Intangible", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r151", "r515" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r514" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r58", "r61" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r151", "r514" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Amortization Period (Years)", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r514" ] }, "cah_Fiscal2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Fiscal2022Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2022 [Member]", "label": "Fiscal 2022 [Member]", "documentation": "Fiscal 2022" } } }, "auth_ref": [] }, "cah_Fiscal2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Fiscal2023Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2023 [Member]", "label": "Fiscal 2023 [Member]", "documentation": "Fiscal 2023" } } }, "auth_ref": [] }, "cah_Fiscal2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Fiscal2024Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2024 [Member]", "label": "Fiscal 2024 [Member]", "documentation": "Fiscal 2024" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract [Member]", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r663", "r675", "r684" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "stpr_GA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "GA", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GEORGIA", "label": "GEORGIA" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r787" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Litigation (recoveries)/charges, net", "label": "Gain (Loss) Related to Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r814" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r189", "r293", "r516", "r666", "r685", "r800", "r807" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r150" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation adjustments and other", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r301" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r296", "r303", "r666" ] }, "cah_GoodwillImpairmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "GoodwillImpairmentAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment [Axis]", "label": "Goodwill Impairment [Axis]", "documentation": "Goodwill Impairment" } } }, "auth_ref": [] }, "cah_GoodwillImpairmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "GoodwillImpairmentDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment [Domain]", "label": "Goodwill Impairment [Domain]", "documentation": "Goodwill Impairment [Domain]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r13", "r294", "r300", "r305", "r666" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r666" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Purchase Accounting Adjustments", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r806" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r138", "r223", "r256", "r270", "r276", "r279", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r494", "r664", "r817" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r20", "r473" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r20" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r20" ] }, "cah_IPRDTrademarksandOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "IPRDTrademarksandOtherMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks and patents", "label": "IPR&D,TrademarksandOther [Member]", "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [] }, "cah_IVCApril2023AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "IVCApril2023AgreementMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IVC April 2023 Agreement", "label": "IVC April 2023 Agreement [Member]", "documentation": "IVC April 2023 Agreement" } } }, "auth_ref": [] }, "cah_IncomeAsAResultOfPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "IncomeAsAResultOfPrepayments", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income As A Result Of Prepayments", "label": "Income As A Result Of Prepayments", "documentation": "Income as a result of prepayments at a pre-negotiated discount certain future payment amounts" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings/(loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r136", "r175", "r256", "r270", "r276", "r279", "r521", "r532", "r664" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r174", "r176", "r215", "r229", "r231", "r232", "r233", "r234", "r242", "r244", "r245", "r484", "r520", "r866" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r215", "r229", "r231", "r232", "r233", "r234", "r242", "r244", "r245", "r246", "r484", "r520", "r866" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r678", "r679" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r16", "r21", "r28", "r116", "r117", "r118", "r119", "r120", "r121", "r123", "r124", "r125", "r156" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r313", "r319", "r605" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r319", "r605" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r224", "r442", "r446", "r450", "r451", "r454", "r456", "r459", "r460", "r564" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for/(benefit from) income taxes", "terseLabel": "Income Tax Expense (Benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r179", "r180", "r236", "r237", "r264", "r444", "r455", "r539" ] }, "cah_IncomefromSettlementsofClassActionLawsuits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "IncomefromSettlementsofClassActionLawsuits", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from Settlements of Class Action Lawsuits", "label": "Income from Settlements of Class Action Lawsuits", "documentation": "Income from Settlements of Class Action Lawsuits" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other accrued liabilities and operating items, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in trade receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r307", "r310" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r153" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r59", "r153" ] }, "cah_IndemnificationReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "IndemnificationReceivable", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification Receivable", "label": "Indemnification Receivable", "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r715", "r723", "r733", "r750", "r758", "r762", "r770" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r768" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r704", "r774" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r704", "r774" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r704", "r774" ] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Recoveries", "label": "Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": [ "r140" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Intangible, Total other intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r189" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible, Total other intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r56", "r60" ] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangibles, net", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r111", "r178", "r210", "r260", "r504", "r606", "r697", "r870" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income (Expense), Nonoperating, Net", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r659", "r694", "r695" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r197", "r662", "r685" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r486" ] }, "cah_January2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "January2023Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2023", "label": "January 2023 [Member]", "documentation": "January 2023" } } }, "auth_ref": [] }, "cah_June2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "June2027Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2027", "label": "June 2027 [Member]", "documentation": "June 2027" } } }, "auth_ref": [] }, "cah_LawsuitTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "LawsuitTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "documentation": "Lawsuit Type [Axis]" } } }, "auth_ref": [] }, "cah_LawsuitTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "LawsuitTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawsuit Type [Domain]", "label": "Lawsuit Type [Domain]", "documentation": "[Domain] for Lawsuit Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r133", "r173", "r530", "r685", "r790", "r798", "r854" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Deficit", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r33", "r187", "r223", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r465", "r468", "r469", "r494", "r685", "r817", "r857", "r858" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r116", "r122", "r155", "r184", "r185" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r31" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r35", "r814" ] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability, Current", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r35", "r814" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Expense", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term obligations, less current portion", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r27", "r524" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term obligations and other short-term borrowings", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r32" ] }, "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]", "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]", "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment, Period", "label": "Long-Term Purchase Commitment, Period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r330", "r331", "r332", "r336", "r815", "r816" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r330", "r331", "r332", "r336", "r815", "r816" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r330", "r331", "r332", "r336", "r815", "r816" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r330", "r777" ] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": [ "r814" ] }, "us-gaap_LossContingencyClaimsSettledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyClaimsSettledNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Claims Settled, Number", "label": "Loss Contingency, Claims Settled, Number", "documentation": "Number of claims settled." } } }, "auth_ref": [ "r815", "r816" ] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Estimate of Possible Loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r331", "r332", "r335", "r336" ] }, "cah_LossContingencyLawsuitsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "LossContingencyLawsuitsNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "documentation": "Loss Contingency, Lawsuits, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r330", "r331", "r332", "r336", "r815", "r816" ] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Number of Plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r815", "r816" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Pending Claims, Number", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r815", "r816" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r285", "r674", "r820", "r867", "r868" ] }, "cah_MaturityDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MaturityDateAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date", "label": "Maturity Date [Axis]", "documentation": "Maturity Date" } } }, "auth_ref": [] }, "cah_MaturityDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MaturityDateDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date [Domain]", "label": "Maturity Date [Domain]", "documentation": "Maturity Date [Domain]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r401", "r512", "r551", "r573", "r574", "r626", "r628", "r630", "r631", "r642", "r657", "r658", "r665", "r672", "r680", "r686", "r819", "r859", "r860", "r861", "r862", "r863", "r864" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r742" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r742" ] }, "cah_MedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MedicalMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical", "label": "Medical Member", "documentation": "Medical [Member]" } } }, "auth_ref": [] }, "cah_MedicalUnitGoodwillImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MedicalUnitGoodwillImpairmentMember", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Unit Goodwill Impairment [Member]", "label": "Medical Unit Goodwill Impairment [Member]", "documentation": "Medical Unit Goodwill Impairment" } } }, "auth_ref": [] }, "cah_MedicalUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MedicalUnitMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Unit", "label": "Medical Unit [Member]", "documentation": "Medical Unit" } } }, "auth_ref": [] }, "cah_MedicaldistributionandproductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "MedicaldistributionandproductsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical distribution and products [Member]", "label": "Medical distribution and products [Member]", "documentation": "Medical distribution and products [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r401", "r512", "r551", "r573", "r574", "r626", "r628", "r630", "r631", "r642", "r657", "r658", "r665", "r672", "r680", "r686", "r819", "r859", "r860", "r861", "r862", "r863", "r864" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r38", "r172", "r223", "r289", "r337", "r340", "r341", "r342", "r348", "r349", "r494", "r529", "r584" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r88", "r163", "r166" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r761" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r769" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r285", "r674", "r820", "r867", "r868" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r743" ] }, "cah_NarativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "NarativeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Narative [Abstract]", "label": "Narative [Abstract]", "documentation": "Narative [Abstract]" } } }, "auth_ref": [] }, "cah_NativeAmericanTribesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "NativeAmericanTribesMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Native American tribes", "label": "Native American tribes [Member]", "documentation": "Native American tribes" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r218" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r218" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r145", "r146", "r147" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc.", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r137", "r147", "r177", "r185", "r202", "r205", "r209", "r223", "r229", "r231", "r232", "r233", "r234", "r236", "r237", "r243", "r256", "r270", "r276", "r279", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r484", "r494", "r535", "r602", "r619", "r620", "r664", "r697", "r817" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r167", "r202", "r205", "r236", "r237", "r534", "r785" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging [Member]", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r97" ] }, "cah_NetOperatingLossCarrybackAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "NetOperatingLossCarrybackAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Operating Loss Carryback [Axis]", "label": "Net Operating Loss Carryback [Axis]", "documentation": "Net Operating Loss Carryback" } } }, "auth_ref": [] }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net tax proceeds from share-based compensation", "label": "Net proceeds/(tax withholdings) from share-based compensation", "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Financial Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "cah_NewYorkOpioidStewardshipActMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "NewYorkOpioidStewardshipActMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York Opioid Stewardship Act [Member]", "label": "New York Opioid Stewardship Act [Member]", "documentation": "New York Opioid Stewardship Act" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r712", "r723", "r733", "r750", "r758" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r739" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r750" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r769" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r769" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r872", "r873", "r874", "r875" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r86", "r393", "r791", "r792", "r793", "r871" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r20" ] }, "cah_NuclearPrecisionHealthSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "NuclearPrecisionHealthSolutionsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Solutions [Member]", "documentation": "Nuclear Precision Health Solutions" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r796" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r796" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating earnings/(loss)", "terseLabel": "Total operating earnings", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r256", "r270", "r276", "r279", "r664" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r273", "r279" ] }, "cah_OpioidLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OpioidLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "documentation": "Opioid Lawsuits [Member]" } } }, "auth_ref": [] }, "cah_OpioidLitigationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OpioidLitigationAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Litigation [Axis]", "label": "Opioid Litigation [Axis]", "documentation": "Opioid Litigation" } } }, "auth_ref": [] }, "cah_OpioidLitigationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OpioidLitigationDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Litigation [Domain]", "label": "Opioid Litigation [Domain]", "documentation": "Opioid Litigation [Domain]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "cah_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OtherAgreementsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Agreements [Member]", "label": "Other Agreements [Member]", "documentation": "Other Agreements" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r198", "r685" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r191" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r40", "r208", "r496", "r499", "r502", "r783" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain on derivative instruments, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r200", "r201" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r200", "r201", "r470", "r471", "r474" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments and other", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r472" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income/(loss), net of tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r19", "r26", "r203", "r206", "r212", "r496", "r497", "r502", "r517", "r536", "r783", "r784" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r17", "r165", "r203", "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r207", "r212", "r444", "r457", "r458", "r496", "r500", "r502", "r517", "r536" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income)/expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r142" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense) [Member]", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r742" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Short-term Borrowings", "label": "Other Short-Term Borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r581" ] }, "cah_OutcomesDivestitureAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OutcomesDivestitureAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes divestiture [Axis]", "label": "Outcomes divestiture [Axis]", "documentation": "Outcomes divestiture" } } }, "auth_ref": [] }, "cah_OutcomesDivestitureDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OutcomesDivestitureDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes divestiture [Domain]", "label": "Outcomes divestiture [Domain]", "documentation": "Outcomes divestiture [Domain]" } } }, "auth_ref": [] }, "cah_OutcomesDivestitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "OutcomesDivestitureMember", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes Divestiture [Member]", "label": "Outcomes Divestiture [Member]", "documentation": "Outcomes Divestiture" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for Legal Settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury shares", "terseLabel": "Purchase of treasury shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments and other adjustments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r318", "r786" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on common shares", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire Businesses, Gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r43", "r462" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r144" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r741" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r750" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r743" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r739" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units", "verboseLabel": "Performance Share Unit", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "cah_PharmaceuticalDistributionandSpecialtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "PharmaceuticalDistributionandSpecialtyMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceutical Distribution and Specialty [Member]", "label": "Pharmaceutical Distribution and Specialty [Member]", "documentation": "Pharmaceutical Distribution and Specialty [Member]" } } }, "auth_ref": [] }, "cah_PharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "PharmaceuticalMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceutical", "label": "Pharmaceutical Member", "documentation": "Pharmaceutical [Member]" } } }, "auth_ref": [] }, "cah_PlaintiffTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "PlaintiffTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "documentation": "Plaintiff Type [Axis]" } } }, "auth_ref": [] }, "cah_PlaintiffTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "PlaintiffTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plaintiff Type [Domain]", "label": "Plaintiff Type [Domain]", "documentation": "[Domain] for Plaintiff Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, without par value:", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r128", "r582" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r128", "r378" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r128", "r525", "r685" ] }, "cah_PrivatePartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "PrivatePartiesMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Parties [Member]", "label": "Private Parties [Member]", "documentation": "Private Parties [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestitures, net of cash sold", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromHedgeInvestingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from net investment hedge terminations", "label": "Proceeds from Hedge, Investing Activities", "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [ "r219", "r779" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r143" ] }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from investments", "label": "Proceeds from sale of available-for-sale securities and other investments", "documentation": "The cash inflow from sales of available-for-sale securities and other investments." } } }, "auth_ref": [] }, "us-gaap_ProductLiabilityAccrualPeriodExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductLiabilityAccrualPeriodExpense", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Liability Accrual, Period Expense", "label": "Product Liability Accrual, Period Expense", "documentation": "The amount of loss reported during the period pertaining to product liability." } } }, "auth_ref": [] }, "cah_ProductLiabilityLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "ProductLiabilityLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Liability Lawsuits", "label": "Product Liability Lawsuits [Member]", "documentation": "Product Liability Lawsuits [Member]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings/(loss)", "terseLabel": "Net earnings/(loss)", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r185", "r202", "r205", "r217", "r223", "r229", "r236", "r237", "r256", "r270", "r276", "r279", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r463", "r466", "r467", "r484", "r494", "r521", "r533", "r566", "r602", "r619", "r620", "r664", "r682", "r683", "r698", "r785", "r817" ] }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "ProjectCostsOnInvestmentAndOtherSpending", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project costs on investment and other spending", "label": "Project Costs On Investment And Other Spending", "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r522", "r531", "r685" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for bad debts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r216", "r292" ] }, "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Purchase of available-for-sale securities and other investments", "documentation": "The cash outflow from purchases of available-for-sale securities and other investments." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r738" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r738" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r394", "r401", "r429", "r430", "r431", "r511", "r512", "r551", "r573", "r574", "r626", "r628", "r630", "r631", "r642", "r657", "r658", "r665", "r672", "r680", "r686", "r689", "r811", "r819", "r860", "r861", "r862", "r863", "r864" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r331", "r332", "r333", "r334", "r394", "r401", "r429", "r430", "r431", "r511", "r512", "r551", "r573", "r574", "r626", "r628", "r630", "r631", "r642", "r657", "r658", "r665", "r672", "r680", "r686", "r689", "r811", "r819", "r860", "r861", "r862", "r863", "r864" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r685" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r209" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r40", "r208", "r496", "r501", "r502", "r783" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r209" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assets by Reportable Segment", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r53", "r54" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Profit by Reportable Segment", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r51", "r54" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reduction of long-term obligations", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r45", "r562" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r304", "r305", "r666" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r304", "r305", "r666" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r714", "r725", "r735", "r760" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeverance" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Employee Severance", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r315", "r316", "r318", "r321", "r327" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and employee severance", "totalLabel": "Total restructuring and employee severance", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13", "r322", "r324", "r812" ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringChargesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges [Abstract]", "label": "Restructuring Charges [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r317", "r318", "r324", "r325" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r324", "r325", "r326" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r318", "r323" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r130", "r163", "r528", "r555", "r557", "r563", "r583", "r685" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r181", "r226", "r227", "r228", "r230", "r235", "r237", "r290", "r291", "r438", "r439", "r440", "r452", "r453", "r475", "r477", "r478", "r480", "r483", "r552", "r554", "r567", "r871" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r24" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r211", "r223", "r257", "r258", "r269", "r274", "r275", "r281", "r283", "r285", "r289", "r337", "r338", "r340", "r341", "r342", "r344", "r346", "r348", "r349", "r494", "r521", "r817" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r769" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r769" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": [ "r402", "r794" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r238", "r402", "r777", "r794" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r40", "r855", "r856" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r80" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r286", "r287", "r288" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r486", "r487" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r58", "r61", "r514" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r58", "r61" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r666" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill by Reportable Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r666", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r22", "r153" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r324", "r325", "r326" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring and Employee Severance", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r63", "r65", "r66" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r64", "r67" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r48", "r49", "r50", "r55" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r161", "r162", "r163", "r193", "r194", "r195", "r251", "r378", "r379", "r380", "r382", "r385", "r390", "r392", "r559", "r560", "r561", "r562", "r672", "r776", "r788" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r47" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r700" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r702" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r253", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r285", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r320", "r326", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r666", "r781", "r867" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r283", "r284", "r569", "r570", "r571", "r627", "r629", "r632", "r643", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r660", "r673", "r689", "r820", "r867" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r268", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r285" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]", "label": "Segment Revenue from External Customers by Geographic Area [Line Items]", "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]" } } }, "auth_ref": [] }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]", "label": "Segment Revenue from External Customers by Geographic Area [Table]", "documentation": "Segment Revenue from External Customers by Geographic Area [Table]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution, selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r141" ] }, "cah_September2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "September2025Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 2025", "label": "September 2025 [Member]", "documentation": "September 2025" } } }, "auth_ref": [] }, "cah_SettlingStates": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "SettlingStates", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settling States", "label": "Settling States", "documentation": "Settling States" } } }, "auth_ref": [] }, "cah_SettlingUSTerritories": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "SettlingUSTerritories", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settling U.S Territories", "label": "Settling U.S Territories", "documentation": "Settling U.S Territories" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee-related costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r681" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled and forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in shares)", "periodEndLabel": "Nonvested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r418", "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in usd per share)", "periodEndLabel": "Nonvested at end of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r418", "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r404", "r405", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target performance goal (as a percent)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r821" ] }, "cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "SharesThatWouldBeAntidilutiveAsAResultOfNetLoss", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares that would be antidilutive as a result of net loss", "label": "Shares that would be antidilutive as a result of net loss", "documentation": "Shares that would be antidilutive as a result of net loss" } } }, "auth_ref": [] }, "cah_ShortTermCreditFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "ShortTermCreditFacilitiesMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short Term Credit Facilities Member", "label": "Short Term Credit Facilities Member", "documentation": "Other short-term credit facilities and an unsecured line of credit" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating and Reportable Segment", "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r183", "r253", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r285", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r314", "r320", "r326", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r666", "r781", "r867" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r19", "r37", "r181", "r207", "r208", "r209", "r226", "r227", "r228", "r230", "r235", "r237", "r250", "r290", "r291", "r393", "r438", "r439", "r440", "r452", "r453", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r496", "r498", "r499", "r500", "r501", "r502", "r506", "r552", "r553", "r554", "r567", "r621" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r283", "r284", "r569", "r570", "r571", "r627", "r629", "r632", "r643", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r660", "r673", "r689", "r820", "r867" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement of Stockholders' Equity", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r226", "r227", "r228", "r250", "r513", "r558", "r568", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r601", "r603", "r604", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r690" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r238", "r402", "r777", "r778", "r794" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r226", "r227", "r228", "r250", "r513", "r558", "r568", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r601", "r603", "r604", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r690" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r19", "r128", "r129", "r163" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r79", "r128", "r129", "r163" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r129", "r131", "r132", "r149", "r584", "r600", "r622", "r623", "r685", "r699", "r790", "r798", "r854", "r871" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 deficit", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r86", "r87", "r89", "r181", "r182", "r208", "r226", "r227", "r228", "r230", "r235", "r290", "r291", "r393", "r438", "r439", "r440", "r452", "r453", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r496", "r498", "r502", "r506", "r553", "r554", "r565", "r584", "r600", "r622", "r623", "r644", "r698", "r790", "r798", "r854", "r871" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r160", "r222", "r377", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r393", "r482", "r624", "r625", "r645" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOtherShares", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Other Shares", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsDomain", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "http://www.cardinal.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r749" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Tax Credit Carryforward [Table]", "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r82" ] }, "cah_TaxMatterAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TaxMatterAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "documentation": "Tax Matter [Axis]" } } }, "auth_ref": [] }, "cah_TaxMatterDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TaxMatterDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matter [Domain]", "label": "Tax Matter [Domain]", "documentation": "[Domain] for Tax Matter [Axis]" } } }, "auth_ref": [] }, "cah_TaxMattersAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TaxMattersAgreementAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matters Agreement [Axis]", "label": "Tax Matters Agreement [Axis]", "documentation": "Tax Matters Agreement [Axis]" } } }, "auth_ref": [] }, "cah_TaxMattersAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TaxMattersAgreementDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matters Agreement [Domain]", "label": "Tax Matters Agreement [Domain]", "documentation": "[Domain] for Tax Matters Agreement [Axis]" } } }, "auth_ref": [] }, "cah_TerminalGrowthRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TerminalGrowthRateFairValueInput", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminal Growth Rate, Fair Value Input", "label": "Terminal Growth Rate, Fair Value Input", "documentation": "Terminal Growth Rate, Fair Value Input" } } }, "auth_ref": [] }, "cah_TotalOpioidLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TotalOpioidLitigationMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Opioid Litigation [Member]", "label": "Total Opioid Litigation [Member]", "documentation": "Total Opioid Litigation" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r741" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r748" ] }, "cah_TrademarksAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TrademarksAndPatentsMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks, trade names and patents", "label": "Trademarks And Patents Member", "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r768" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r770" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cah_TransactionDataSystemInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "TransactionDataSystemInvestmentMember", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Data System Investment", "label": "Transaction Data System Investment [Member]", "documentation": "Transaction Data System Investment" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r771" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r772" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r773" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r771" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares acquired, average price per share (in usd per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common", "verboseLabel": "Treasury Shares", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares in treasury", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares acquired (in shares)", "negatedTerseLabel": "Treasury Stock, Shares, Acquired", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r19", "r129", "r163" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Common shares in treasury, at cost: 83 million shares and 76 million shares at December\u00a031, 2023 and June 30, 2023, respectively", "negatedPeriodStartLabel": "Treasury, balance at beginning of period", "negatedPeriodEndLabel": "Treasury, balance at end of period", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r36", "r75", "r76" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r19", "r75", "r163" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r317", "r318", "r324", "r325" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r767" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r443", "r448" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest and penalties accrued", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r447" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r449" ] }, "cah_VestingPeriodinyearsforShares": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20231231", "localname": "VestingPeriodinyearsforShares", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "documentation": "Vesting Period in years for Shares" } } }, "auth_ref": [] }, "stpr_WV": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "WV", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WEST VIRGINIA", "label": "WEST VIRGINIA" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r795" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r241", "r246" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r240", "r246" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r776": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r778": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 84 0001628280-24-002813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-002813-xbrl.zip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

8C./&T PHUFG/SLO %7V9;7 ZY@0O$[\ M?M\@2#2YQCSN6@O\2FABWP Y@9KJG>\32B+[X]QZ)"$6S [X5'@);Z;."[+Q MZ\X#U")'Q?1:[V+ZY'[*%\\M_2"U-;+H[W]^N_' T?:_VYA<-IU@ZA6AP=;J MOOL+-\RY.*T(%,JY5S M,F7X0X8_9/BCN?"')L,?,OPAPQ\R_'%T^,,N KN53I#BL]I96//@[ZWK7I0N7077CY:UO&$< M%&PF2=W5XMKVR"D/5V*!P6^-K^K%*5.C-3+[;<,PH_1HM)A3=#R4:<66^-J\ M*;,S%^7LERXBRD8]HFQB45;;1F^8$F4I4L*(E#P=2XF46H](]0@,:%OK#N3Q M*&59'H^-'(]F/;+<)[CW[6Y?$^%\//>Y&.^\@,RG7/J>O0+P'4R^W=-U1<:2 MK]WU U)^G?[J>79PY]H/R']R)BAXP/0L*B(#;$&:;7.8MB %.>WD& 3.=/D! M5ZCVCE7NDH4XTWX'3/O*6,CH@H$PP.K/D.I/\FX3IFQUO*NV M1L-^NS],AW'%FE=3V*;F!HD_FUE^];T@4&C)T^7-]JW=]"7DO?>]J1,6E1@- MAFT-C+2]((BNYS"PDVLMKH(X1#)B:?7Q0<,\2,XT2#0 M^ZJP=K>4 !$DH'9S_@@),$$"M'Y?!%V[NXM+^8[R>O&N/Y]*O1VH M.$L$Y=+N(P!N0@-0<).GJK/4>$!Y??/7GWO>[;T3A+XS7L'ATE8"-,<_>6PK MC\C%?#TGR$"6O7!<^!D!%(GY7";GRD0H'BB%?Z7TO7/MNPWJ?J#$+6HN0%U* M6QND73=!#&89J.;,LCT09:B'BZ$BHZT.54YBUI*;&HH4U,--@]9(:QN#KM2) MDHN;\/;KX>(A<+$^2->;BI7'$\4<_H;P?JTF(863!.L7+99S[Q4A;!O#N!9W MDNK**A(IXU8\&FA(2E#VW./D=("^%_^&.])[O=M0$6$E%5N8P@<*;*4Q9J?7P[!)LUG5Z5'"2VYDL9K;5Q M4*\+P5.9[9&<6Y,96Q_GJJW1H+).*1ECW<\#OV%7XY%&6*]\-/'PNAP4O'D[ MH=M3WHSEW;/+5N9753;,,E'X1OVX[]Z:U@\H#.=LG&&*_Z%;-FVTII"_90C@ ME')3B%$.]9669!0=T)O3D2K)*>*JE$-]GR4Y!9"'TZ$BR2CBJI1#[9$E&<7$ M9T]&66_CG"(Q35(M2:U#129?YC0?*="'Q7>^%G/FX;0(V=Z*%+R>I< MLWKM]:3Y6'T(]K8$(I'7"WW]N5=_?"5UQU<.D>0W;QE*PZ65>%09&R<4_>*Y MWJ:6C!LYMQ5E'P"#TW7WA0U0F5#DUT,YDD/4UNB86+AD$-Y4R"%?HBB#:)FV MEN00<57((1.\*(?HK5$:U+MQ!CGWDH-/,/\6!:%RM!W%>YZG]I!U1,K=+&VT M1L)&4F36D;.0QP&3[3 WFJV1QLO8!,D6#05]#[-%#[.%L"DUR8Z<::D#5N%A M=NQC,_#HVOMF"B&@\6ANO<)"T6XNNL1?2<+50[B+*;WYL%EPHXS1U/.10H/ M2FB]E(3I%3IMUH!'$V7+/OK>XAV^U'%7F!0LG>:YP2]D'^COOL,N?'@)?0M3 MTW$M__53B!8!]OGAH;Y'4 ,CA9^AZ2'3/!06Q5)FFD40F0:+>9H5'LA=ZQ6$ MW"7_?[&5 M2O>^]^0$H%RPT+^]&B,739U0F6+=\*8RUY5;O=N0=XJU* L>_D+IFZ$IH=A M%WW@K2QUX,8>*.8"YN%07=9+<<0B#7E9>1C#P*JK*[J')/F2&]55S)7)PZ%F M5E&+,'5:YY8H^8+"2KJ3BY*'*SFIW?2DLXZSVX@&O=9(-X55V67EHL;RBGJ" M6D)S>(-&[%Y>AUYDO0*("LEN7+-;[0;Q7B8;8(7:$S8Q+#ER^N0 MQST&VZ$);I/57+(,3A).B%]5DG_+$U:1UXMW_;GWMOV&@N!&249$%"L,?6>\ M"JWQ'"FAI[@;R7;%8=GV2YI>5B62 *;UN@;B+D'K[U[>LH9A-VM*A$3'Y,HN MKK!/K03+) >+3YT79%__A7PO@Y54<-8&FJK=*9^B((J>$;GXO2ZO+:A;(V2D0U+F8#O+%)].5?^@:QY.&LKF I/;A\2Z#V.R.#\EJVQ: M2RQ4*U9J(6\N;W["FQ<.(=EC^+\<)@>S39DUHLQO)"RT1#Y^S\4"Z\%@9ODH M7YSH9F>BL "I"F^HO+Z>Z\\](?Z+%3B38V+1/%ERQ[IE6:_'@[%6W/.Z1_X# MJ*R]@4JM.%@!OB_A&'9S9LMU8UMNT!JI'4/T3@<.\G.BBN"QSA2O(EC"7]HE M@\:6#)9&#CDDC,/6J-O)0,H4,5\MJCS((^F0.*CU'DEX8>1,2L-:RS/I0F10 MGDD'A=!LZ$Q2NRH<2MUCVL-/51##;30CFP_>._-5B.Q29;;E6Q$<2055>7QV"*K=N3?8)][_D'\B^MO"*K$>DN*O% M&/F*-]W(U0:*MPJ#T'+)2\F4[!E=?Y$IV8I>5!!KE8IPP2Z+2#/<4<7PA>B% MKU-RG@=?U]J T#==AZ9V8:(8]>BN'()6[0=?)5IZ/_5HN+'_< MJPJM2Q591E7I\'?5]3G[QG[923%5(/6!72%':553G/4G?O-NYQ ]X5VV8? BZQ"7$L4+\CZGC6NX$GAB$^(,% M7FRPA@O=?E%V^SXF\.W2"QS8L1L?S:W0>4*WSXX=SB)62US%Z-)=7V*-\0I6 MX>Y+=M%O]//8?SO:N;Y\&T$Q,.+%$<[!&S*WE@&ZB?ZXC69/."ZA++GH=O,! M@!6[Q3+D>?1K]G+#86=@ZO!^+"C$'LQ>O8-?_6WZ,W.&YQN]Q(,Q7-EI'.+I)39%A]]3X M^&R35-,W)7I/QN0(NA[2+8U2? M^1]E#>\:!-='^/_L>72\-?M=.]M:G>^F/ M#EA#BM;5#.6CYR\4M7O]>V'VWU1#D6&2\V6^.PML$WQ!S\HW;V&YQQD92KG# M^(]5$#K3USW'>O*_<%BBF;^FVB.Z'OO(^G%M3;' WUCS9^LU /HEUXL7FS1P=MDF^:V]HM9*X[8) M?CGL@'>+&B>:T>D-M$HL"A.[ 6KV)45OI:D=M9O+.,GO4B-#G>KFEGN1M [H M]Q7FYEA:L2:]]S$V]Q]B6_38;;E4N*JCM/M(-T)5KP7>Q= MO4MZ5VLB0X\'=I:7/IKAWV%O2:%]70RO+Z4C*CV9M%SOCE; MQ 8;V>3'NU*+*C!3[>CFL!*MHW8[FM8K=*O=GYM&-2Z?7%2A1>UWCG-Z>IFZ M;YC'<:&BPTV"X/O,1TCYC'\W"Y0/6*_9RGLT0:1335?;.8Z+LR/)@_.2DR U MA06:C1339=EHXM$.XQML$2$??H5/"<=5\,/FT'B=52$2A>:97MWV)::<>JB!P4X94H]3!0%3S$*\5RLE'9&7!B:-S,V6YR:MNY M3K"H?6K;O>]-G3![:(6J#F 8C;"(-AP.HRE44B&RM,IY,_DP?\J.9=LOM\,S M',IV,:(C#[I2!]V!]KV] J-U\4'72PN,/.BDM,J#[J2#U?;+K8H/NB'GYYQL M I775]<$RFVT(OL$_QK.:#MG(J'IL(0FB5V4@ZW;<\K(ZT]X_;G#UGWT?/Q/ M5YFL?!^YDUEB)J8Z,, M(H%N2_?@'=N"[[ #](EWKOU]O1]W\79\0>'7Z7?K)RE4?+<14L9#:^ MV1/I=\0.;Q#Z*^(8M!47_]R;*J'U4LHUR" .5RKHI*X!0$I]G'O/_T#V(_H5 M;P1\> >='-^@QS@(G"FF1J2(LM5-KS42/>/-0:S_+'CYI Y!%;S<;XW4H]T MR52<*<@#FU;EX>9D7_3L-394/GA7.7_4[?Y-B< M_NZ%^$;>H;S1T89T4?)Q)7@GM;+W..MZ-]/B$.1T*"M1-8:JRE?ZGRWOG]0J MW\?[:FN4470I>? ,>9"36/X^;M2RXAB%HZ:2#[GF0TX"_OOX4,=:,0WX]GP0YPM!WQBL" MD/+=^^*Y\"#?F^/U/7Z"EET4A%GZV8#6!V$S'M),$4%.&FR,:T!B3(AQ'--= M)YE6!*:M/5'3 *OVH(%;]/I6*2=I,OW2[=57E]Y>XJ M)T#D^;3+;R@(;C)]4<5*"#[,,W W1!__BLK^<T&TI9Y#+@"J+3!_Q2K'77 MT;^RJC:SD$36CG-UC%>85BO!,U//7UCAWUO.2W@S=5Z0??T7\KTL7AJ"<3G0 M5.U6=KUPQ59U9,JJUT5&MS6J($DAF89?EZ(&IE&Y.,!D8TK#C2F'9HB)F_C9 M@?-\*/&3LKFWAM:T <.^4[2@LC(R\P075"VX5P6TX4'=GS*-EJ77-4B)Z:)& M3>O24C46R%>RUA)08^>E6ZJ%(CL3W<)'ZC%+R^C'IA&EH%^HH$LC@K-T;99X M&V>$G2UUR\7H%FE$<)OBSM(R9FMD'A.XY$'.YMR M^'K5P]<-.7Q=#E]O\JWE\/5S';[>E\/7Y?#U \9)_@" '+Z>9$0Y?+W@\/5? MK#DF-U(>9@BM"2V$C/>QJ:\:U0RXUCKF,/NK,E.W*UJ4VM',_3I,#E+._\:< M3;M-#L=6"1"MJGYSY6+%+V;08!C*_G+#JD1;C+PCAK3?[G6RG:P MAL\U?ORDU*QS'A!GVW(7!"B?.2-;;CC9,@KD'BH6V;IR$YLJDB8Y@*O@\0(H MF60:$?ISY3Q9\RQ?HLB[\I2KK*@.@KMTX_&E#+T#I0R8*>Y<&_[GPYHM[L)W M>)6OF!3_8\U7:+/]QETMKFV/V*APVZQ<)""GM\VA! <^^C0252 K*A[@3B"/ M[XWKGT(@^R"072-=R2P6PK$H1^UWW[*1XF.G%F_@>([HL \Y +#,"?5M3<4O M*&0&:&$!@ YCM=T?I,<'"7(DR;Y"L?1X-6P[)&RK&^GJT=.PS[G[2)_<)[Q- MGN\.?:'R*:EHGO#B!28!@RN"6#6XT<>94R[Y PKPQS-<0&OWJ> M_>S,Y^NNV1F9;[\LT MLPR#-91FKH&)U=:HU^X.TDS,95A,0*!OP9P)DANK(!3'K9@VF1 '^/]RL8>> MUAJI[>Y0]+B;=!L$.5RJX5J=<*UQ]&ER8G_A/* )H+AR &*QQ+Q:@&%!Q+RAI%EA,3>QF.MM0^U7 MY$KR/_8VG=9+HQU7"/EQUC<_?["2WQQK[,R=T&$UYP\SRTG\EK(E(69>[R02O/@R4I?4*[982TH1O!(7Z M_1S&$/>4'TJ6#_6@=LYH:^90<+^'@P21J"(H04S*^B#5B&"_-=*&[8$J84L: M0@ACMM#2\PD'>%-E[KF/U]@.7RC>&"^.5.,O-4 MZMSZ#9/Z.R;D>S0."0+0T@FM^6_("M#7->W+RA( H+15B7\B,U+-' $%N3G- ML,/6J#^4I6N-U@U,)OX*V4E?6!:LE2\BH-1,!(Y*ZNY^EW38Z](3D:5J#583 M5,:^*O:DV]T,1UI:\74P0C)236;]88T>>JQ^H((F?-Y-F_H-]36!"W8U)P5G MZKP@^_HOY'M9,J.!DAUHJG8KJM*7!KM82K\\5Z>Y5V^-#-%-]S-NU:_(OA>P M9;G)LZ&LN03CX@=M;2!LSV$I 3I%M=71+H* $M#D.5)6 DS2N=_OIB6 -TZL MLA")N\H!67EPP-'*RHVTE3D*@OBH9:D4&4:K+R-26+U 9K]MZJ;@YZL,IXER M(M;#QH!OTQYV95BM&89XCZ8(ZW1;<=R)MT!*:+TDX8>/=JIX#T#4KNTC G^W M7K"4D!ATPI8LW];6'[1&@[8Z%#9](B-I8NG[VAAY"(S<,ZL"-./"^U?.4)QLV5VU I MF71#;>[Q37\_J9'4@:GZ)A8X?WU\>_M.,58MQU4T'BDG+C_V-73T&F, MD1]";_*#Z*=@_:KY#EL]/FP'W<+KZS6Z/K4U,KOIL3.I#Q009KQ)]JFLW5BO M? J"E6@\5V)/Z6L>3/8GME)K0A2*+TMOC0 WZ3"+Q<<#5G72ZRV*5IK_?>8L%WG%IW-=MW"\L_]%QK^E7 M-_KF3?Y8!:$S?6UV_S5>K'WM:&L_/2>=L/41IG1")_6.- MK75R_->J;6;G* M;3L?;]<\D6INFL^X,?/+,%O1_F4RQ0N54 MG/4>3=!BC'QJK>AJ6]&ZFGXR@D "\I\K%REZ=W,ETADK[HPEQ"G#L#TL1T/: MJ96IKJ4S)IVQRIVQHQE6!8;M&T>CODEG+"]8T6JQHCU9]@&T,)%KJK(U]=51 MJCK :\=_;8O -Q1:^$GV!\MW 7PB06*&QY;%]QITJ*35]!M9A,>3IBS$,"E5 M62G#Z*V1J:?'CS;.,#+ L6T";P2X%,=50A]9PZG$VT!ZN+F?_]V *5E\[YF"3/B/WEE#E M;-/'YG-[J'+ -I?D,=)&@XFW6/IHAMP :U!E[@67!-)4BPN9H#&IUGZ7I/ G MTN[Q&R;S%Q1^G7ZW7K($ N#U,L)^TI\\(RU:'_<,@7O28Y>$<2Z+#'O@0-/N M&[/TSO+Q:O$?_T#6/)RU%;R#'6K6LVKWOQT5N2M*,:ZDJD&=3(P31G$8@AR^ M%C12M&X7&B0-(]WW5=A(X6)V4)&UE+6*Q63+!I5]!6RITAQA&A^)+[8\=\,: M^O#PCWQOCK][A$G=R$=!R;&IO)M#M6?./SNNYV-I^,3(F,7X&F9\41/CTCP7 M*S&>AQ]AW*G@X GG.>HTV-U;*FWN1FWN&/KQGN(8W86A[XQ7(4SU^.YM'J%K M42MH$!G43D_7H/!E$$D[76@[O1%6-JEM?TPHAV?;GBV*50"DYT*>YW$TWQK] M6.!X:HR@/(W-JG9\=P6TX4'W-8D\>^?:%<0I>N.L! M(<7U0FSWA!XP@XW< (%&M'1SV/_ M[6CGC=@Z^W@;;Y=>X !?W)!Q)\X3NGUV[' 6L7CB*O;<[OH2:XQ?917NOJ3D M^O*]*.&']>((_^&=G5O+ -U$?]S:3K"<6Z\WCDNVB%QTN_D L**W>(\\CW[- M7FXX[ Q,'=Z/V?[LP>S5._C5WZ8_U[6.JIN97W4[:N;G>VYE:(.J;J7J_;VW MRL:G,_?!TV5J (2TOF;D[E5O_!X'O+DC*K^;53D9-EZ-C\\VR*$G9&]%:B5T M/:1;&J7X5L7#ODIAQH$UT?X_-10IYZ3![]K)WOIT+_W1 9L+BK(-Y2,VS12U M>_U[8?;?5$.1A9/S9;X["VQ#?,+:1733SUU1[1-=C'UD_KJTI M%O@;:_YLO09 O^1Z\6*3!LXNVZ0R:RIUH\9M$_QRG2Y]P2+&B69T>@.M$HO" M[':&:O8E16^EJ1VUF\LXR1\A0(8ZUQ]AO>(C] MACQ01#G?/Y^%E?\V&?Y;+BFJ[CS1#M*5M<-%;MJ[I)NV)C*,=7_8J&=\OQ6\ MCMZKTC-)R[7ZJW^YULIV\(K?'%)68!V;NU1YXXZ56<*QPKK R/ZJJ,(Q.H/^ ML-"==G]N&OLUE\AK&G2,7H^S-?%()Q[7-.QHJL[9FGCDIV&GVS^H53*.Q$@9 M N9K27C_O8?O,(_G3(U6;L+CK+><]@KGL$X.61]X/:D:CUV62';@F;\P0_$^ MMDQ[HRQ5162KJ .35\;BC%Q)WB$M5L29W>BS(I_\MJ\74M(RJ^S]T\&R=ZG< M%AAUKB6HFHXGX&@]7(8"'S7"M!EV6CBT1'G-ROL4OOP*^R@.FX$ M]A&DBOIRIW*$4QOTH&+8KL>$:8KDVLO&<$KD\SDF_=W"6[F["]_STZ,BLLK= M20N&E @I$4W=9LSI3HJEV6Z.>60&XL] R>:G&VVY>S;;>,+?DX]<]H,-I%E1;HT%ZFNME<: \ M%>2I<*28E8&SU50-4)"-C&G*4OZD_%VJ_*DG-\L H*E7 :BN%$HIE-P*92&9 MU)J);*1%T:@.*TU*(V_26"U@BR#26 &N&CZ@>$:C4DT"K#84TZP].M%V_."K M$U3GH5!!;"Y9[KJLBF6)S30C?UR>>][4R?<)93]"HQL#D529)8X'K;O@*;>SQ%0WY&1F!($ M@*]67CQU(=9)[,.O&1/ ''+0MQ47VX[>5 FMER,LQRVB%#XBY/7R>CFXX(CS MH-P(,4V%$6)I1U_\*1>GOEYD9JW=>,G#K)D!KGO+1VY6H%GK9O*Q( 9/K?)3 MT.#9_KG\E?Q5G;]J.C[;M"KXL%C.O5<$H$+>Y(>"W]T-%%!/3T[X&EO?;/[[ MLQ/.9FAN0\1>0=&5V#3?TRHFLIM<25N$:FZ<-GIF%H7V0KQ?^9 [P:OR;%I3 M1_[[BQ4@&\XC?!B1SMW-E,G4>4'V]5_(][).'A74_4!3M5L9@Q&9N;+"'0]XY]?47Q+L[%..!T1\U*T9=*L:S8*XLQ5B. MLPHJ1ACP=G1L@D/>N?3K19:=VF,CU8B.V1J9:9M"D'#(6>=_FJ8]X1G%1\N5 M/YEAUE&6OO?H6XO8!\V#AR%#J-SY'O?6*X%E_NCYW^+-_3I-@ !DZ84>A$EE MO%\R:PW]C0=LPHU^*^ICW$W^7#E^)D2%!E.\CB] Y8E%+XE%2O@,Z7Z\B#W> M>4'X&84S+Y-1=M2Z",TJEWZ]R*)208/ 1>AK*0 D@B_DG)IB:'WV/JVD6L' ML-=S?!SFPL<4TN&_Y(!!%2?G@0FJ,2=E"+T.A1%:NF*_\&!Y&4"3U_-RO*NFHHB^R(-&!\[=RFM>_2L/B5.O _)&Q65&.1N92=LLA/83*\0.8(G MCKGTZR](8DKT>>Y4IKFK;G2SLJH;#J5'9.ZIP_ OIFRSV*7'\9E<541P#\(M5I%.-;-4= M33QRE;F0O&J6&JY43GZ,KPJI(J .R3(!N9PRH ]@RL# 3*-F2G4DU9%41T*I MHV+QO9./4="'K9&A'8/7>ZG"+ZWY8XL6M11:?/E9#$:W-1I4D%J[.#:69Y@\ MPXXZPPI)<:E1#X8*HQ[ZVC'5&FDR&B:UC=0V8FN;0J9&^7*F)J+TAD$F6 ;J)_KB-'N2XA$_(1;<+ MRW]TW(@4YC*U?/) ^O7MLV.'LYOAL&.:.AQEK!R!/9A^JW8PW[U-?ZYW.ZJ1 M_17^)O/S7;#:R$X5 M5&D;Y^RYMZT#)DE.AF4*)@D:: ^:9*RN6U ZU;^:O'##.[>JSBV8I- M5_]6Y.X=SV9!T$%\2+-L\+E0 = ]PJ5 PU:HUJGT//-;U+Q2\5?5*+*E>8, M(2@^&-0YKEJ*&@^,)T5MOZ@UG;Q*B:()8%,9'H\41"F(8@MB(3DLC)A2E?BI MU6%F2 F4$LB5!!8["E--EES5<9A03MKN\VVRGCO^ZA<4*G,OV#U8[]0HAZ>^ M7F24Q0IT2-Z()>:C]?3:+&$'V+.,.4:<0"Z*R9N7?OWYR6:AXSW5L[PU&\7W MIDY(Y3$W3G7G=$T,KPFR4&Q"L..6/C@Y(>"W]T-XN&KL3U+ZY&49R>< SBBK& M%/_VNA64'7#(OA?$/EFJKQSO%%-]/16KOJ,[9#CDG4N__K)E)\^4EZ-%1VN- M,H! 3B,ZYYZ0(+NB^&BY\B?6L1^W'FP#VB&K:Z-=AMKIT>SW+$XU\!G! MZW0GR2)E)H 5X0]B4$3L\SB'!]TMBS4OAAGN]B9> #_)>:D+''N8UM>&YZ^ MI(\G?I+7BWW]A>N# P?_7G4PX$0=R.H;^2L^JV^8^7HV,Y4/(E_NAP MZ'"= MVQ2V:M+4!S1V?E3,WK &5$P^,-+K6F6)[OES&9]0;6N]\.,3*DBWY$E\-MYM MW^\"$F?_^&2I5 M2+4BU4"9"DP*!:QJ9J@_S&WO5X6U;-RP%8I]5+J+U?JBQWY*10YKD!B M^V2 E*:FAY"+8A'D'N-+YT#**;Z'[W29DV!YG+K*(YUX7).@6EB.+G8PNF8XT#^*3YJPW[?3F#NTXVXTH$+V_B3J&>BP-"=:(0RJ"6 MRC\IHE)$^7CC8GU1*3"4QE.D("YVL&F1NKE! MMS62@TGE"7#A)T IT2I5S#90H9AMJ%ZNLI6[>,'KJ3=D)1+Z[>RAGHHHE /HSHC]'0)E%!G9#Q U-B\)E MC-@XB>67-?A[CKDB<^QW<8MPBR1 %W9/"Y?-]UO*2^#< MN,[\[ZW0AXJ0"H;),G4W[.+UI/V[JJ.](OO@%81E4OF7&L92#M762$94942Q M\K:=35M,KV>4]5"3HZP%YYXLQ9<'W^=HQ0?H?>G)(>+SSJ5?+[+LU!ZXKT9T MC-;(3/=HR?C^.;4PRQ':_.Q%E5Y#J1':0P"^RY@W*T=H2V8]NG_L@+57;(3V ML-<:'3,/CD,6O206*>$-E!P,/.RW1@/SS%CETJ\7653JR']5(RF#UJC/@Z2< M>])!CM"^"">_BC,Q!86;?V;N<-@::1F1+SE"6UXO[/4BZX/Z#_X]ZD#O=CE1 M!^<>4"-%1]P&S4Y]OP5!NP/G>;K#DG#39LODU'E!]O5?R/>RQ%R%0/E M4[7;,XSB71#WY VBY>[5)9RT"XA)[U:18>>08R[]^O.3F&(.5/D)MTSSIB4E M$S="Z'"BR$S28#EY 1XQN."1LH&T:N;2<&"A9S-' K5[/WQY0<_SW,8L%ZQ2 MV5$?>""MDQO66^^:V;#>8M6C<#X/KII5Y@(9JEEJN%(Y^1&(*J2*@#HDZW1N M: ID(50BO=NCJ$2F5$=2'4EU)+8Z*N8M-#V>,JU[^JV1H:4U3^%0_L4)O[3F MCZWBTPX,%"D _JYW!ZW10)=L+,\P>88U>X85DN(R./-Z%T:*M/O:,6 )4KRE M>$OQ+B/>IYXHI*M=P+:7)JH4?BG\S8;+M-0LF:9$7LT"")71,*EMI+812ML4 M,C7RP@J>)DJO:JV1WC8R!HV*8HB0%/Y;0I0(6A7_)UIM:E X9A?RV_AUZ,+P MJ\RM98!NHC]N(Z OQR4,0"ZZ75C^H^-&[V@N4^LBSZ-?WSX[=CB[&0X[IJG# M&<7J#-B#Z;=J!S/4V_3G>K>C&ME?X6\R/]]U*Z,SZ \+W6GWYZ;1/]LU#3I& MK\?9FGBD$X]K&G8T5>=L33SRT[#3[>_7*@2#TG+\>3-6SZ\'D"+=JV(PK$3SG$6[']Q4=$JH3>5]T@8B6BA28IX^*6-B>1RDT;TXFJ-8JR!>I'E6M,#'/) _*%+@H_9:(U-.FI>* M_[(5?Q&)*E5LH\(DMK:JI0'>I:A)4;LD4=-/;F,-6B-5E6>>%,1S$\1"L'7GY]H%I+,5+GEUM /WYLZX2YQE$/4!&&)6K3U?MX 4#,)#EO[SA+ ,/QF MB9'4"EAD\:C9T'J1V+'R>BZO%QDFL I%FYJXU=38>5TSH-3M](""/'&CY.9& MS(8:F-GD@YDO(OAS'XUUQ+:%NQ&Y4QP6N@MD-$A>+Z^7_F6YF,-GQ_5\DC6@ MZN0]FD!!"_KH>XMOR$:+)3PBT^GL976,"QT>O'1>J8U5^ERPRKF')SXLEG/O M%4'[L#?YH2SG^%;Q(.@X1D$+1Y5G)YS-T-R&8C4%15>&U@L*CFF,$DP^BI;7 M;J+9ZCD'M],2VUV3VW-/A]$&KJ+Q=*L-&R-U J2 M^SPQT*FO/S\&+JH=\\S'*JH=4ZRK=[.,":G_!&*?+/57CG>*:3U=;8WZZ>I> M\7GGTJ^_<-EI0G2TULA,=ZB<1G3.?<0XV17%1\LH_+OTO4??6L3.'+<3QR\] M@I+7B+^W7A?(#8./GO\MWN:OTP1\1I8,ZE@&946>9-AJ6X8/6%X;#8[45K^; M_+ER_$Q8%]TXTK'DD$3TOUU^X/CA@%^Q5!P-.U,&YQ^1()2VW<3?AKB\4X(;S M\B5P;EQG_O=6Z /$TJ$N>+)=:RD9X@>FAYN&/D,+I\DN/, MKK]T;[?\=!$FO:G3SE"SFF"%#@E=.I-4SR.9C=+"1#NJF53#K1F5 ./?/Y6@ MH'MP;O.>*RG(T@\ >>5'ZS?J0.OG=5!;-:LL@>IU+H/:JH7\$GY0V_$5/H<$ M^303 @PR(:"?,9]-J@6I%J1:J-]ZUD\.$VB8K9%91?SQXH1?6K?'5B[I!WI; MBPP[,'JM4:\Z!/;+86-YALDS[+@SK(@4EQJP8/1;(Z.M53C+1(JW%&\IWOG$ M.R_N5GTF*@QU,*I#LI;"+X7_^[ =.]:7;R/(-JX71W@&;\C<6@;H)OKCUG:"Y=QZO7%<0EERT>WF \QE MBF7(\^C7[.6&P\[ U.']6&T">S![]0Y^];?ISW6MH^IFYE?=CIKY^9Y;&=J@ MJENI>G_OK5@5QA;'F*3T;L<)FRFU"&E]SGI84Q#1V[33 M:GQ\/_/Q6B\WI.H1=#VD6QJE^#O+Q^^!;_8/9,W#F;*']HP#:Z+]?_8]NEX: M_*Z=[*U/]](?'3"/H/K*4#YB*TI1N]>_%V;_3344&28Y7^:[L\ VP1?TK'SS M%I9[G)&AE#N,_U@%H3-]W7.L)_\+=P5;TAD;7=NVQKJ-!IIA(7TPU&Q]V.NK MNJZA_GCP[[[>BBZ:^6NJ/:+KL8^L']?6% O\C35_MEX#H%]RO7BQ20-GEVV2 MW]HK:JTT;IO@E^MTZ0L6,4XTH],;:)58%&:W,U2S+REZ*TWMJ-U'$X %O.>E5O6RHBP#'%LEV.5*?'^>""9+,(.6BG M<- J4]];*-X2@?BXCQ&CX>$6/9[%,?375UDC/J*^N/F*4CX&%'3@KJE@=FY[F5:QX MF9UK:ES-SMW*5('WO#M5)2363YGKS]TLN+,A DU#,Z&G^-C#\9/:Z"6&![1$!..N%P M6D-9+H49TT95-:^<@,&)H*@_+9:6X].C&_3TU:/EN&_>PE&M8$Z G(07X$=Y M4\4* A0&9!!?*0W..QQ0#1I\AT7_*Z8QV/-?W0DW\B '78XN6IJ]'8DF7JXS+E7N\F-G'I['TL:2/U8B/E9\M M!ZV1(XH71;:-FTB 4F)^]/SWWFH< M3E?SN\D$TRC,-'^'6"C3UJ\@9X5TW,0Z*PHR9Z^+#9ET.I%+U^R<[';L+;N/ M2''<9!J,>-8D*C=WK+$S)RDQ$G^#4)!Z(0K M_\CJK'--IE(MH'4TGMGBDSL!^"C"&*%OV3!5=X*<)R@-OZ33NE!=Q8'C.J+I M>T3_]Y/[;4W3+)6H@A&==NXD;#]79V:5$XL*LXC6&@TYJL*IY,0423H6#[X+,S5KU:N1]WU.R%I8,$]!@C0Q 2!E!DM9P#1&DZCFX M!];!, //6/PP$^\*GDP= ]7NK]!&6(D$C=:Q)R=$BR-*O7BWADYA3Q/2?XTH M_,Y:.J$U_X(*X__U^F :=?4*X,"E<2VN<5T9.PT(._4X8*>REG:1SG(1D@%? M\K;''&.2YR8:5Y)6N[V.:0\-[_>,\K^\_BM -I:VB/IW,?$+"QJ .K?[&7I; M+,.]L+35:-67APXX6PFIW1\H(B$I(>AW6Z.>ENX'YY 594?K172TY@,]@01# M()M3A8"QV5GR-D'(9ON9+(^(*RJ(S865B'U!/F^U=7"$PA\Q@=^OZ?MU^LLJ MP,\-@NP306V-TIE304PBZ4>+9;OD8M&D63]U7I!]_1?RO2S6U8!A!IJJW[P,FD17NB!^XZ-XO"5Q%;1GRMG"8UQ%Y1'JS*@>F^]DB[E[]X= MU#KZZ)Y1]WYNN>&=:W^(")PEJ5"0T#VF'$%FK02+F!['+U!^8)JGYY=+L\K7 M: ,5*D_>S9Y&+7-HV_XZ+20,)E:>TD*7%GK3%GH)5NUEL2J7MKCPIN[]RI_, M+.PQ@;:F\;']$Q!$ME?JLV\GUNPF(J4WM9XL9PY%-=@)#0!@ TU6/HDVXF/0 M@Y1O@M)9 M#/$@!IYG*E+JLP(#H?,X7IOE!FR'Y$2(G_AN 24 MY9*LX9H"%O\ FGZ*\N][JTL&*K9^)2:BM+T;#U7L9M+ND#H7!E>S&. MKM'B/KR0LK:X@&S8X R6X]B09!./01"IG0UW%+N:A8I=>2UME*61Q8I=IW2N M<743_D0K7^:^3HK[!0KOYG]#]HH>']Y4F7ONXS5X]8HWQLNZ.,^^RCJN;VC) M*G.^3G_#=/V.R?H>C;.RN0,3SLW3IR6D1]U4T581YNAAYC@&'D;0G)7M/$7W MWIP-#X/JV2=@(-(^I5-XRZ'U M5;B2AI< B5'K^43'[E3WYA*D<$QL1^=L+9 MS)L#'6A. :A-B#W9#P\^Z,N,E\QX-9#QJHI?!UFM0ERFN:2!7C=KOG<@$N/: M9$P99IP%_A_"2=(P/Z[!XNLT)NT[0M:'T)O\R!+'86ND\5 D+^WSIILJ3#]5-2Z$*T* "%KYK\?H0][ME>;TX4?/QVXI(^_7Z0%^5UNC MOIG&MY#07&>O$_?Q23&DH*$&2$$:#VPD(;EV5 %DY4@D'%?SA0 ?HWTH#\PU MU D"7A7X_1(;BVMV/7W!0!7L2J#13:T"QTOB9W&:@!8^.O.!#*)G2V ME6^%2*%_TY@-'*=1<_<39O++ZAVLT%.AQ/XZ_;^A M(/2=28AL^.+.M3<_2/PR2^^8 F<+9*1)U(.T(>;N93$W;U$J;K(*\E"_Q$/] M"VEVH@#D;Z]L!D7^!MQA>9A7=9@?I=GN\>H].PT6/YFO@)Q)'4KU:I8JA%GV M&5/#Y4DO3_I:3_JF.;^@V\WF)%Q@R5G3W/4NXS!1K% 9HT?'=2'F"OA@9,,O M*+=51.3Z-9XQA04'YMVWN^*.O)<9.=XJS0YDY)ID;_PVP-Y]-=W>Q65AVJ%8 M\+J8>"L<+&Y&;T_34\8A@V .VJ[CI3$B9DHL5_3[Z72TX4&+'7]&]WA28C#C MOFT.18_O5J[$ZL_/'K?6I'5PDU>90-C3ZHE MB'WV-@2TKZCQ*='2E;C/!),*^8Q/1C^/_;>CS7ZIG9U@^J9D;MRH&H93NXT!(<;T0D6D(F,%LY-(6,)?0U,*L$152X2<&(?Z E-)U=KXHNWT?FMV6 M7D!F+=SX:&Z%SA.Z?7;L^(J1I?N^A)KC%>P"G=?4NM&D-U?+XYP&]Z0 MN;4,T$WTQVV4>W%<0EERT>WF \# WN(T\CSZ-7NYX; S,'5X/^86L >S5^_@ M5W^;_ES7.JIN9G[5[:B9G^^YE:$-JKJ5JO?WWBH[1;47R2)3WA'2^IJ1.TO4 M^#T..'I'])T?781_^?O7=M4AO)%D7_ MBH(S<\:.H&@0;_>^%5$NVSV>T^WRN*JG8W_:(5 ":@N)T:.JF-@__JZU,E-* M(0DD$!24=>+LGC*@5.;*]7X:WZ^,&1#\.\-^,M8^PD_=+VQ657#R=)/4N?;4 M34ZNB#;R+JZ5:VKK7#?8GSNYHXE..(XXHC3-+'\-[P M+1_GOS ?MDU- 6X<\QZV9\T NYW@9CH%XL'V>U_AP%.+^0^PW'N;2JZD[P"P M@(' 6^'YO) E.6F*+2G?;3"]"2Z;8G'N2K"VWJBE=WI;&?5@FP"J2/GH%L*: M3DLCX&*@0P4OQ4/NPR7L>XW?*;#68F!K$MH;DG>?R]VXPC7_;\8U]K*NL5+M M22\$NDRX5:&!G-0Q'(M[]WS^ZR5_V\)X M9-J$,4=CMD7MU9G9TAY@0W 1HH?;8C/E6,4V#,\)H]#A7QX MI#*@H(9&^!#^AJJM"2;P,NY:PO>%*V3)ZH_D9+LF[G;%L/B'V>M\/]>Y(@Z0 M,_.8,^5"I_'$F@VMX88>_ ]>E@\W8QL>MG]RX-I\#F @F'^&A@>W;*^U;VSE M>@$6@$3&![J#"5K_YK_"&"R _P.;LN6$>=PWT.TTT6;I:F]HP4;T=.,MW2G* MP*1)V]0^.],6[7='I+]C)M_ M:V80G*D4YQ^AP[1NNZ4EKW>F6(H(10(_)QF_'-&("T)X*N_W<0.4SB6O'#@-%- M;=I%D\N,=1^*S58F7Y*0D\ADN#ZC$75D. +A):H-A MXH8X@!P0#[Z/FBHBA:'-# L%CZ+-"N&\'YU)':&%U .H"99K;/GD . ML$C"123"=^J'TT5BN\@"4?V >P1ZL>E^/213CR[7P#GT+<[DX.2&F"/>3& Y MUW/$&?$()#?AY2JGEN3!,YCHO8 Z$;C@EN G)JA>R#LEC.3:A,6(4Q- HF=D ML-%K@'6'<+ -^8&;3W-MHL,]9$3H&*%)A _@:0K^!J^PUTW-7[BA;>+&/&:8 M@H#_#!T>S([XGUR@&(51Z!!^P*.4*.L-R^$$B\AWXSA(;&F=Y?_%0$G"0P@Q M30HJ[0VNTZ _HX<;;SP\3N__7%S/]OC&,U@#Y? :VG_"M*+8Q M""S'!#TT[65Y@1U_ ;K_;P:VN^FB;+TX$? '0Q$K-7$#3X&T;H%,G'*#SY-W M8O$[4=0,7]X$JA_X_/;[TMZ[\#^@:7RZN7\/FH;+.4 I#N9K3PRE%(IE9,+P M=;@R#>&B [[]:+FA+\Y$SS0U"V2" ^R-I+<;*^A)CG&>\IN6>V<%\*YIH700 MTIT$.P7HG^.9=NDD7]Q'LDJ%&4*(!1@C$3 3M7XG) #:R>2TU7H"$HY4NN' 0+SPWGBX0F#Y2F>FSD:J@A &WX*.Y!"YF' MEC1&@ I0@R!U&-4,E):A+\5JC.)]1:*B/$9P1LLLX:)Q&6.ULBV&PCKPW-CJ M0XB@J@5;A]6YNJ-H1RT-V0<<%'4LSB38HV&'!L&9;!?B(Z252=9"ZI!Z%,$& M%&"%80Z!S/M8L:I8\HCQKO?Q?4-M;B,Z-!R$E"W^K:[@$9]Z=]I%ID6U^6F>FUIFI=69J MG9EZQ,S449V96F>FUIFI=6;JP9FI.&"ZSDS-U42&;;U.3*T34R\_,?4828VE MHD4?1++3+X!"*S_JP82^%!XS(2-1\ M!IXU 7.6[/B[,$"WDU^]AC%H]0N<(L,P1Y/FJMO*$!(XD0P7:%P__/82*A%7 M(61&(T+S(\_#AOO&VB1XVUPMFP$-<3694NC/MO0T, M_1M0EH9#-36&BMT&Y/7[I>'VV]-=+I$39MY:D5NY;@3HA)03W5T_7=H!>O?6+# AFU($H@N=T\.\_R%M?K*/+0]0"\I5B=^I-1S!#3SI="[KFI//\R? 3V;<)B@(BF5Y9SU<+ MRS29\PXW,FY M#H@4 U "7B8AP60X")PND9*E*,L[%NPRH>IB1=V+F/\$W$C4F2X0&N:L+1GC M )YZ%H4+4 I.X)\V4+HUP["2R,J33%!S(\62L_'Z'O:_!PY+ "K&Z 0C_;HP M@&M,64C[EID ,=UO$.S% /QHOIJJO3[GDQ1(_7W":4#* /7[H7!W/-EFFVG7 MV6K$'9 86-09-FKLO*'S,1Z[6)JA0)MG]2]7MKMFF L$H,'P]A%8QJ#0_@ZI M!+R?+I@9VNQNEH-0MZX?9%1V=O3B;H#S,:-1)H%]9KM/I$&C(\?7?"JYA%4P M#WOCEIF\95_>,@ 4 /)N%YM!KK?1@/.%PKQ[EOWWAJWQL%>-2Q1XX0Z7:/%7 M='O=ZC:E'^*GW>IE'!<)#'*,.)O^F0\+#S#]-VY/?DS8DQJ8D@G'[)&BS,<[ M0:ODF /[4A\D01[>,?AWL$$BW-QTR/3SY!R M7ON(10)_[/0OX\: MX:4*K'IJVV6PX])8.6A<'SP9YX7'IFUK%__JQN(\N %O-;'3#;FG2#T0C.>D MZ55KFAT*F'/@.T>WVQ(A@MN%XR\^[&^T3I0>!GLN#16ZE5XVNI( M81TI/$=5KXX4GMQR*^CAU[N9I>X7(@U?/+)01PK/0%S_R'SDZ/9D43[2:USW MTJU'+HV>L_I+'=S$H=K2Z).6:VZZDGGMI=+C&]N)6#YUG>9](7B?B@ESV,RB M7[J/ELF;@$O-R->>%FYBU-"C:X=.(/KOBV68V=3,D'?"9MK*6'NN;8OW\]$U M 781P9>Y3NCSAN38&]N,^K-@"QM+MM'&[O@M+8MGV@(HJ^7C&0LUZ>*/NS#[V$K3B2GTQ.(IP @>8X(@3]H18@\TB8+?P MX'P==Z6"F^3]I@"8MBMZO,\\X+A/KO>=HX7LX!$-A+#@D(0VT5@ON0T*M,%& M?88M#OC9KWSC$;OX:$MFB*[V'TH!0Q-PT)LERK&WP&RO[2N[K[ZV'OX!5,?> MKQ_6*_@.;?)T?;V^=733N9)(1GU]7%Z/4V&I.47B?FS+F C^D>(P11!@9R6^ MTDXBOS8_AMG).Y\.,/.E9.I-MS4LF2^3MU1GT-)W-$XODWI3;J6+VU3OH,:N MEQ$8J#+KY7+2-")5DS1ET?M$(W]IB7/N2&FY''!$BBIZCPDDR'W)A_PC &6+ MS_6'RN5Y;]A\[E&0G*M969SV!_'U[#KXZ_#E#,JD?0LM.,N9,VA<]WK'SA"X MZ,2:FFQ>$]F4\8%N(1NLNJJIYA*IYMC9H^='-8<'((?5$,TH,W!PD0'((U#K M:T^!NX%M4KOB5YGT5H%H&I0)S^4E%XVS>CG5F6<7CAIE&' >:G3;P'YKU#@K MU#AQ;E >9G0:UYVT.GLA@OF%,R$O1?Q^-=;Q9!$Q1=O$4,SV06#;J"L# F=% M7=F >%.E4)90_>1Z"5++HC+,^TW+YI1KOR3"O8156&-',;E8+N,Z.7+L:Z'^4,4"2AAG,\VF>"BG4L"])N];M8 Y M7TY32@J-*G'/=?N-ZV[:0+PL*^#\ZP,JVV@A-WW-2&I&4IR1C*MA)(/&]<6V MB:CY2,U':CYR(!^IAHT,01])6STU'ZFLOFG;ITINMP##$':?,7(RZFLHIQ)& MZ=QTY';\B#&!$X9!_B-9[1D/K:AZH3Z/XW%KU.^6S37OZJU.MU])!C4LU=-' M52W5V9$A+CP#&Q@#D&J4ZS@G9DL>U+7NF&L<*>F<,/J4!209'.V(K\]I;SC> M&/JZ5VK[+KCNXBTGA?BMX<$Y8+&_,\,.%ML&'^\[9;48[/_W168NTZO_J;_8 MJ5_NT)\L5&_0!]C3/KG>4NNTK_Y9&OV3;$C*]H*'>;"6S->^L"?MF[LTG,-J MSXXV0WIS_G.Q$.'%4)NSJXG'C.]7Q@P(_IUA/QEK'^&G[A;I)ZEQ[ZB:7TG%:[[6&>O979?6'?KLU'HVKZ1,-2^THQBL=I&"]SJS;W]#4 M55V ?U]AG%_8!D?B7?P)1XTQQV?O "-CV.']*(]H)B&**5?%EMK=N MKX2OE*HH_L5US2?+MF\<\[,3&,[<@IW=^#X+MHY[[XZV%1.G:/*P4?"]K5SJ M?*:Z]UJ:!*<6%[?%8-4X7,]EJGO5^KA>:!,20I54P:S>=2? Y_ >L,?LKY=;_7[E4UQ& S. MKI2\UQJ4U#Y.L*E.JS\NY%*IZ]L+G/C,"KJ_+@QO:4Q92+MYW=7;V1#XC9FX M#>U-I\S-7N#Q7[!X78B9L[GSH]>OGW,8L>YPOU]A87M[J%!JL0W0_8"E!O]? MPWH.WCGA\LIT2:[@DQFQPQXVOF\.>A?1^_XERW1KFGI]-+4C\7AOFL(JH>9X M:@?;%9+J<@Y==>%Q\[1J?_#BT/F^$ZC+>C M#;WIPO"IV28JU@>6ZYU[,6P%HD\O1J=?!6!OIE-T#0(T;F+8)HEX9CTS\^H_ MS'.SZ+>+%#/2._K/=6'U!>!2J?JM86I NP^;A[_VQ*HT]O0:U^EY#,6KNFJ4 M.?N2OZHQIG\6&//:2^4_N1[\T]&HQ[PS7?/V\K9HU1W?T(%SW,Z]!O9T\E@ M_%; ^R$&]R^&Y?SJ^J6$\J RH5P755^\4"Z"6FD4&M;%^&>$-R\@F?=#F]%9 MH$U%!C/'@',IMM]A.UO+E6%Y*)5KT_@@4?PY F19L3NN;>%+0IX#Q6XQ[$EA M2;_=N.Z/#F&2-7*P;?.OK>3DB%QE\JX+KG-T\W!,.PZT9R@_#4';,@-B;H6 +QV9W>+&];VJ& M4C.4FJ%4WN]F;WZ"@[:;;?UB>_*]+#\I4T]:M*#KA "GJK:=I-A9%'H M,9%FWZ2B-UEX$56W3:?A,N0#%N=I9ZEF@RFN/1F^]I=C2%!N\C/S)M[%-O]B M'DF,8Y+H-Z[[K70(7)OP0B("2[FCE/)>5'D4G+S6&N;X2L5Y:"[SBN$H7V:O M-\9X%QY7?WKL+EC4^0?CL^$=-P"PX(SWF06(:CAKS7(0D0/7\S$33L'8U+CO MK9.MNS3<&">DAQ[ $J=SX].($7X3Q\C;H2F7D[3S.WQY>1/34Y._$W"Y9ZM M ";B%T],8S;@%I\-/5FO#)\7TOX[A-,$U-X+QT0SWX\J95?,0S3'G\!MB=]D M,98 )]'CK'372P$7[I#A*P%"< ,>PQ1'4;3K6?[WJQENW\**+EA$P\'J6N@S M4_[&M'Q*EZ%O6MH=W*S)X,=+RXGFCN/O< =+XGPSV)7V:-CP6O%=8CN6KTT, M? $R$. /R\G&2K!+=\FN^(^,UE">Q/Z5%Z4:FH"BK8$@ M?\*AX+L.!&\&I$H=:9A[I ?QAE_H!54<;+1%6=6AK;RL*#_ M6>6,TP5($**JMXE MIZD/@R]$,@=?##2>:O=F;EC.VY](9X6M8-\$UX<] "@-ZA_",^>%M ?P@4J! M" E_D5U!LL"/>N'@<\SP'-BD_],;7/4MWCAN(G5;>#33 V'G8.\(57"59?>C M=BYOO*4&%I^="MG^0,]*28F(($NB8K4!MM6PU^7E-*>8Y'(DNB7:T*^MY5:5 M8;. F(!?#L:=4XC4 ?K[TM5P$KBM2IJDG9$.N4FS.A%E2K/4B<\+11$>.TA5 M% 296$/^7N6T.0U?4JH>9][RD"KWYJOA-["<9-M9V^431:00/6/:=?MK5%>T;!8MG)L7*04BZQ;*NNN_8KB9?2^/Y M2O3:;?6'G;_^C%T)14\=_D&Z#5BCZ.+;.XCU_WJ$_K/%^EWM: )V4/NK3Q9@ M-/L5+C?5O.T!/8+IME@XZ>U5M,7RX[Y88LZ?%8.8ZTFHPTQM-/>-(.IY=0G- MJO1>JS\>5-47JCTLU^#R!'VA1JTA-O4[KTV=*:1Z[>UMO0IVT,I.Z>M<8-NA M[:E8=4.QS=!RB:KUL[CUG!QX#]0M4CUB25?5Z?=JGG]Q$%1B.@3'FR6&"?Y# M"%9#L@PDO["@QL0#X/<'_8.95]H-;,F8,^T;6QH6NJ@T%2NUK["\:VIO_IL9 MW@:S>SW5N=E2[C-P_!FI]U>V-6.*=NN_*X)MI9N8%,;!O0KSZIV]],Y>>X.9 M!\\P&49HN!=]!7(NHX7,P14L9\4D2@]P>X5I::,=B?,Q(\WTDWQ\%LD16L^.%%Y*>=3RE937R70'Q1>6N-W35VOSKL/C?1,JI%2Z55RH=IM.>% MJU]^NJG$YKW0HMP7=/_V%M7J=TQ^PDV"KL M=/K.#+TU,[P82WN-ZW&J1 MWCDG!#U,_SE+U,Q11H65?8_#1E=11NW$]J/VE-=*^/-)F*ZDC M#%,-ZB!5[2\MKZ0.3Z:DCO3&]>@H_M)7F&-?9]B?* .T:AUWU,61"L->NH/\ MA7#C5Y(16I-#U>104?[!J(C2HW! 0-MF/,QZ76PDYS5?+6M[U]+EC0>7L>4$U1709=E-& MZ5Q)T3@D0ZI_L:*Q>IYT1&_8*69=UMRFYC878:&.+MQ"K3E/S7EJSG-T/0?L M_<.U'$J)Z/8N/;K\P_&:TYNEYTMCF7T)ZUZ M[=&Y#;P J)0\WPDV!9#JZ$>;PM'IG_44CFP6G9A=5T_@J"=P''3Z'V/N03V! MXT03.%Y/T6,]'.(5[>RU%T"\[A$,V6>^_#[9V>+[8 M+-^:""Z!"$0;V1K+SN(V7BN6G1NK[9P1JZW3\>N6]T<@HQW53U50D5X%%;V2 MU,8?"0WWTQGJB[ZXBSXS?M.]"'Y3MPL_X^=?N]NT;M==M\NNVV6?V& =G[;V M==SC[;+3_=PNUHM38]*AF%114NZXCVVK]1JW:MS:U0YE/&A?U($^.@,6BA<&Y M<)G7;O+^@*U-*\#YSDE-WWZ[S5N;GDOLMC9/S@"3"HO>?KO3N![H!W/4&GE> M#_)DBMY^6\>!">F>")=EV[["#)$Z/^1$\=K*);=HV'C^\=LZC> RT;(:#WB_ M3=$5O3(#O4;4&E$/;6#8;U,#P][@_+EGW5-N5XI&W5/NZ%GQKZ77R@FR\H[0 M4Z[?'O">N-3/Z*JUV4-;Z;*5[(K531)3W'>K.E3IM'?ABAX;&8;"PC5WEC8WM"?# MU_Y2!K&ZVQ%+%1IWLTTT*XU2X\;U(#WB1;8FHO!LJ=WW3KG[3KMQ/4Q;[-'N M834-K$#X/X\Q;0D;7?@:S?[1)O];YI94/)>NMO1JOF"!_P"ZSX\,?N1_48( M4?ILO<:UGA&C/H>SX5T]/+FECX1)Y>TS/A(RX-*'&@ .9N3)[\_:*C_7)S3A&XR!"WNYY7K6]1OD-<6/3+1+50HN3>BZIQT4(G[YXZZG?+=D_MZJU.MU]) M3U!8JJ>7ZYZZ=5?;.Y5FE\WVMU7-9MH C.E#O7=8L\!CKG&DWJ&$T: -==O.6D$+\U/#@'+/9W9MC!0ML">X&!1X+]_VY[ M]7%A\$_]Q4[]P;JCL6YVQX-AI]O5V7 R M^A\LZ1$/+;P8:G-V-?&8\?W*F '!OS/L)V/M(_S4_<)F504G3S=)G6M/W>3D MF@@'N;]=(Y#*S7F77[&QY+ M51?@WU=8"B%\I$?B!T; EEO+#%,:T4Y %%.LBB^S M?2)")7Q%62]%',IW&Z0WL=WI]Q2AN2M!8+U12^_T=HV.[&Q:A!_8)/@ 8L%V M_=!C#_#+]_B>V)8;<1/3AYP&KT%;H MEA"N$)[PY-,=T?.3Z(Z:Z+JLTE6"8$:@XWMN'),0 _^^=9<3.!Z&MD.G8!+> M.":G<:4QN.-L4F\WKD'N9LPYVG3H3*2?*H"K $MBB\L:)V&(C\4XC)9V8]MT MUP[)"H^M/.;CG8>.S^#^F:DB"%[PAN72U#X[TQ8M[QG.=XW].S1L>PV8I%&$ M#A]9&6L4.=J3!?N#;_$S-_0T]FP!-0"RX=.S,(#7*>_%#^%?(8H/>"%ZU='C M/($_'.;[+7@QP)GY 7K%5P8(E%7H^:$!+P*11Q$9N ;:,_Y#.49+>UC *<69 M#7@KF\VD%U]+O%&L9%L&P-D*+.;+S2Q"@5 M&)E.$9W\KWS]6TZA@'=?7$>0:VE4ZX %WFMEQ.M#(>G M0A^E2&,CMG,. HC+1Z', :K=>$!R\PUU[E+$T6>X$M#[")> RJ:&OZ"; 9B M/<+MPIFXP%DQ'&P#QZ6?S&SWJ2FE$-#AE-.8;<%CL-I:4"+3#'Z=I?!VK&_G M];_"*>YFM\"=K."3,46.L/[->+:6X3)256Z-%7P3K$MC@4Y(JOP+5S]-6GCOW#!##8,T OYJL-:,-[T@E..KIL1J@T(U; M]I:"R(SQ/C(@T'52'8RT]"8&9]\K@X"-T\]$=FG8,DFAL_NAN.E\A&/[&)%QK>.KYOV!G/ M7\"#7PXW&&[G!EON6"9)Q*#H$_J/4$O4[MDJX'DX/&GC"=,M'/8D %0$,R(^ M*]^TZ<#_%!*N-K5??[W5WF!K9;W]\^W?/]%?G9_?1@_&FQ&:1C^]1[C%S?5! M3TF^HG'[]ZOXP\9;R@$#B8J:,_RA^PF@(_&=$%J_M\_D?A-O(7> MX7ISPP$,-?%Z2_K1C^-Z/CG14:Z0:S.T.%8N6!( L$FX1@BIL$7XX34('F8] M6B89,=QL\=%&"A;XN/H061R69UZM# _Q#E2EK1+98=XX-)213T,(1(O[FD7$CP*@3^V@2(J]6MC7%W^W"3=BUR7Q@Q]QL MFS \!&R"A 6_IR:H2;AKL M0EC3!T74GZVY<\0V+&Y=6H&OGI?S)A'GYIR@ZA.N1Y[!%+LDKL!KO MZ*(W>#)>3 %68Y&W 91VM/D)!3"A+# 099/X[; @)B \) _8(F!43!A =;"YRE$_=1P9_!RVZ M-A4&FR&OE*J0Z31>&L]7(HFBU1]V_OHSAIM$*(-_D'8K1Z&L4N[D6P(^&85@ M4M_2SN<,3L7\;5YF/%X'6P7MTL;.Q[T]:&D*^$&* M2^@'VJ^*"PEIY%?XN)J"OF-I<@&NU,, *F+*0N )WVB#T'K.A!S0#LIK/ M,D8M-_H"5%Q,E@;88 8EGIW'+V;:5OXX3MLPPEO_5:A6,09^A>==,V&W $RG M[\S06U-^L^25V-*OO2G0-?P-2/U-R( $F[NP870VYP$E!#5G33M'JP=DF ,* MS,*P9U+!0&W0FEJ &@&YOK6;< X8@W*M0W<&1XQ,/F/N,7(+HESEQF#D$(\, M$9J+#8^/N1O%8U(>FUP:?V?:O\&6@F=@9\*%SW6U^*ZBV@=Q$_BW$7LES\)K MFI" 9\YBT#+Z;]?[KMVM+-T\("/5_X<3GB9H-#>X/?->[N;QIO*::CP9^H MAXH2#* #((0YOJ^<$R0GY#2@'E-$RFAPH7$5_0# M3_ D"U1>0TO[G5P% 0>CL!&C==3W;;Y.>W)#VT2+2^4@P#+@3F7L6#*'^"!< M2J!- 6S%7R #$C_B(6I0[U<+P"B>LD[.%S4V :"F3R5J1Y' YXMX]BQ#:GA M+3BFX1&O!G.0 =DX9#TZB*/#EG8/YBJ\!]Z!=5EI)'7@$Q"/ 8*1[-FE:UHS M2R"J$^45"BPL(+KUK:A_C>11D5PC>V_\ BQ7RDDA'-<7*:)28W ;CAK[1RX?NQ MQ%G?X,$-^Q; B.ZA?QEVR+B6\=E!1N4S,%7I?TOS#VR"N8-[4,49&+I(4G!P M,YPR LP*K';+#7T0["PN6>-;E2%ORWET@?A-"6DIZA,41+BJ(#T%(DBQB,.H M(OX %Z7Z].,[+ALA'^^8@)!] S=!X@Y*0QL[26Z'=E,(+O214CH"L)19"*Q7 M<**9Y8&^)E0JI/N1 M"2-7RKI/ H1/FRES:!' M=@;26&2<*> 3RH-PG< 2JU :H<0V4/,#6V4!XN")7F&H3QM$[4"OZ-"=<=4# MYVD@C# G280"E2'JD0^2ID@"!HT?T!H\%Y17_!!$AB?A=G6W;X6NA+'-YX,\E]S:QQNW7;7C.>2P;UC>,4(3;PD#&!3 MO@OY 'B^RPJ$')61*VYLP7Z (@DU??X=>M5I#9"B4UC7%\/@4$=R*3P4DJQ4 MWQM]R#T2+F)Q[!H'Y$6EG@(TN$/Z*]HD"Q;DTA"[P2\R"SLV@B&I.ZUK3>M: MT[K6M*XUK;K6M%/7FM:UIG6M:5UKFE-K6I>-5E8V.ACIE96-=K;7>A;>5:?5 M:1?2*NJRT5=0-AJESV0E,?'LEHR<%SU)N<3I= DC\S,!:D5 M4[1F9QY8A&2T&Y,0\^T, .X5>D^X&X.\-OC1Q+,FS%O30K%/)V$9@Y5+;]AJ MZFXX;Z0):Z\+^W&4.I1FVO4G0P9,9#*N7.90#BQYJRB+$QWCEL/=R=1,#M=X M-#QTL&LS!CAL4/C-I\"G(:,?*GC1,0;PLK"N#7\J7/#Q1S-,BA/#W)L\6\!B M7FQT6XX)WWKK5)J L.AC&'&O6[&33"FL9UH(,IL\// >^2_I,I)1KRC,)Q,C M1;@ ,_;ARGCLQQQ@@8EB.'V 6(&W&#^T O5V N]RW=7E^'RJU?60\ M=(71B1RG\K]#"W!T&;D1>6)+P.MX &4?#0HR6IXI?3^$K[[B>FR*@ [_K?00 M4;ZK%PB77C*;)(62#26$?D@P%YBH5:%.:UO,C)YR%M3:> ZK/0;FDWJ&VA UND'(8 /E6F)D]Y58#KZJ>&8^N1_\V^;Q4GMS%^2^Z2PF#\=WN M%/;8%"%>Z1%68OC & "@O&SZ3RE:"304S/&U/T-SSE M<2ABEAF&I<%43+X"+R!%H)3EQB.[OG@?ORXS2G$6:?PF5J0'C.<'Q0 &(4-0 MY%!&6C&MV0Q6YHR: "HA?9D2"!,=YEBH(W, Y,FT^/;A0N@KJJ"-4/M)J&.2 M<0L1[TZY;*(Z7%3DJ%CBPF$3YS]P0[6/UB.*.$"04+I6(D*"3^RSG!Y9GB8T>3_] 9/ M]/9G;>$^8?E$DT[()+G(-]&.7)_BNS,,-]'>)>A,]S%8% M*2)JGX2BREF/2-Q#2P'U.$;T+]:_P"0'D7SXJQHT_9Q0J,_X2-DDD*K@XF;$ MUV16\M/"!.L:D4HGZ@"8U%=0*8P MGIJK?]^P!4# X(H^.S,[Q!=RU>*6V]_:':_HX9F<9S#T^(U*AX2BBKQ>2E@X[#>*8,><.2WA7@=4)/QI06;LLC M>6)IC'8#%9/(D5>&@B?R+]V+UXN[ 1: M^ .6ZP;2R_(/A"PL_J;QX>X?F!R??=XIW* M_3^;[A_52Q3C1O1CJO2EC^ 5 M\$X\3,2*-R B4D]D+Q?!S4/A"P1T 03#3Z-N#EG?@;HSE<5SY#\RN9*OYJ)+ M%Y30V;(8IA^5NTS=N+>,* %-[SWZ=>AP:PZ3E1QY+%%5C1J>;O#M,M)B38O@$@O<>"N;IQ'XEN%_L, M]M+-TWCJ0=00BBQ_4Q*@KWB5X;@\E_>@DV4TS]@XV6V99E=*,G*O<=W3=Y6. M6'ZLBJ/]0+0J#VUO5*/&XT&8J/U 7VFZE3 R;%!9_P=!L MO#R*D-Z6#$/Q&"Z7C7*28IX65M+5PA%?*-:**2IMVEW.%^H54=;%@A_BK=AK MZ9/ 5?B"S>@M9">(< #&@E@0V#R,@#Z>T/>Y^]O \=?-:XIBNUK_]=8KG[6OKJ([FBMWH<35&7]B[3D-_H_\>Y&!K9W%3K-DRLX M-0\IX'VKA8)O,%\DGD-&!94?E!\TWE+7S146%Q-OHW#J(T5A%)*,*XYY3>87 M^3)9N1G_]$;^%):FZD3\AE[\""HP(-Z?8'5S.USRI42Z.H\932AMFL)./K]6 MT@NC2_652T7&!!139$\8@@:9'3<$1=^ *&$EM4=/1(REIT*%6#.*PHDO"[U7 M6M2Y"@<_95KG2 R":ZNEJO0>X #WXDFA1[1C/:(/>D1&RTS^JJ9R,FZ.W(*8 M6DXL@T"=NU'07T!-=&=L*Q]MOW[_,Q>EJFPD#*1A0*.XNW2[1Z@Z%8=Q7:PO>+,MJ>\MFZ(K!7])+?F_:+ZA#X*GU"CVH+64['6+W 6I2D; MQ42,Z4)6E\?$BXXN4 57=M1-B&DWMC$QED9D\VO40 15'(XVHER0B?)IJI=& MYOI,N@BPVI+6QZ[FI]7Y MJZP5>\%YG%XM.^:#0*GY6]X\R:01'46C4*AN'\R6:$15E\O4Y3)UN4Q=+G/, MIRV7JIRF1^[7$;/+)?IUN4RL,>2QOK./OLR%!-[ M=L1(\-(F^@@GT>^PT'FVX>Y\Q"@=D==VE$]'3.9XJ=;XY3F('F0G3<.1_O=> M'!6G'E#DFMCJ&3O,Y[-C?,E7T;83U!EJU10C4T%/CQ)5QYZGK;2_-1%4;R:; M-_IT?A4\F#PA*T:41 T1J93?R"$@/#(U03\E!JXHML:>5[)IC+'>"=LXRB77 M#%?X;$DP[YB'4B&8>S3X;;PC=T%VC=';W1$/NQ9R"%/V3W0WF&_H\""'2)'D M ],4"E7C&G_+SC_,3N'!:07H^D(?,;K9\'9\)A*C-ANO8[R1$LVX$QY;SY : M/MRHSMN,M/#1;<["WRU M==@5J;X:)8O;CPR36N>NQ[L/RH-A1U.>@D*] 2^TX=.VV+.8;1HSA@L[&Z9, MPD7]R\+-64;ZPK^0IUF[H7Y.L#4D&N;S<0N4:T$N\W+4P9.!*7X5C2-1@LZR MKW:,J9R7H+VQXJ62HJ\YQL6-J!2).C-B.H[<39+&#?36XXP62H":, >X0$!@ MG+ 9SIPPHD112KG!7R6!PX=88-*%$J6X-2:8%'V+8HB7)]\*>O\[;[858"!! M2;OF"9NK%3.HLQRO#A09+B*B\@FH"ENF6]X4" ;7YB"^H:=2($B=-3.:E0S* M9T=?!.!4KH7_CFDX'UOB1L.J]L?S%O!?4?-@D$ES2KO9@GE

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end XML 85 cah-20231231_htm.xml IDEA: XBRL DOCUMENT 0000721371 2023-07-01 2023-12-31 0000721371 2024-01-26 0000721371 2023-10-01 2023-12-31 0000721371 2022-10-01 2022-12-31 0000721371 2022-07-01 2022-12-31 0000721371 2023-12-31 0000721371 2023-06-30 0000721371 us-gaap:CommonStockMember 2023-09-30 0000721371 us-gaap:RetainedEarningsMember 2023-09-30 0000721371 us-gaap:TreasuryStockCommonMember 2023-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-09-30 0000721371 2023-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0000721371 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-10-01 2023-12-31 0000721371 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000721371 us-gaap:CommonStockMember 2023-12-31 0000721371 us-gaap:RetainedEarningsMember 2023-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2023-12-31 0000721371 us-gaap:CommonStockMember 2022-09-30 0000721371 us-gaap:RetainedEarningsMember 2022-09-30 0000721371 us-gaap:TreasuryStockCommonMember 2022-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-09-30 0000721371 2022-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0000721371 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2022-10-01 2022-12-31 0000721371 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000721371 us-gaap:CommonStockMember 2022-12-31 0000721371 us-gaap:RetainedEarningsMember 2022-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2022-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2022-12-31 0000721371 2022-12-31 0000721371 us-gaap:CommonStockMember 2023-06-30 0000721371 us-gaap:RetainedEarningsMember 2023-06-30 0000721371 us-gaap:TreasuryStockCommonMember 2023-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-12-31 0000721371 us-gaap:CommonStockMember 2023-07-01 2023-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-12-31 0000721371 us-gaap:RetainedEarningsMember 2023-07-01 2023-12-31 0000721371 us-gaap:CommonStockMember 2022-06-30 0000721371 us-gaap:RetainedEarningsMember 2022-06-30 0000721371 us-gaap:TreasuryStockCommonMember 2022-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-06-30 0000721371 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-12-31 0000721371 us-gaap:CommonStockMember 2022-07-01 2022-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-12-31 0000721371 us-gaap:RetainedEarningsMember 2022-07-01 2022-12-31 0000721371 cah:TransactionDataSystemInvestmentMember 2023-12-31 0000721371 cah:OutcomesDivestitureMember 2023-07-01 2023-12-31 0000721371 cah:TransactionDataSystemInvestmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-09-30 0000721371 us-gaap:EmployeeSeveranceMember 2023-06-30 0000721371 us-gaap:FacilityClosingMember 2023-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2023-07-01 2023-12-31 0000721371 us-gaap:FacilityClosingMember 2023-07-01 2023-12-31 0000721371 us-gaap:EmployeeSeveranceMember 2023-12-31 0000721371 us-gaap:FacilityClosingMember 2023-12-31 0000721371 cah:PharmaceuticalMember 2023-06-30 0000721371 cah:MedicalMember 2023-06-30 0000721371 cah:PharmaceuticalMember 2023-07-01 2023-12-31 0000721371 cah:MedicalMember 2023-07-01 2023-12-31 0000721371 cah:PharmaceuticalMember 2023-12-31 0000721371 cah:MedicalMember 2023-12-31 0000721371 cah:MedicalUnitMember 2023-07-01 2023-09-30 0000721371 cah:MedicalUnitMember 2023-06-30 0000721371 cah:MedicalUnitMember 2023-12-31 0000721371 cah:MedicalUnitMember 2023-09-30 0000721371 cah:MedicalUnitMember 2023-07-01 2023-12-31 0000721371 cah:MedicalUnitMember 2023-04-01 2023-06-30 0000721371 cah:MedicalMember 2022-10-01 2022-12-31 0000721371 cah:MedicalMember 2022-07-01 2022-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2023-12-31 0000721371 us-gaap:CustomerRelationshipsMember 2023-12-31 0000721371 cah:TrademarksAndPatentsMember 2023-12-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000721371 cah:IPRDTrademarksandOtherMember 2023-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2023-06-30 0000721371 cah:TrademarksAndPatentsMember 2023-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000721371 us-gaap:CommercialPaperMember 2023-12-31 0000721371 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2023-12-31 0000721371 cah:ShortTermCreditFacilitiesMember 2023-12-31 0000721371 cah:CVSHealthMember 2014-07-31 2014-07-31 0000721371 cah:NewYorkOpioidStewardshipActMember 2018-04-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2022-07-01 2023-06-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2023-06-30 0000721371 cah:TotalOpioidLitigationMember 2023-12-31 0000721371 cah:OpioidLawsuitsMember 2023-12-31 0000721371 cah:OpioidLawsuitsMember stpr:AL 2023-11-30 0000721371 cah:OpioidLawsuitsMember stpr:AL 2023-10-01 2023-12-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2021-07-01 2024-01-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2024-02-01 2028-06-30 0000721371 cah:OpioidLawsuitsMember stpr:WV 2022-07-31 0000721371 cah:OpioidLawsuitsMember cah:NativeAmericanTribesMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0000721371 us-gaap:SubsequentEventMember cah:TotalOpioidLitigationMember 2024-01-01 2024-03-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2024-01-26 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2024-01-26 0000721371 cah:OpioidLawsuitsMember stpr:GA cah:PrivatePartiesMember 2023-01-01 2023-03-31 0000721371 cah:OpioidLawsuitsMember stpr:AL us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2024-07-01 2024-07-01 0000721371 cah:OpioidLawsuitsMember 2022-07-01 2023-06-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2024-01-26 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2024-01-26 2024-01-26 0000721371 cah:IVCApril2023AgreementMember cah:ProductLiabilityLawsuitsMember 2023-04-30 2023-04-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:IVCApril2023AgreementMember 2023-04-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:IVCApril2023AgreementMember 2023-05-01 2023-09-30 0000721371 us-gaap:SubsequentEventMember cah:OtherAgreementsMember cah:ProductLiabilityLawsuitsMember 2021-07-01 2024-01-26 0000721371 cah:ProductLiabilityLawsuitsMember 2022-07-01 2023-06-30 0000721371 srt:MinimumMember cah:ProductLiabilityLawsuitsMember 2023-12-31 0000721371 srt:ScenarioForecastMember cah:MedicalUnitGoodwillImpairmentMember 2023-07-01 2024-06-30 0000721371 us-gaap:SubsequentEventMember cah:MedicalUnitGoodwillImpairmentMember 2024-01-01 2024-06-30 0000721371 srt:MinimumMember 2023-12-31 0000721371 srt:MaximumMember 2023-12-31 0000721371 cah:CareFusionMember 2023-12-31 0000721371 cah:CareFusionMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000721371 us-gaap:CashFlowHedgingMember 2022-10-01 2022-12-31 0000721371 us-gaap:CashFlowHedgingMember 2023-07-01 2023-12-31 0000721371 us-gaap:CashFlowHedgingMember 2022-07-01 2022-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-10-01 2023-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-12-31 0000721371 srt:ScenarioForecastMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:September2025Member 2023-12-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:June2027Member 2023-12-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:January2023Member 2023-12-31 0000721371 cah:January2023Member 2023-07-01 2023-12-31 0000721371 us-gaap:ForeignExchangeContractMember 2023-10-01 2023-12-31 0000721371 us-gaap:ForeignExchangeContractMember 2022-10-01 2022-12-31 0000721371 us-gaap:ForeignExchangeContractMember 2023-07-01 2023-12-31 0000721371 us-gaap:ForeignExchangeContractMember 2022-07-01 2022-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-10-01 2022-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-12-31 0000721371 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000721371 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000721371 cah:A250MillionShareRepurchaseProgramMember 2023-10-01 2023-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-11-02 2023-11-02 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-10-01 2023-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-12-13 2023-12-13 0000721371 cah:A500MillionShareRepurchaseProgramMember 2023-07-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-07-01 2023-12-31 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-10-31 2023-10-31 0000721371 cah:A500MillionShareRepurchaseProgramMember 2023-04-01 2023-06-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-04-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-08-16 2023-08-16 0000721371 cah:A250MillionShareRepurchaseProgramMember 2022-10-01 2022-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-10-01 2022-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-10-01 2023-03-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-01-13 2023-01-13 0000721371 cah:A1BillionShareRepurchaseProgramMember 2022-04-01 2022-06-30 0000721371 cah:A1BillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000721371 cah:A1BillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-07-01 2022-12-31 0000721371 cah:A1BillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-12-23 2022-12-23 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthSolutionsMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthSolutionsMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember 2023-10-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember 2022-10-01 2022-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-10-01 2023-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2022-10-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthSolutionsMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthSolutionsMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember 2023-07-01 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember 2022-07-01 2022-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-12-31 0000721371 country:US 2023-10-01 2023-12-31 0000721371 country:US 2022-10-01 2022-12-31 0000721371 us-gaap:NonUsMember 2023-10-01 2023-12-31 0000721371 us-gaap:NonUsMember 2022-10-01 2022-12-31 0000721371 country:US 2023-07-01 2023-12-31 0000721371 country:US 2022-07-01 2022-12-31 0000721371 us-gaap:NonUsMember 2023-07-01 2023-12-31 0000721371 us-gaap:NonUsMember 2022-07-01 2022-12-31 0000721371 cah:MedicalUnitMember 2022-07-01 2022-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2023-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2023-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2023-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2023-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-10-01 2023-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-10-01 2022-12-31 0000721371 us-gaap:PerformanceSharesMember 2023-10-01 2023-12-31 0000721371 us-gaap:PerformanceSharesMember 2022-10-01 2022-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-12-31 0000721371 us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 us-gaap:PerformanceSharesMember 2022-07-01 2022-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000721371 srt:MinimumMember cah:Fiscal2022Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 srt:MinimumMember cah:Fiscal2023Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 srt:MaximumMember cah:Fiscal2023Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 srt:MaximumMember cah:Fiscal2022Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 srt:MinimumMember cah:Fiscal2024Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 srt:MaximumMember cah:Fiscal2024Member us-gaap:PerformanceSharesMember 2023-07-01 2023-12-31 0000721371 us-gaap:PerformanceSharesMember 2023-06-30 0000721371 us-gaap:PerformanceSharesMember 2023-12-31 0000721371 us-gaap:SubsequentEventMember 2024-02-01 2024-06-30 shares iso4217:USD iso4217:USD shares pure utr:Rate cah:states cah:numberOfUSTerritories cah:lawsuit cah:plaintiff iso4217:JPY cah:segment 0000721371 --06-30 2024 Q2 false http://fasb.org/us-gaap/2023#GainLossOnSalesOfAssetsAndAssetImpairmentCharges 10-Q true 2023-12-31 false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 Common shares (without par value) CAH NYSE Yes Yes Large Accelerated Filer false false false 243233153 false false false false 57445000000 51469000000 112208000000 101072000000 55599000000 49806000000 108594000000 97795000000 1846000000 1663000000 3614000000 3277000000 1283000000 1191000000 2480000000 2388000000 28000000 17000000 53000000 46000000 63000000 71000000 127000000 142000000 -1000000 -710000000 -538000000 -863000000 11000000 207000000 52000000 180000000 482000000 -119000000 468000000 18000000 16000000 7000000 18000000 5000000 8000000 25000000 22000000 50000000 490000000 -137000000 464000000 -27000000 136000000 -7000000 104000000 -8000000 354000000 -130000000 360000000 -19000000 1000000 0 2000000 1000000 353000000 -130000000 358000000 -20000000 1.44 -0.50 1.45 -0.08 1.43 -0.50 1.44 -0.08 245000000 261000000 247000000 266000000 246000000 261000000 248000000 266000000 0.5006 0.4957 1.0012 0.9914 354000000 -130000000 360000000 -19000000 6000000 20000000 -5000000 -38000000 4000000 10000000 1000000 6000000 10000000 30000000 -4000000 -32000000 364000000 -100000000 356000000 -51000000 1000000 0 2000000 1000000 363000000 -100000000 354000000 -52000000 4591000000 4043000000 11788000000 11344000000 18451000000 15940000000 2816000000 2362000000 12000000 144000000 37658000000 33833000000 2446000000 2462000000 5371000000 6081000000 1098000000 1041000000 46573000000 43417000000 34259000000 29813000000 1188000000 792000000 2839000000 3059000000 0 42000000 38286000000 33706000000 3535000000 3909000000 8199000000 8653000000 500000 500000 0 0 0 0 755000000 755000000 327000000 327000000 2855000000 2747000000 -425000000 -534000000 83000000 76000000 5724000000 4914000000 -155000000 -151000000 -3449000000 -2852000000 2000000 1000000 -3447000000 -2851000000 46573000000 43417000000 327000000 2728000000 -654000000 -80000000 -5400000000 -165000000 1000000 -3490000000 353000000 1000000 354000000 10000000 10000000 0 27000000 0 30000000 57000000 100000000 4000000 354000000 254000000 123000000 123000000 1000000 -1000000 0 -1000000 327000000 2855000000 -425000000 83000000 5724000000 -155000000 2000000 -3447000000 327000000 2576000000 -301000000 65000000 3880000000 -176000000 1000000 -1780000000 -130000000 0 -130000000 30000000 30000000 0 21000000 1000000 26000000 47000000 150000000 4000000 400000000 250000000 129000000 129000000 327000000 2747000000 -560000000 68000000 4254000000 -146000000 1000000 -2212000000 327000000 2747000000 -534000000 -76000000 -4914000000 -151000000 1000000 -2851000000 358000000 2000000 360000000 -4000000 -4000000 8000000 1000000 49000000 57000000 100000000 9000000 859000000 759000000 249000000 249000000 0 -1000000 -1000000 -1000000 327000000 2855000000 -425000000 83000000 5724000000 -155000000 2000000 -3447000000 327000000 2813000000 -280000000 54000000 3128000000 -114000000 3000000 -706000000 -20000000 1000000 -19000000 -32000000 -32000000 2000000 2000000 0 -16000000 2000000 74000000 58000000 -50000000 16000000 1200000000 1250000000 260000000 260000000 -1000000 -1000000 327000000 2747000000 -560000000 68000000 4254000000 -146000000 1000000 -2212000000 360000000 -19000000 347000000 341000000 -538000000 -863000000 57000000 48000000 43000000 59000000 487000000 919000000 2536000000 1643000000 4446000000 2954000000 1034000000 1064000000 1734000000 620000000 9000000 0 206000000 155000000 2000000 2000000 2000000 5000000 1000000 1000000 28000000 0 -168000000 -157000000 15000000 13000000 1000000 9000000 255000000 271000000 750000000 1250000000 -1019000000 -1525000000 1000000 -1000000 548000000 -1063000000 4043000000 4717000000 4591000000 3654000000 <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2023.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></div></div> <div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").</span></div> <div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2023.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></div> <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023, we signed a definitive agreement to contribute the Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the six months ended December 31, 2023, which was included in <span style="-sec-ix-hidden:f-409">impairments and (gain)/loss on disposal of assets</span>, net in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.</span></div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the divestiture of the Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business does not meet the criteria to be classified as discontinued operations. The Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business operated within our Pharmaceutical segment.</span> 0.16 53000000 147000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="ib40ddab3de824ae3892d39671332e7b8_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and six months ended December 31, 2023 were primarily related to certain projects resulting from review of our strategy portfolio, capital-allocation framework and operation and the implementation of certain enterprise-wide cost-savings measures. During the three and six months ended December 31, 2022, restructuring and employee severance costs were primarily related to implementation of certain enterprise-wide cost-saving measures. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8000000 10000000 20000000 7000000 28000000 17000000 15000000 29000000 38000000 17000000 53000000 46000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 44000000 2000000 46000000 8000000 4000000 12000000 18000000 1000000 19000000 34000000 5000000 39000000 <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,649 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,649</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,024</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) At December 31, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified any indicators of impairment during the three months ended December 31, 2023 within our reporting units, including the Medical Unit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit due to an increase in the risk-free interest rate used in the discount rate. Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the six months ended December 31, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss). This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,175</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">818</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,743</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,335</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,755</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,347</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $63 million and $71 million for the three months ended December 31, 2023 and 2022, respectively, and $127 million and $142 million for the six months ended December 31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $127 million, $226 million, $206 million, $174 million and $148 million.</span></div></div></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,649 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,649</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,024</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) At December 31, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.</span></div> 2649000000 1960000000 4609000000 0 -3000000 -3000000 0 -1000000 -1000000 0 581000000 581000000 2649000000 1375000000 4024000000 5300000000 4700000000 0.11 0.02 0.02 0.02 581000000 0.01 0.10 709000000 154000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,175</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">818</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,743</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,335</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,755</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,347</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12000000 12000000 12000000 12000000 3175000000 2357000000 818000000 P9Y 546000000 394000000 152000000 P7Y 1022000000 657000000 365000000 P8Y 4743000000 3408000000 1335000000 P8Y 4755000000 3408000000 1347000000 11000000 11000000 11000000 11000000 3174000000 2274000000 900000000 546000000 380000000 166000000 1021000000 626000000 395000000 4741000000 3280000000 1461000000 4752000000 3280000000 1472000000 63000000 71000000 127000000 142000000 127000000 226000000 206000000 174000000 148000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both December 31, 2023 and June 30, 2023. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $34.3 billion and $29.8 billion at December 31, 2023 and June 30, 2023, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December 31, 2023, we were in compliance with this financial covenant. 4700000000 4700000000 34300000000 29800000000 2000000000 2000000000 1000000000 0 2000000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="ib40ddab3de824ae3892d39671332e7b8_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation ("CVS Health") for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during first quarter of fiscal year 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or </span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">system and other healthcare providers, businesses and Individuals. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil request for information, subpoenas and other request from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, as of December 31, 2023, we have $5.47 billion accrued for these matters, of which $420 million is included in other accrued liabilities and remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrong doing. Please see below for additional description of these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we reached an agreement in principle with the Alabama Attorney General, under which we would pay approximately $123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the three and six months ended December 31, 2023, we recognized a </span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to this agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through January 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.9 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayment of Future Payment Years </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we made payments of approximately $238 million to prepay at a pre-negotiated discount certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we expect to recognize income of approximately $100 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings/(loss) during the three months ended March 31, 2024.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of January 26, 2023 were 395. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs; however, we are vigorously defending ourselves in all these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle 2,798 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in </span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product liability lawsuits. We intend to vigorously defend ourselves against these claims.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At December 31, 2023, we had a total of $300 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $31 million and $71 million during the three and six months ended December 31, 2023, respectively, and $66 million during the three and six months ended December 31, 2022.</span></div> P10Y 100000000 -6000000 3000000 5470000000 420000000 48 5 123000000 22000000 1500000000 4900000000 124000000 136000000 238000000 -344000000 100000000 395 103 21 8 10000000 400 4500 4375 275000000 275000000 2798 -103000000 300000000 31000000 71000000 66000000 66000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December 31, 2023, the effective tax rate was 27.7 percent and 22.4 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December 31, 2022, the effective tax rate was 5.4 percent and 30.0 percent, respectively, and reflects the impact of the tax effects of the goodwill impairment charges recognized during the three and six months ended December 31, 2022.</span></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2023, we recognized a $581 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to these charges is $45 million for fiscal 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the six months ended December 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the six months ended December 31, 2023 resulted in recognizing an incremental interim tax benefit of approximately $65 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended December 31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at December 31, 2023. This interim tax benefit will reverse in future quarters of fiscal 2024.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $959 million and $1.0 billion of unrecognized tax benefits at December 31, 2023 and June 30, 2023, respectively. The December 31, 2023 and June 30, 2023 balances include $864 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and June 30, 2023, we had $52 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $30 million, exclusive of penalties and interest.</span></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. As a result, the indemnification receivable was reduced. The indemnification receivable was $20 million and $82 million at December 31, 2023 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div> 0.277 0.224 0.054 0.30 581000000 -45000000 65000000 959000000 1000000000 864000000 873000000 52000000 65000000 0 30000000 20000000 82000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="ib40ddab3de824ae3892d39671332e7b8_106"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and Liabilities Measured on a Recurring Basis</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets Measured on a Nonrecurring Basis</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib40ddab3de824ae3892d39671332e7b8_82" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment during the six months ended December 31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div> 1708000000 0 0 1708000000 102000000 0 0 102000000 0 -73000000 0 -73000000 1253000000 0 0 1253000000 101000000 0 0 101000000 0 -73000000 0 -73000000 0.16 147000000 <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December 31, 2023 and 2022, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million each. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive income/(loss) were immaterial and a $2 million loss for the three months ended December 31, 2023 and 2022, respectively, and a $1 million gain and a $2 million gain for the six months ended December 31, 2023 and 2022, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $1 million and immaterial for the three months ended December 31, 2023 and 2022, respectively, and $2 million and immaterial for the six months ended December 31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December 31, 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $16 million and $43 million during the three months ended December 31, 2023 and 2022, respectively, and $5 million and $21 million during the six months ended December 31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million during both the three months ended December 31, 2023 and 2022, and $7 million and $8 million during the six months ended December 31, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $3 million gain during the three months ended December 31, 2023 and 2022, respectively, and an immaterial loss and a $3 million loss during the six months ended December 31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are the Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December 31, 2023 and June 30, 2023 approximate fair value due to their short-term maturities.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,527</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,723</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div> 0 0 0 0 200000000 200000000 -2000000 1000000 2000000 1000000 2000000 3000000 18000000000 120000000 18000000000 120000000 38000000000 300000000 28000000 -16000000 -43000000 -5000000 -21000000 4000000 4000000 7000000 8000000 3000000 -3000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,527</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,723</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4527000000 4417000000 4723000000 4701000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Deficit</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $750 million and $1.3 billion of our common shares, in the aggregate, through share repurchase programs during the six months ended December 31, 2023 and 2022, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $1 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(155)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 750000000 1300000000 250000000 2000000 101.66 103.67 400000 500000000 4400000 90.57 88.22 1300000 500000000 4600000 87.18 91.15 900000 250000000 2600000 76.58 77.50 600000 1000000000 12000000 66.74 73.36 1600000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $1 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(155)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -137000000 -14000000 -151000000 -5000000 5000000 0 0 4000000 4000000 1000000 -5000000 1000000 -4000000 -142000000 -13000000 -155000000 -102000000 -12000000 -114000000 -38000000 11000000 -27000000 0 5000000 5000000 5000000 -38000000 6000000 -32000000 -140000000 -6000000 -146000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and six months ended December 31, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 3 million and 5 million for the three and six months ended December 31, 2022, respectively. For both the three and six months ended December 31, 2022, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 245000000 261000000 1000000 0 246000000 261000000 247000000 266000000 1000000 0 248000000 266000000 1000000 1000000 2000000 2000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we announced a change in our organizational structure and have re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other. The following indicates the changes in our reporting structure effective January 1, 2024: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">Pharmaceutical and Specialty Solutions segment: This reportable segment will comprise all businesses formerly within our Pharmaceutical segment except Nuclear and Precision Health Solutions.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">Global Medical Products and Distribution segment: This reportable segment will comprise all businesses formerly within our Medical segment except at-Home Solutions and OptiFreight Logistics.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">Other: This will consist of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,190</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,391 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,520</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,673 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products and Distribution (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,928</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,448</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,470 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,469 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,872</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,938 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">654</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104,526</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,501 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products and Distribution (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,688</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,214</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,076 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,072 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56,241</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,333 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,207</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,448</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,470 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,469 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109,798</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,810 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,416</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,214</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,076 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,072 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation </span></div></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib40ddab3de824ae3892d39671332e7b8_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized cumulative pre-tax goodwill impairment charges of $581 million and $863 million during the six months ended December 31, 2023 and $709 million during the three months ended December 31, 2022;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $14 million and $5 million for the three months ended December 31, 2023 and 2022, respectively, and $20 million and $11 million for the six months ended December 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">482</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,018</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,077 </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,817</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,738</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,210 </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,573</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,417 </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 2 2 2 <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,190</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,391 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,520</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,673 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products and Distribution (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,928</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,448</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,470 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,469 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,872</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,938 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">654</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104,526</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,501 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Products and Distribution (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,688</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,214</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,076 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,072 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 53190000000 47391000000 330000000 282000000 53520000000 47673000000 3167000000 3099000000 761000000 698000000 3928000000 3797000000 57448000000 51470000000 -3000000 -1000000 57445000000 51469000000 103872000000 92938000000 654000000 563000000 104526000000 93501000000 6243000000 6239000000 1445000000 1336000000 7688000000 7575000000 112214000000 101076000000 -6000000 -4000000 112208000000 101072000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56,241</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,333 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,207</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,448</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,470 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57,445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,469 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109,798</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,810 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,416</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,214</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,076 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,072 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 56241000000 50333000000 1207000000 1137000000 57448000000 51470000000 -3000000 -1000000 57445000000 51469000000 109798000000 98810000000 2416000000 2266000000 112214000000 101076000000 -6000000 -4000000 112208000000 101072000000 581000000 863000000 14000000 5000000 20000000 11000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">482</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 518000000 464000000 71000000 17000000 589000000 481000000 -107000000 -600000000 482000000 -119000000 1025000000 895000000 142000000 9000000 1167000000 904000000 -699000000 -886000000 468000000 18000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,018</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,077 </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,817</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,738</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,210 </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,573</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,417 </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31018000000 28077000000 9817000000 10130000000 5738000000 5210000000 46573000000 43417000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended December 31, 2023 and 2022, respectively, and $8 million and $6 million for the six months ended December 31, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.37 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.80 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.26 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96.55</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $60 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 15000000 11000000 10000000 28000000 25000000 38000000 32000000 19000000 16000000 57000000 48000000 4000000 3000000 8000000 6000000 P3Y <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.37 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.80 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2200000 57.37 900000 90.69 1000000.0 60.80 100000 69.55 2000000.0 69.44 103000000 P2Y 3 0 0 2.34 2.34 0 2.40 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.26 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96.55</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 82.17 600000 94.66 400000 62.26 0 0 1400000 96.55 60000000 P2Y 1200000000

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